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Integrin Affinity Modulation in Lung Cancer
Lung cancer accounts for the most deaths due to cancer in the United Kingdom and
yet has historically been one of the most ignored of neoplastic diseases. The work
presented in this thesis explores the fundamental processes that govern cell behaviour
in the context of lung cancer and contributes to a deeper understanding of this
behaviour at a molecular level. The work covers three main areas, centred upon the
molecular regulation of integrins, proteins that are the key communicators between a
cell and its local environment and which provide powerful signals governing cellular
behaviour, including motility, cell survival and proliferation.
Recent work has shown that the transmembrane protein CD98 is able to influence the
affinity with which (31 integrins bind to extracellular ligands. The first part of this
thesis presents confocal microscopy and co-immunoprecipitation experiments that
confirm the physical juxtaposition of the two proteins within the cell membrane,
suggesting a direct link between the two, rather than an extensive signalling cascade.
It also demonstrated that cross-linking CD98 stimulates both phosphoinositide 3-
kinase intracellular signalling and increased p 1 integrin-dependent cellular adhesion.
Because of the role of CD98 in integrin affinity modulation, the
immunohistochemical expression of CD98 and its ligand, galectin-3, was studied in a
variety of human lung diseases including lung cancers. The major finding of this
work was a striking distinction between high expression of galectin-3 in non-small
cell lung cancer and low expression in small cell lung cancer. This may have
iii
significant implications for the differing clinical behaviours of these two groups of
cancers. The final section of this thesis returns to describe experiments aimed at
defining the molecular regulators of integrin affinity more clearly. A genetic screen
of a cDNA library was undertaken to identify candidate genes coding for proteins
able to rescue integrins from the low affinity state induced by the small signalling
protein H-Ras. This identified a candidate cDNA 480, recognised to be part of a
novel gene Nessie, coding for a large protein with multiple transmembrane domains.
Both 480 and Nessie appear to have the ability to rescue integrin affinity from H-Ras
suppression.
This thesis thus moves from the basic molecular science of integrin function to the
cellular behaviour of lung cancer cells, both in vitro and in vivo, and back again. The
understanding of cellular behaviour is central not just to lung cancer, but to all
cancers and it is only through furthering this understanding that significant advances
will be made in treating these diseases.
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Section A: Lung Cancer
1.1 Epidemiology of lung cancer
Headlines from the press over recent years emphasize the increasing social vilification of
smoking in Europe and the United States. Together with multibillion-dollar litigation
suits against tobacco companies, this might suggest that the tide has turned against lung
cancer, one of the most devastating effects of smoking. Sadly this is not the case. Lung
cancer remains the most lethal cancer in the world. It has been estimated that more
people died in 2002 in the U.S.A. from lung cancer than from prostate, breast, colon and
cervical cancer put together (Jemal et al., 2002). In the United Kingdom alone, lung
cancer is estimated to have caused 33,600 deaths in 2002, an average of 92 people every
day, or one person every fifteen minutes (Cancer Research UK, 2004). In the year 2000,
approximately 1.2 million people globally were diagnosed with lung cancer, with
estimated deaths of 1.1 million as a direct consequence of lung cancer (Mathers CD,
2001). In particular, the continued high levels of smoking amongst younger generations
and a burgeoning population of smokers in developing countries such as China (Liu et
al., 1998;Zhang and Cai, 2003), targeted by the tobacco companies, mean that lung
cancer will remain an enormous healthcare burden for the foreseeable future. In 1998 it
was estimated that approximately one third of the 0.3 billion (i.e. 100 million) Chinese
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males then aged 0-29 years would die of tobacco-induced disease; approximately 15% of
these would be from lung cancer (Liu et al., 1998).
In populations with low tobacco smoking, the age-adjusted incidence of lung cancer is
low, at around 1-3/100,000 (Doll and Peto, 1976). The highest incidences are found in
industrialised societies: in 1999, Hungary and Scotland had the highest age-related
incidences of lung cancer in the world, amongst both males (120.7/100,000 and
92.7/100,000, respectively) and females (39.6/100,000 and 62.9/100,000, respectively)
(IARC, 2003). The incidence of lung cancer rises with age as a result of trends in
tobacco smoking over the past 50 years. More recently there has been a decline in the
number of male smokers, at least in the U.K., but the number of female smokers has
continued to rise. A worrying rise in the incidence of lung cancer in women (Osann,
1998) has been blamed partly upon this, but there is also emerging evidence that women
are at greater risk of developing lung cancer for fundamental biological reasons (Osann
et al., 1993).
1.2 Aetiology of lung cancer
1.2.1 Tobacco smoke
The clear, causative link between tobacco smoking and lung cancer was established in
seminal work by Doll (Doll and Hill, 1954). By studying the smoking habits of a group
of over 40,000 British doctors over more than a decade, Doll found clear evidence of a
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link between smoking and deaths from lung cancer (Doll and Hill, 1964;Azzarone et al.,
1986). Pipe and cigar smokers have a reduced risk compared to cigarette smokers,
considered to be due to decreased inhalation of the tobacco smoke. The risk of lung
cancer increases with the number of cigarettes smoked and the duration of the smoking
habit. Conversely, there is also good evidence that smoking cessation immediately
begins to reduce this risk, although it takes many years for it to approach the risk of
lifelong non-smokers. More recently, Peto has suggested that smoking cessation rapidly
reduces the risk of developing lung cancer, such that cessation by age 50 or age 30
reduces the cumulative risk of lung cancer by age 75 to 6% and 2% respectively (Peto et
al., 2000).
There are numerous known carcinogens in tobacco smoke, both in the particulate and the
vapour phase, as shown in Table la. Historically, post-mortem studies showed a strong
association between the number of cigarettes smoked during life and the presence of
metaplasia and dysplasia found at autopsy (Auerbach et al., 1979). The natural history
of such dysplastic lesions is unclear, however, since not all appear to go on to develop
into carcinomas.
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Table la: Carcinogens in particulate and vapourphases of tobacco smoke














1.2.2 Other risk factors
Other agents than smoking contribute to the risk of developing lung cancer. These
occupational and environmental hazards include asbestos, chromium, nickel, arsenic,
chloromethyl ethers, vinyl chloride, uranium, radon and polyaromatic hydrocarbons.
They probably account for 5-15% of total lung cancer deaths. During the 1950s it was
estimated that air pollution in the U.K., primarily in the form of polycyclic hydrocarbons
from domestic coal fires, contributed to approximately 10% of lung cancer in men.
Asbestos exposure is the most pre-eminent of these compounds. Although most
notorious for its causative link with mesothelioma, exposure to high levels of asbestos,
especially amphibole asbestos (crocidolite and amosite), is associated with increased risk
of carcinoma. Tobacco smoking is an important co-factor in this risk and its effect is
multiplicative: asbestos exposure alone increases the risk of lung cancer by five times
compared with unexposed individuals, but individuals who smoke and have high
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asbestos exposure have a 53-times greater incidence of lung cancer than those who have
neither risk factor (Hammond et al., 1979).
Fibrotic lung disease appears to increase the risk of lung cancer. Idiopathic pulmonary
fibrosis confers a 14-fold increased incidence of carcinoma (Hubbard et al., 2000),
similar to that seen in asbestosis. In contrast to the normal population, carcinomas in
both conditions tend to arise more in the lower lobes, where the fibrotic process is most
pronounced.
Recent studies have implicated viral oncogenes in lung carcinogenesis. For example, in
a small study of just 34 cases, papilloma virus (type 18) was identified in a small
proportion (two cases) of squamous cell carcinomas (Bohlmeyer et al., 1998) and
Epstein-Barr virus in bronchopulmonary lymphoepitheliomas, but only rarely in more
common histological subtypes (Higashiyama et al., 1995).
Finally, not all smokers develop lung cancer. Indeed, the majority never develop the
disease, which affects only about 10% of smokers. This suggests that genetic
predisposition and other factors play important roles in carcinogenesis. However,
although epidemiological studies have shown an excess of lung cancer in first degree
relatives (Ooi et al., 1986;Lynch et al., 1986), in such studies it is difficult to control for
the pervasive confounding factors of smoking and passive smoking within families. By
contrast, a study of almost 6,000 pairs of male twins failed to confirm any genetic
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predisposition (Braun et al., 1994). Nevertheless, the case for genetic susceptibility to
cancer remains persuasive. In particular, enzymes responsible for carcinogen activation,
degradation and subsequent DNA repair are being studied, since mutations affecting
enzyme activity in these key processes might significantly influence the risk of
developing lung cancer.
1.3 Classification of lung cancer
The World Health Organisation has classified lung cancer into four main subgroups,
which together comprise 95% of all lung cancers (WHO, 1999): squamous cell
carcinoma, adenocarcinoma, large cell carcinoma (collectively described as "non-small
cell carcinomas" (NSCLC)) and small cell carcinoma (SCLC). A number of uncommon
types are also identified, that include mucoepidermoid and adenoid cystic carcinomas,
and carcinoid tumours. Most tumours arise within the airspaces or bronchi from
epithelial cells, of which there are four main types - basal, mucous, neuroendocrine and
ciliated. Apart from the ciliated cells, which are terminally differentiated, all are capable
of division and thus considered to have malignant potential. Amongst lung carcinomas,
SCLC and squamous cell carcinomas show the highest rate of growth when measured by
volume doubling time (Geddes, 1979;Hasegawa et al., 2000).
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1.3.1 Squamous cell carcinoma
These carcinomas arise endobronchially and centrally within the lung and are considered
the least malignant phenotype. They show either keratinisation or intercellular tight
junctions, or both. They tend to metastasise late, causing symptoms by local mass
effect, such as atalectasis or segmental/lobar collapse. Historically, squamous cell
carcinoma has been the commonest histological subtype.
1.3.2 Adenocarcinoma
The characteristic of adenocarcinomas is the development of glandular or papillary
structures, with mucin production. They metastasise earlier than squamous cell tumours,
possibly by aerogenous spread and aspiration into other areas of the lung, forming
disseminated satellite lesions. Bronchioloalveolar cell carcinomas are a subtype of
adenocarcinoma, in which the tumour growth is along the alveolar walls in a "lepidic"
pattern, with preservation of the alveolar framework.
1.3.3 Large cell carcinoma
Large cell carcinomas represent a group of poorly differentiated tumours that display
neither squamous differentiation, nor glandular differentiation with mucosynthesis.
Rather, the tumour cells appear as monotonous sheets, with plentiful cytoplasm and
prominent nucleoli.
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1.3.4 Small cell carcinoma
Small cell lung carcinoma represents the most aggressive form of lung carcinoma and is
the most strongly associated with tobacco smoking. These are the fastest growing
carcinomas and metastasise early, such that over 70% of patients have metastatic disease
at presentation (Elias, 1997). The classical "oat-cell" morphology describes cells of a
high nuclear/cytoplasmic ratio, in which the nuclei are pyknotic or have a finely granular
chromatin pattern and indistinct nucleolus.
There is a distinct, but uncommon subgroup of mixed tumours, in which SCLC cells are
found combined with either squamous cell carcinoma or adenocarcinoma. It is difficult
to truly assess their incidence, since the presence of SCLC tends to preclude surgical
excision and detailed analysis. In a surgical study, Hage et al. reported an proportion of
26% mixed tumours in their very small total of 100 patients undergoing resection for
SCLC over 17 years (Hage et al., 1998). There is an overt surgical bias in this study and
other authors report a lower incidence of mixed tumours, up to 10-14% of SCLC cases
(Fushimi et al., 1996). Patients with such mixed tumours fare worse than those with a
"pure" NSCLC morphology.
1.3.5 Changing prevalence of histological subtypes
Over recent decades there have been changes in the prevalence of the histological
subtypes of lung cancer. There has always been significant variation in reports,
depending upon the nature of the population studied and the origin of the tissue for
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diagnosis: surgical resection specimens give a more reliable diagnosis than
bronchoscopic sampling, but will result in a falsely low incidence of SCLC, since it is
rarely considered possible to resect this subtype. Nevertheless, there has been an
increase in the proportion of adenocarcinomas (Vincent et al., 1977). Data from the U.S.
National Cancer Institute shows that for 1973-77 there were twice as many squamous
cell carcinomas than adenocarcinomas in men, whilst adenocarcinomas were marginally
more frequent in women. By 1990, adenocarcinomas had increased to levels equivalent
to squamous cell carcinomas in men and in women were now 1.5-2 times more frequent.
Analyses of birth cohorts suggests that these two related epidemics - of squamous cell
carcinomas and more recently of adenocarcinomas - are related to patterns of smoking
amongst populations, with both an increase in women smoking and a move towards
lower yield, filter-tipped cigarettes (Skuladottir et al., 2000). The effect of filter-tipped
cigarettes is that smokers have to take more frequent, deeper puffs to fulfil their nicotine
kick. This in turn means that tobacco smoke reaches more distal parts of the
bronchoalveolar tree, where adenocarcinomas are more likely to arise than squamous
cell carcinomas (Wynder and Hoffmann, 1994).
1.4 Development of lung cancer
1.4.1 Phenotypic changes
The bronchial epithelium exhibits a marked potential for metaplasia. In airway damage,
one of the earliest events is basal cell hyperplasia, then replacement of normal ciliated
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epithelial cells by stratified squamous epithelium. These cells may undergo further
differentiation into mucous cells and ciliated cells, but may differentiate into
neuroendocrine cells or metaplastic squamous cells in the presence of carcinogens in
hamster models of carcinogensesis (Reznik-Schuller, 1977). Current evidence therefore
points towards the bronchial epithelial cell as a common origin for all lung cancers, with
the final histological subtype a mirror of the molecular changes that have induced
carcinogenesis. This is supported by work showing that neuroendocrine features can be
observed in up to 25% of adenocarcinomas (Mabry et al., 1988). Additionally, SCLC
can be induced to mutate into a large cell carcinoma phenotype (Mabry et al., 1991) and
different histological subtypes can be induced from the same bronchial epithelial cell
line (BEAS-2B) following transformation with c-myc and c-raf-\, producing tumours
with phenotypic relations to adenocarcinomas, large cell, squamous cell or small cell
carcinomas (Pfeifer et al., 1989;Pfeifer et al., 1991).
Therefore the sequence of hyperplasia —> metaplasia —» dysplasia —» carcinoma-in situ
—» invasive carcinoma is more clearly understood. Indeed, it has been demonstrated
clinically by periodic sputum examination in uranium workers at high risk of evolving
bronchial carcinoma. In these subjects squamous metaplasia, then increasing atypia,
were followed by frank carcinoma of either SCLC or squamous cell type, the period of
dyplastic change being prolonged for an average of 16 years (Saccomanno et al., 1974).
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1.4.2 Molecular changes
The molecular changes that accompany these phenotypic changes are the result of
multiple, accumulated alterations to the cellular machinery. It is estimated that
established lung cancers have acquired 10-20 genetic abnormalities in dominant
oncogenes or tumour-suppressor genes (Kerr, 2001). Growth factors and their receptors
are not usually affected by mutation, but their upregulation and stimulation of autocrine
and paracrine growth loops, gives them a supporting role, which has clearly been
established in both SCLC and NSCLC (Sethi and Rozengurt, 1991;Sethi et al., 1992).
The major cellular oncogenes implicated in lung cancer include those of the ras and myc
families. Overexpression of c-myc is common in SCLC and NSCLC. c-myc encodes a
nuclear phosphoprotein transcription factor, which promotes programmed cell death, or
apoptosis, in normal cells. However, amplification or over-expression of c-myc in
transformed cells with impaired apoptotic signalling pathways, whilst not being essential
for the transformation process, promotes cellular proliferation, (Gazzeri et al., 1991).
Overexpression of myc protein is accounted for by either amplification of myc genes (in
20% of SCLC and 10% of NSCLC) or by mRNA hyperexpression (45% of lung
carcinomas) as a result of other, upstream events such as growth factor activation. In
addition, there is evidence to suggest that myc mRNA transcripts are abnormally
stabilized in some lung cancers in vitro (Bernasconi et al., 2000).
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The ras gene encodes a membrane-associated protein involved in signal transduction
from tyrosine kinase growth factor receptors. K-ras is a mutation found in 30-50% of
NSCLC, causing dysregulation of Ras signal transduction. It can be found in early stage
adenocarcinoma and in pre-invasive, atypical, hyperplastic cells and is therefore
considered an important early mutation (Westra et al., 1996;Cooper et al., 1997). It can
also be induced in vitro by nitrosamines and benzo-a-pyrene, found in cigarette smoke
(Osann, 1998). The presence of K-ras mutation appears to be associated with more
poorly differentiated tumours and a poorer outcome after surgery (Slebos et al,
1990;Rodenhuis and Slebos, 1992).
Other oncogenes found to be aberrantly expressed in lung cancer include cyclin Dl,
normally involved in cell cycle control and, specifically, the transition from G1 to S-
phase; bcl2, responsible for protection against apoptosis; c-erb-B2/neu and epidermal
growth factor receptor (EGF-R), both resulting in cellular proliferation. All such
dominant oncogenes require only one allele to be affected - and therefore one genetic
event - for their carcinogenic potential to be unleashed (Kerr, 2001).
Inactivation of tumour-suppressor genes, which normally promote apoptosis or anti¬
proliferative functions, requires a double "hit" - one allele mutation followed by loss of
the normal allele. This resulting loss of heterozygosity is frequently described in lung
cancer and may occur during progression from primary tumour to metastasis (Shiseki et
al., 1994;Okamoto et al., 1995). Recurrent allelic deletions at specific chromosomal
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sites have helped identify tumour-suppressor genes lost in lung cancer. The fragile
histadine triad (FHIT) gene has been isolated from a 3p locus; abnormal mRNA
transcripts were detected in 80% of SCLC and 40% of NSCLC, while 76% of all
tumours exhibited loss of FHIT alleles (Sozzi et al., 1996). The p53 gene is the
commonest genetic alteration in human cancer, normally encoding a transcription factor
for G1 arrest or apoptosis of damaged cells. It is altered in 70-80% of SCLC and 50% of
NSCLC and is associated with loss of heterozygosity at 17p 13 (D'Amico et al.,
1992;Mitsudomi et al., 2000). Amongst NSCLC, a recent meta-analysis has suggested
that p53 alterations are of adverse prognostic significance for patients with
adenocarcinoma rather than squamous cell carcinoma, even though it is less frequent in
adenocarcinoma (34% v. 52%, respectively)(Mitsudomi et al., 2000). Similarly, the
retinoblastoma gene Rb is encoded at a frequent site of allelic deletion, 13ql4, and loss
of expression occurs in 90% of SCLC and 10-15% of NSCLC. Loss of Rb expression
results in loss of control of the G1 arrest phase of the cell cycle. Although Rb may be
normally expressed in most NSCLC, its phosphorylation is frequently deregulated by
either overexpression of cyclin D1 or loss of the negative regulator of Rb
phosphorylation, pl6mK4 (Kratzke et al., 1996;Brambilla et al., 1999).
The end result of these molecular events is that cells accumulate progressively more
genetic damage. Although initially some may be reversible, with increasing damage
cells are more likely to escape the natural protective mechanisms of cell cycle arrest and
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programmed cell death, such that cellular proliferation and a cancerous cellular
phenotype result.
1.5 Lung cancer - the clinical problem
At a clinical level, lung cancer usually presents with features related to local effects in
the lung, such as cough, haemoptyis, chest wall pain or breathlessness. Apical lung
tumours can produce shoulder or arm pain, with brachial plexus involvement or Horner's
syndrome, whilst mediastinal involvement may result in hoarseness due to recurrent
laryngeal nerve palsy, superior vena caval obstruction or phrenic nerve damage.
Disseminated disease may present with features related to metastatic sites: jaundice and
abdominal pain due to hepatic involvement; headache, confusion or seizures from brain
metastases; bone pain or fractures from skeletal metastases.
In addition, tumours may present with paraneoplastic features due to polypeptide
hormone production. Such hormones are detectable at elevated levels more in SCLC
(70%) than NSCLC (15-20%), but only around 5% produce clinically relevant effects.
In squamous cell carcinomas this characteristically includes hypercalcaemia due to a
parathormone-like peptide, but paraneoplastic syndromes are the feature of SCLC par
excellence. These most frequently include the syndrome of inappropriate anti-diuretic
hormone, Cushing's syndrome (due to adrenocorticotropic hormone) and ectopic
production of calcitonin and parathyroid hormone (Spiro, 2003). In addition, production
14
of anomalous antibodies directed against tumour antigens can result in a variety of
neurological disorders, including cerebellar syndromes, peripheral neuropathy and the
Lambert-Eaton myasthenic syndrome (De Aizpurua et al., 1988).
1.5.1 Non-small cell lung cancer
Management ofNSCLC is dependent upon classical tumour (T) node (N) metastasis (M)
staging, initially devised in 1946 and upgraded in 1997 (Mountain, 1997). This remains
the best prognostic indicator for outcome in NSCLC and emphasises the importance of
tumour size, lymph node involvement, proximity to the main carina, involvement of the
mediastinum or involvement of the pleura or chest wall (Mountain, 2000). The most
effective treatment for NSCLC remains successful surgery and the staging process is
directed at identifying those patients suitable for surgery. However, up to 60% of
patients are deemed inoperable due either to extensive disease or to comorbidity.
The TNM classes have been grouped into three stage categories deemed operable (IA
and B, IIA and B, IIIA), with different survival rates. Stages IIIB and IV are deemed
inoperable. With progression through the stages the prognosis rapidly becomes
increasingly bleak (Table lb). Thus, predicted 5-year survival for a patient with
clinically staged IA disease (T1N0M0) is approximately 60%, whereas for IB
(T2N0M0) it drops to nearer 40%. Ipsilateral lymph node involvement, as in Stage IIA
disease (T1N1M0), further reduces this to 34% and by the time Stage IIIA disease is
reached (T3N1M0) 5-year survival is only 13% (Mountain, 1997). Unsurprisingly, these
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figures are improved if the disease is staged pathologically, post-operatively, but in this
lies one of the difficulties of lung cancer management - how to accurately stage the
burden of disease pre-operatively, so as to avoid unsuccessful surgery and to target
adjuvant therapy more effectively to those patients who will benefit most.
Table lb: Survival in NSCLC according to clinical (c) orpathological (p) staging.
c/p Stage
Months after treatment (cumulative % survival)
12 24 36 48 60
cIA 91 79 71 67 61
cIB 72 54 46 41 38
cIIA 79 49 38 34 34
cIIB 59 41 33 26 24
cIIIA 50 25 18 14 13
cIIIB 34 13 7 6 5
cIV 19 6 2 2 1
pIA 94 86 80 73 67
pIB 87 76 67 62 57
pIIA 89 70 66 61 55
pIIB 73 56 46 42 39
pIIIA 64 40 32 26 23
Taken from Mountain et ^/.(Mountain, 1997). cStage, clinical Stage; pStage,
pathological Stage.
Radiotherapy
The role of radiotherapy in NSCLC depends upon the context in which it is considered.
In 1998 a meta-analysis (PORT, 1998) revealed no survival advantage to radiotherapy
following complete resection of T1-2N0-1 tumours or T3N0 tumours. Indeed, a more
recent update of this meta-analysis suggests that post-operative radiotherapy is
detrimental to outcome, reducing overall survival from 55% to 48% at two years
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(Cochrane, 2003). For patients found at resection to have pathological N2 disease, pre¬
operative^ clinically staged as N0-1, management is less clear. These patients had
pathologically Stage III (N2) disease and there was no clear adverse effect (Cochrane,
2003). Adjuvant radiotherapy is often given in cases of incomplete resection, although
there is no evidence that this reduces the rate of recurrence. Additionally, radiotherapy
may be used for a tumour that is potentially resectable, but where an operation is not
possible, due either to patient comorbidity or disinclination. Such radical radiotherapy,
aiming to cure, involves higher doses of radiation (at least 60 Gray) and there is
continuing debate over the best way in which to deliver this dose. Recently, continuous
hyperfractionated accelerated radiotherapy (CHART), delivered over two weeks, has
been shown to offer a significant survival advantage over conventional fractionation
delivered over 6 weeks (Saunders, 2001).
Chemotherapy
NSCLC has been considered to be relatively chemoresistant and historically
chemotherapy has played little part in its management. However, this philosophy has
been challenged more recently in the context of both inoperable, disseminated (and
therefore not readily amenable to radiotherapy) disease and in operable N0-1 disease as
adjuvant or neo-adjuvant therapy. In 1995, a major meta-analysis of 52 randomised
trials of chemotherapy showed a limited survival advantage with platinum-based
treatment of up to 5% at five years in potentially curable disease, or up to 10% at one
year in palliative care. This analysis covered 9387 patients in all clinical settings of
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NSCLC, from patients treated surgically to those receiving supportive care for incurable
disease (Non-small Cell Lung Cancer Collaborative Group, 1995). Since then a global
effort has been made to clarify the role of chemotherapy in NSCLC in a number of
large-scale trials.
Palliative care
The largest proportion of lung cancer patients falls into this group, being unsuitable for
surgery at presentation. Radiotherapy has a clear role in the palliation of symptoms such
as thoracic pain, intractable cough, haemoptysis, dysphagia or impending lobar collapse,
but no effect on life expectancy (MRC, 1992). The role of chemotherapy remains
unclear in this group of patients. In the eight trials pooled in the meta-analysis
comparing supportive care alone with supportive care plus chemotherapy, although
median survival was increased, long-term survival was less clearly influenced (Non-
small Cell Lung Cancer Collaborative Group, 1995). In addition, the risks of
chemotherapy increase with poorer performance status, although quality of life overall
appears to be no worse after chemotherapy and symptomatic response rates of 60% may
be seen (Gregory et al., 2001). It remains important, therefore, that further studies are
carried out in this area of care.
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1.5.2 Small cell lung cancer
Primary chemotherapy
By contrast with NSCLC, small cell lung cancer is almost invariably inoperable at
presentation, yet has a clear response to initial chemotherapy in 50-90% of patients.
Rarely, a patient may be confidently assigned to a Stage I or II disease (T1-2N0M0) and
go on to surgery, but for the majority of SCLC patients the TNM system is unhelpful and
the disease is classified following the Veterans Administration Lung Cancer Group as
either limited disease (LD) - confined to one hemithorax, including ipsi- or contralateral
hilar nodes and ipsilateral supraclavicular lymph nodes - or extensive (ED), extending
beyond this. Patients with ED have a worse prognosis than those with LD, but this is in
the context of an untreated median survival for SCLC of about three months. Other poor
prognostic factors include older age and male sex, poor performance status,
hyponatraemia, and elevated lactate dehydrogenase and alkaline phosphatase (Thatcher
et al., 1995).
Even with chemotherapy, median survival only improves to a median of 8 months in
average to poor prognosis patients (MRC, 1989). In better prognostic groups, with
carefully staged trials, median survival of up to 23 months has been documented with
chemotherapy and consolidation radiotherapy given as twice-daily accelerated fractions
(Turrisi, III et al., 1999), but there is no definitive chemotherapy regime. Regimes used
include: cysplatin plus etoposide; cyclophosphamide, doxorubicin and vincristine;
cyclophosphamide, doxorubicin and etoposide; and ifosfamide, carboplatin and
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etoposide, with or without vincristine. Primary chemotherapy is usually limited to six
cycles for better prognosis patients. In intermediate and poorer prognostic groups this
may well be limited to three or four cycles, achieving a partial response rate of 50-70%.
Radiotherapy
Patients with limited disease and a complete radiological response to primary
chemotherapy achieve a modest benefit from radiotherapy with 45-55 Gy (Pignon et al.,
1992;Warde and Payne, 1992). This group of responders has also been shown to have a
reduced incidence of brain metastases (27% v. 49%) and improved survival with
prophylactic cranial irradiation compared to controls (Auperin et al., 1999).
Radiotherapy is also of benefit in treatment of localised, painful bony metastases.
Relapsed disease
Relapse is almost inevitable in SCLC, being about 50% in the first year and 40% in the
second. Conventionally, second-line therapy is with a different regime from primary
chemotherapy. However, relapsed SCLC exhibits marked chemoresistance and overall
response rates are only in the order of 10-30%. The outlook hereafter is bleak, median
survival being only two or three months.
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1.6 Chemoresistance
The development of multidrug resistance is not unique to lung cancer, but is seen in a
wide range ofmalignancies, often following impressive initial responses to therapy, as in
haematological malignancies, ovarian, germ cell or breast cancer. Many cytotoxic
chemotherapeutic agents induce cell death via the final common pathway of apoptosis
(Hannun, 1997). This includes etoposide, adriamycin and czs-platinum, all of which
may be used in treatment of lung cancer. Cells that survive the chemotherapeutic insult
are able to pass on at least some of their resistance "factors", as demonstrated in murine
models of leukaemia (Koyama et al., 1982;Palyi et al., 1989). Thus, there is an inherited
component to multidrug resistance - chemotherapy breeds chemoresistance. In addition,
recent evidence has started to suggest that interactions between the cancer cell and its
local environment play a significant role in multidrug resistance.
1.6.1 The genetics of chemoresistance
Cancer cells may acquire the ability to reduce intracellular levels of chemotherapeutic
agents by exporting the drug. It is now recognised that several ATP-driven efflux pumps
can occur, contributing to drug resistance. These include P-glycoprotein (PgP/MDR-1),
multidrug resistance-associated proteins (MRP2 - 7), breast cancer resistance protein
and lung cancer resistance protein (Biedler and Riehm, 1970;Kartner et al., 1983). The
genes for PgP and MRP have been cloned and it is clear that these pumps have a broad
specificity, from endogenous proteins such as leukotrienes, to drugs of different classes
(Gerlach et al., 1986;Cole et al., 1992). In both SCLC and ovarian tumours, even very
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low levels ofmRNA for PgP have been associated with resistance to chemotherapy and
PgP expression has been shown to be increased in tumours after treatment with
chemotherapy (Holzmayer et al., 1992). However, other studies in SCLC have
suggested that PgP expression is not necessarily a principal cause ofmultidrug resistance
- PgP mRNA was elevated in only four out of 23 SCLC cell lines and three out of six
primary tumours and never to very high levels; in addition, there was no correlation
between expression and response to therapy (Narasaki et al., 1996). MRP shows
elevated mRNA expression in a significant proportion (35%) of primary NSCLC, with
greatest expression in well-differentiated squamous cell carcinoma (Nooter et al., 1996).
The role of other drug transporter pumps is not yet clear. Breast cancer resistance
protein appears also to have a broad substrate ability and is associated with resistance to
methotrexate, mitoxantrone, topetecan and adriamycin in a variety of tumours (Doyle et
al., 1998;Lage and Dietel, 2000;Volk et al., 2000;Scheffer et al., 2000;Faneyte et al.,
2002). The lung cancer resistance protein localises to nuclear pore complexes and may
divert drugs from the nuclear target, rather than necessarily out of the cell. This has
been found to be elevated in chemoresistant NSCLC cell lines, acute myeloid leukaemia
and prostate and ovarian cancers (Scheffer et al., 1995;List et al., 1996;Volm et al.,
1997a;Volm et al., 1997b;Arts et al., 1999;Berger et al., 2000;Van Brussel et al., 2001).
Another way of dealing with a harmful drug is to detoxify it. An example of this is the
glutathiones-transferase system, in which toxic compounds are conjugated with
glutathione, prior to further metabolism and excretion (Salinas and Wong, 1999). It has
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been shown that this mechanism can protect against czs-platinum- and doxorubicin-
induced DNA damage in vitro, but although elevated levels of glutathiones-transferase
have been demonstrated in a number of cancers, including NSCLC, it is not clear how
important it is in vivo (Buser et al., 1997;Nakanishi et al., 1999).
Chemotherapeutic agents such as adriamycin and etoposide induce apoptosis by
inhibiting the nuclear enzyme DNA topoisomerase II. This enzyme normally regulates
DNA structure by cleavage of both strands, causing transient double strand breaks, and
subsequent reannealing at the cleavage site (Smith et al., 1994). By inhibition of the
second, reannealing part of this cycle, these agents permit the accumulation of DNA
strand breaks, leading to apoptosis via the final common pathway in which caspase-3
(formed from pro-caspase-3) cleaves the chaperone inhibitor of caspase-activated
deoxyribonuclease, triggering DNA fragmentation. Several mechanisms of
topoisomerase II multidrug resistance mechanisms are now known. It is usually due to a
reduction in both topoisomerase II level and activity, although still at a level allowing
cell survival (Lage et al., 2000;Kobayashi et al., 2001); mutations resulting in decreased
drug sensitivity have also been identified (de Jong et al., 1990). Again, it is unclear of
the clinical significance of this mechanism ofmultidrug resistance: although SCLC have
much higher levels of topoisomerase II than NSCLC and are much more etoposide-
sensitive, paradoxically other studies have shown worse chemotherapeutic responses
with higher levels of the enzyme in SCLC (Dingemans et al., 1999).
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1.6.2 The role of the tumour microenvironment
An immunohistochemical study of 23 resected SCLC samples revealed high levels of
fibronectin, collagen IV and tenascin in all samples (Sethi et al., 1999b). This high
expression was localized to the reactive, desmoplastic stroma around areas of tumour
infiltration and the basement membrane in these areas was markedly thickened by
comparison with normal, uninvolved lung. Additionally, in up to 25% of tumours,
fibronectin and laminin staining was visible within the tumour cells, suggesting that
SCLC cells may directly synthesize some of the components of their local ECM.
Therefore, SCLC in vivo is surrounded by a matrix rich in ECM components, which
might influence cell behaviour through cell surface receptors such as integrins (see
below). It was demonstrated that in vitro adhesion to laminin, fibronectin or collagen IV
strongly protected SCLC cells from chemotherapy-induced apoptosis by comparison
with cells non-specifically adhered to plastic. This protection was mediated through (31
integrins, since the effect was abrogated by co-incubation with function-blocking (31
integrin antibodies, but not with isotype-matched control antibodies.
This phenomenon of ECM-mediated chemoresistance appears to have general
application in cancers. An earlier report by Fridman et al. showed that matrigel and
laminin were able to enhance SCLC tumourigenicity and drug resistance in SCLC
(Fridman et al., 1990). In xenograft-derived endothelial cells, culture on gelatin,
collagen IV, laminin, fibronectin or the integrin ligand peptide Gly-Arg-Gly-Asp-Ser-
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Pro (but not the integrin peptide Gly-Arg-Ala-Asp-Ser-Pro) prevented etoposide-induced
DNA damage (Hoyt et al., 1996). Tumour-derived endothelial cells also exhibit
cytoprotection when plated on surfaces coated with antibodies to a5, pi or P3 integrin
subunits and by clustering of integrins by soluble antibodies. Myeloma cells adhered to
fibronectin are protected against chemotherapy-induced apoptosis in a mechanism
mediated through a4pl and a5pi integrins (Hazlehurst et al., 2000). In mammary
epithelial cells, apoptosis could be enhanced by antibodies to pi integrin or by
stromelysin-1, which degrades the ECM (Boudreau et al., 1995).
The intracellular signalling mechanisms mediating pi integrin-induced drug resistance
are beginning to be defined. Tyrphostin-25, a selective inhibitor of protein tyrosine
kinase (PTK), blocks adhesion-mediated drug resisitance in SCLC cells.
Phosphoinositide 3-kinase (PI 3-kinase) is an enzyme that acts as a direct biochemical
link between a phosphoinositide pathway and a number of proteins containing tyrosine
kinase activity. PI 3-kinase requires tyrosine phosphorylation for full activation and
would thus be a target for PTK activity. Protein kinase B (PKB) is a principal
downstream effector of PI 3-kinase, so the PI 3-kinase/PKB pathway may indeed be a
key mediator of integrin-induced chemoresistance. Both PI 3-kinase and PKB suppress
anoikis and the induction of chemotherapy-induced chemoresistance (Schmidt et al.,
2002). The introduction of a constitutively active form of PKB conferred resistance to
anoikis in mammary epithelial cells; the same construct inserted to A549 NSCLC cells
also resulted in profoundly decreased chemosensitivity to mitoxantrone and cisplatin.
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PKB has been shown by other groups to be constitutively activated in NSCLC and to
confer resistance to both radiation- and chemotherapy-induced apoptosis (Brognard et
al., 2001).
To better understand the mechanisms underlying the relationship between a cell and its
local environment, it is necessary to describe the key cellular proteins involved at this
interface. These are the integrin family of proteins and the following section will





Integrins are transmembrane receptor proteins that play a key role in cellular adhesion to
and communication with the extracellular matrix (ECM) (Tamkun et al., 1986). They
mediate signal transduction in both directions: extracellular ligand binding transmits
signals into the cell, controlling cytoskeletal events and gene transcription, so-called
"outside-in signalling"; conversely, intracellular signals influence the ability of integrins
to bind these ligands in a process called "inside-out signalling". By controlling cellular
adhesion integrins critically influence cell survival and cell motility and dysfunction of
integrin function has been shown to be the underlying problem with an array of human
diseases, including atherogenesis, cancer and clotting disorders.
All members of the integrin family comprise an alpha (a) and beta (p) type I
transmembrane subunit, non-covalently linked in the cell membrane. To date, a total of
18a and 8p subunits have been described in vertebrates. In vivo, the pairing of a and p
subunits is limited, such that only 24 different pairings have been identified (Plow et al.,
2000;Danen and Yamada, 2001). Early work assigned a confusing array of names to
these proteins, such as lymphocyte function associated antigen-1 (LFA-1, now aLp2),
macrophage-1 receptor (Mac-1, now aMP2) or very fate after activation (VLA) antigens,
but more recently a simplified nomenclature has been adopted, described by the a and p
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subunits involved (Hynes, 1987;Ruoslahti and Pierschbacher, 1987;Albelda and Buck,
1990;Hemler, 1990;Diamond and Springer, 1994;Schwartz et al., 1995).
There is considerable evidence of conservation of integrins through evolution. Families
of homologous proteins are described in Caenorhabditis elegans and Drosophila
melanogaster that are responsible for binding to ECM components, specifically laminin
and an Arg-Gly-Asp (RGD) motif, which is found in fibronectin, vitronectin and other
adhesion proteins (Felding-Habermann and Cheresh, 1993). Here they are responsible
for epidermal adhesion, muscle attachment, neurite outgrowth and tissue morphogenesis
(Zusman et al., 1990;Brown, 1994;Stark et al., 1997;Brown et al., 2000).
1.8 Integrin complexity
The integrins are now classified into subgroups, dependent upon their p subunit
interactions. Although integrins are expressed on almost all mammalian cells, the
integrin expression profile of cells varies markedly both between cells and within the
same cells under different conditions. For example, allbp3 integrins are expressed on
platelets, where they play a critical role in platelet aggregation. In addition, integrin
expression changes markedly under different cellular conditions, such as seen in
granulocyte maturation (Lund-Johansen and Terstappen, 1993), or during cellular
differentiation (Jiang and Grabel, 1995). Complexity and flexibility of the integrin
system is further increased by the presence of alternative splicing of some of the integrin
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subunits. Alternative splicing of intracellular domains has been described for pi, P3, P4,
a3, a6 and a7 subunits (Altruda et al., 1990;Suzuki and Naitoh, 1990;Cooper et al.,
1991;Hogervorst et al., 1991;Tamura et al., 1991 ;Languino and Ruoslahti, 1992;Collo et
al., 1993;Belkin et al., 1996), of which perhaps the most extensively described are the
pi variants, piA-D (Armulik, 2002). By tissue restriction and by modifying the
signalling role of the integrin, these vary the overall function of the integrin. For
example, piC appears to inhibit cell cycle progression, whilst plB may inhibit adhesion
during development and P1D, restricted to myocytes, plays a key role in adhesion and
inhibition of cell cycle progression (Balzac et al., 1993;Meredith, Jr. et al., 1995;Belkin
and Retta, 1998). Extracellular domain slice variants have also been described, for allb
and a7 (Bray and Shuman, 1990;Ziober et al., 1993).
1.9 Integrins: structure and ligands
Integrins all share a similar protein structure, based upon the interaction of a and P
subunits. Each subunit has a large (> 700 residue) NFE-terminal extracellular domain, a
single transmembrane region and a short cytoplasmic region of 13 - 70 residues (except
P4, where there is an extensive cytoplasmic tail of > 1000 amino acids)(Hynes, 1992).
Electron microscopy shows a globular head portion ligand binding domain, comprising
the NFl2-terminal portions of the a and p subunits. This is connected to the membrane
by two stalks, the C-terminal portions of the extracellular domains (Hantgan et al.,
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1999). Mutational analysis has shown that the cytoplasmic domains play a key role in
bi-directional signalling and loss of the (3 tail results in integrins that fail to localise to
focal adhesions, and show reduced ligand-binding and signalling ability (O'Toole et al.,
1994).
1.9.1 Extracellular ligands
The ligand binding potential of integrins is shown in Table lc. It is complicated by the
fact that one integrin may exhibit specificity for multiple ligands and, conversely, one
ligand may be bound by multiple integrins, either through the same recognition epitope
or different epitopes on the same ECM protein. The key ECM proteins interacting with
integrins are laminin, fibronectin, collagen and vitronectin; other important ligands
include the soluble protein fibrinogen, which plays a key role in coagulation, and the
cellular transmembrane proteins ICAM-1/2 and VCAM-1, which interact with integrins
to mediate cell-cell adhesion.
A key component of many of the macromolecules that act as integrin ligands is the
peptide sequence Arg-Gly-Asp (RGD), which has been identified as an essential epitope
for integrin binding, originally identified as the adhesive sequence in fibronectin
(Pierschbacher and Ruoslahti, 1984). Soluble RGD peptides can be used experimentally
to block fibronectin-integrin binding, but some monoclonal antibodies to RGD do not
inhibit platelet aggregation and recombinant fibrinogen lacking the RGD sequence can
still mediate aggregation (Cheresh et al., 1989). This suggests that other epitopes exist,
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Table lc: Integrin nomenclature and bindingpotential
Integrin Alternate names Extracellular ligands
aipi VLA-1, CD49a/ CD29 Laminin, collagen
a2pi VLA-2, CD49b / CD29 Laminin, collagen
a3pi VLA-3, CD49c / CD29 Laminin, collagen, fibronectin
a4pl VLA-4, CD49d / CD29 Fibronectin, VCAM-1
a5pl VLA-5, CD49e / CD29 Fibronectin, thrombospondin, Insulin-like growth
factor binding protein-1, Ll-CAM
a6pi VLA-6, CD49f / CD29 Laminin, disintegrin
a7pi Laminin
a8pi Fibronectin, tenascin-C, vitronectin, osteopontin
a9pl Tenascin-C
avpl Fibronectin, vitronectin, fibrinogen, Ll-CAM
avp3 Fibronectin, vitronectin, thrombospondin,
osteopontin, bone sialoprotein-1, fibrinogen, von
Willebrand factor, Ll-CAM
avP5 CD51 / CD61 Vitronectin
avp6 avPx, avps Fibronectin
avp8 Vitronectin
a6p4 Laminin
a4p7 avPp, PLAM-1 Fibronectin, VCAM-1, MAdCAM-1
O.ielP7 aEp7 E-Cadherin
allbp3 gpllb / Ilia Fibronectin, fibrinogen, von Willebrand factor, Ll-
CAM
aLp2 LFA-1, CD 11a/ CD 18 ICAM-1, ICAM-2
aMp2 Mac-1, CD1 lb / CD 18 C3bi (complement), fibrinogen, Factor X, ICAM-1
aXp2 P150/95 C3bi, fibrinogen
adp2 CDllc/ CD 18
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which confer ligand/integrin specificity, as have been identified for fibronectin and
fibrinogen (Plow et al., 2000).
The importance of these integrin-mediated cell-ECM and cell-cell interactions is
underlined by targeted knockout studies on integrins or their ligands (Hynes,
1996;Beauvais-Jouneau and Thiery, 1997). Many integrin knockouts are severe or lethal
- pi knockout mice die during embryogenesis soon after implantation (Fassler and
Meyer, 1995;Stephens et al., 1995), whilst P2 integrin knockouts suffer from impaired
leucocyte function and recurrent bacterial infections (Prince et al., 2001).
1.9.2 Proteins associated with the integrin cytoplasmic domain
Integrins were named for their perceived importance in linking the cell surface with the
cytoskeleton and an ever-increasing array of proteins has been associated with integrin
cytoplasmic domains, reflecting their diverse roles in cell signalling. These associated
proteins have been regularly reviewed and are summarized in Table Id (Liu et al.,
2000;Berditchevski, 2001). Some key features will be discussed here. The proteins
listed include actin-binding proteins, adaptor proteins, enzymes, a transcriptional co-
activator and proteins whose function remains unclear.
Integrin ft cytoplasmic domain binding proteins
Actin-binding proteins provide a fundamental link role between integrins and the
cytoskeleton and are critical in cell spreading, migration and matrix assembly. The first
32
Table Id: Integrin cytoplasmic domain binding proteins
Binding partner Integrin tail
Actin-bindingproteins
Talin piA, piD, p2, p3



















Rackl PI, P2, p5
WAIT-1 P7
JAB1 P2




DRAL/FHL2 a3A, a3B, a7A, p
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to be isolated was talin (Horwitz et al., 1986), which binds to both the p tail (Pfaff et al.,
1998) and also (in platelet allbp3 integrins) the allb tail (Knezevic et al., 1996).
Integrin mutants unable to bind talin are unable to localize to focal adhesions and fail to
accumulate F-actin following integrin clustering, strongly suggesting that talin connects
integrins to the cytoskeleton (Lewis and Schwartz, 1995). Other actin-binding proteins
include a-actinin and filamin and disruption of integrin binding to either of these
proteins disrupts focal adhesion formation. Filamin also acts as an important adaptor
protein for a number of signalling proteins that can regulate cytoskeletal dynamics, such
as RalA: in filamin-deficient melanoma cells RalA is incapable of generating filopodia
(Ohta et al., 1999).
Since integrins possess no intrinsic enzymatic activity, their ability to conduct bi¬
directional signalling requires binding of signalling proteins, or adaptor proteins that can
recruit such proteins. The best characterised of these are focal adhesion kinase and
integrin linked kinase, which will be discussed in more detail later. Another class of
signalling molecule is the cytohesin family, of which cytohesin-1 and -3 have been
identified as P2-tail-binding proteins (Kolanus et al., 1996;Korthauer et al., 2000).
Cytohesins have guanine nucleotide-exchange factor activity for the ADP ribosylation
factor (ARF) family of small GTPases (Ogasawara et al., 2000), which appear to be
important for integrin-mediated effects on cell spreading and adhesion (Geiger et al.,
2000). Adaptor proteins such as paxillin, Grb2 and She have also been shown to bind to
integrin P tails in vitro (Law et al., 1996), although paxillin also binds strongly to the a4
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integrin cytoplasmic domain and clearly modulates integrin-mediated signalling (Liu et
al., 1999a).
CD98 and p3-endonexin are both proteins that have been found to modulate integrin
ligand-binding affinity via their interactions with P integrin tails (Kashiwagi et al.,
1997;Zent et al., 2000), as will be discussed later. The novel protein TAP20 is 55%
homologous with p3-endonexin and binds and regulates p5 integrins, although this
would appear to be a suppression effect, rather than integrin activation as for p3-
endonexin (Tang et al., 1999).
Integrin a cytoplasmic domain bindingproteins
Whereas there is much sequence similarity between the p cytoplasmic domains, the a
cytoplasmic domains are dissimilar, except for a membrane proximal "hinge" region.
They are thus potentially critical for differentially regulating integrin-mediated responses
to extracellular stimuli. For example, the two P2 integrins expressed on lymphocytes,
aMP2 (Mac-1) and aLP2 (LFA-1) respond to the same chemokines differently, an effect
conferred by the cytoplasmic domains of aM and aL, which may be due to their
different abilities to bind to cellular components or to regulate P subunit signalling
(Weber et al., 1999).
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Of the a cytoplasmic domain-binding proteins, calreticulin is noteworthy for its ability
to bind the conserved KXGFFKR membrane proximal region of a number of a integrins,
both by co-immunoprecipitation and co-localization studies (Coppolino et al., 1995),
where it has been suggested that it may be able to modulate both integrin-mediated cell
adhesion and integrin-mediated signalling (Coppolino et al., 1997).
1.9.3 Integrins and tetraspanins
Tetraspanins are a family of over 26 proteins with four transmembrane domains,
implicated in a wide range of cellular behaviour, including motility and metastasis
(Boucheix and Rubinstein, 2001), proliferation and differentiation (Boismenu et al.,
1996). They were first associated with integrins in platelets, where the CD9-aIIbp3
complex was described in association with integrin activation (Slupsky et al., 1997), but
a large number of such integrin-tetraspanin complexes is now known (Berditchevski,
2001). The biochemical function of tetraspanins remains undefined. There is little to
suggest that tetraspanins are involved in cell-ECM attachments, such as focal adhesions,
but they do appear to be important in intercellular adhesion and in the initial transient
cell-substratum contacts that occur in lamellipodia during cell migration (Berditchevski
et al., 1997). A number of tetraspanins are physically associated with
phosphatidylinositol 4-kinase (Yauch and Flemler, 2000) or protein kinase Ca or pil
(Zhang et al., 2001). Tetraspanins may therefore be considered to act predominantly as
scaffold proteins or molecular facilitators, controlling the spatial organisation of
membrane complexes of integrins and signalling molecules (Maecker et al., 1997).
36
1.10 Integrin ligand binding sites
Figure 1.1 shows a schematic representation of integrin structure (Takagi and Springer,
2002), which appears to adopt a folded conformation in which the ligand-binding
headpiece is folded back onto the tailpiece of the molecule (Xiong et al., 2001).
Springer predicted that the N-terminal domain of all a subunits contains a seven-fold
repeat region, each repeat being -60 residues (Springer, 1997). These contain phenyl-
analyl-prolyl (FG) and glycyl-analyl-prolyl (GAP) consensus sequences (FG-GAP
repeats) (Corbi et al., 1987). Within these FG-GAP repeats are putative Ca2+ binding
domains, in repeat 4 in some integrins and in repeats 5-7 in all integrins (Tuckwell et al.,
1992). The predicted P-propeller structure for the a subunit contains seven p sheets
arranged pseudosymmetrically around an axis, each sheet containing four antiparallel P-
strands. The overall shape is cylindrical, with a pocket in the upper surface. That this
upper surface is critical for ligand binding is evidenced by mutational studies in a variety
of a subunits: mutations of residues Y187, W188 and G190 in the a4 subunit abrogated
binding to VCAM-1 and fibronectin (Irie et al., 1995); the same residues are involved in
ligand binding in a5 (Irie et al., 1995), allb (Kamata et al., 1996), and the same region
is involved in a4 binding to laminin. In all cases, the residues involved are present on
top of the p-propeller. Conversely, the monoclonal antibody CBRM1/20 is predicted to
bind to the bottom of the P-propeller of aMp2 (Mac-1), recognising residues 94
2+
positions apart in the primary structure. Although it requires Ca to bind, thereby
2+
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Figure 1.1: Structure of integrins
Upper panel. Organisation of domains within the primary structure of integrins. In some integrins there is an
extra I domain within the a subunit, as indicated by dotted lines. Asterisks denote Ca2+ (red) and Mg2+
binding sites (blue) respectively.
Lower panel. Representative structure of avp3, with the I domain added. Domains are colour-coded as for
the primary structure shown above.
Figures adapted from Takagi J. and Springer T.A. (2002).
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not itself inhibit ligand binding. These findings support the p-propeller model, which
would elegantly explain the proximity of these residues (Oxvig and Springer, 1998).
More recently, the p-propeller model has been confirmed in the crystal structure of avp3
(Xiong et al., 2001).
In at least eight integrins there is also a -200 residue I domain in FG-GAP repeat 3,
whose structure contains a fold similar to that found in nucleotide-binding proteins,
small G proteins and heterotrimeric G protein a subunits (Huang and Springer, 1995;Lee
et al., 1995a;Lee et al., 1995b). A hydrophilic linker segment is present on the C
terminal side of the I domain and suggests a hinge between the I domain and the P-
propeller domain. Within the I domain is a metal ion-dependent adhesion site (MIDAS),
2+
where two serines, a threonine and two water molecules coordinate Mg binding, and a
sixth coordination position is available to bind an acidic residue on the ligand. Residues
surrounding the MIDAS motif confer ligand specificity to LFA-1, suggesting that in I
domain-containing integrins, this is the ligand binding site (Huang and Springer, 1995).
Within the p subunit, a MIDAS motif has also been identified, predicted to fold in an I
domain-like manner, and thus likely to represent a ligand binding site on the p subunit
(Lee et al., 1995b). Like the p-propeller, this has now been demonstrated in the crystal
structure of avP3 (Xiong et al., 2001).
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The role of divalent cations in ligand binding has been controversial. The presence of
2+the MIDAS motif and putative Ca binding domains strongly suggests their central
importance. Early studies suggested that the divalent cation binding sites of the allb
chain were directly involved in ligand binding (D'Souza et al., 1991;Gulino et al.,
2+
1992;D'Souza et al., 1994) and early studies on allb(33 showed that removal of Ca
could induce subunit dissociation and inhibit ligand binding. However, in the absence of
Ca2+ but the presence of Mg2+ ligand binding appears to be stimulated in other integrins
such as avP3 (Dransfield et al., 1992;Hu et al., 1995;Hu et al., 1996). The
demonstration by Oxvig et al. that a Ca2+-dependent mAb bound to the bottom of the P-
propeller structure, away from the ligand binding site, suggested that cations might
influence binding indirectly (Oxvig and Springer, 1998). This is supported by other
work in a4pl integrins showing that mutations in divalent cation binding sites did not
impair binding of the soluble ligand VCAM-1, but did impair cellular resistance to
detachment under shear flow. This suggests that these cation binding sites influence
adhesion strengthening, but not necessarily initial ligand binding (Pujades et al., 1997).
1.11 Modulation of integrin-ligand binding - integrin activation
The ability of an integrin to interact with a ligand depends not only upon the ligand
specificity conferred by the ligand binding site, but also upon the biochemical state of
the integrin itself, its state of "activation". In a highly activated state, integrin-ligand
binding is greatly increased, whereas in the low activation (or suppressed) state, there is
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greatly reduced ligand-integrin interaction. This rapid switching between activated or
suppressed states is of fundamental importance to the functional effects of integrin-
ligand binding, controlling many biological responses, most classically cellular
migration and platelet aggregation. The activation status of integrins is therefore tightly
controlled by intracellular signalling events, which collectively comprise "inside-out
signalling" (Bazzoni and Hemler, 1998).
Integrin activation may be a result of two separate mechanisms termed "avidity
modulation" and "affinity modulation". Avidity modulation results from increased
concentrations of integrins within the plasma membrane, resulting in local increases in
integrin clustering. Affinity modulation results from a conformational change in the
individual integrin, producing a change in ligand binding affinity at the ligand binding
site.
1.11.1 Avidity modulation
Avidity modulation has been well described in p2 integrins, especially ocLp2 (LFA-1).
Activation of this integrin plays a key role in the response of leucocytes to injury or
infection, when they must migrate from the blood to the affected tissues. Although
initial adhesion to the vascular endothelial cells is via selectins, stronger adhesion is then
mediated by integrins like LFA-1 (Stewart and Flogg, 1996) (Lub et al., 1995). In
lymphocytes, a4p7 has been demonstrated to be capable of initiating adhesion and
tethering to lamina propria of veinules, in a selectin-independent manner (Berlin et al.,
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1995). It has been shown that cross-linking of the T-cell receptor (TcR)/CD3 complex
on T-cells causes rapid clustering of LFA-1 and enhanced LFA-1-mediated adhesion to
ICAM-1 molecules on the endothelial cells (Dustin and Springer, 1989). The
importance of this process is clear in the disease leucocyte adhesion deficiency-1, where
individuals lack a normal p2 subunit: unable to mount a satisfactory leucocyte response
to injury, they suffer from recurrent severe infections (Bunting et al., 2002). Avidity
modulation by integrin clustering has also been demonstrated to play a significant role in
the later, irreversible phase of platelet aggregation via allbp3 integrin (Fox et al.,
1996;Simmons andAlbrecht, 1996).
As would be predicted, avidity modulation is highly dependent on the actin cytoskeleton
and disruption of this by compounds such as cytochalasin D are able to inhibit both
integrin clustering and adhesion (van Kooyk and Figdor, 2000).
1.11.2 Affinity modulation
Affinity modulation has been demonstrated in the pi, P2, P3 and P7 families (Altieri et
al., 1988;Faull et al., 1993;Crowe et al., 1994) and has been studied most extensively in
platelets, where the allbp3 integrin is pivotal in the process of platelet aggregation
(Shattil et al., 1998). Platelets normally circulate as non-nucleated single, non-adherent
cells. However, at points of endothelial injury they will adhere to exposed extracellular
matrix by an integrin-independent process. This attachment triggers an intracellular
signalling cascade, resulting in a rise in intracellular ADP and triggering a
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conformational change in the allbp3 integrin, whose normal ligand is fibrinogen (Shattil
et al., 1985). In the suppressed state found in quiescent platelets, allb(33 does not bind
fibrinogen, but following integrin activation an activated platelet will bind
approximately 45,000 fibrinogen molecules per cell, all of which may act as links to
more platelets or the extracellular matrix. Initial ligand binding must occur to surface-
expressed allbp3, but internal pools of allbp3 are then released from a-storage
granules, which further contribute to ligand binding and platelet aggregation (Nurden et
al., 1996). Thus activation of the allbp3 integrin is central to the cascade of platelet
aggregation and thrombus formation.
Shattil et al. were able to identify the high affinity state allbp3 fibrinogen receptor with
a highly specific, ligand-mimetic, monoclonal antibody, PAC1 (Shattil et al., 1985).
This has facilitated further study of affinity regulation: the presence of the RGD
sequence in the heavy chain of the PAC1 antibody allows specific recognition of the
high affinity state (Kunicki et al., 1996). PAC1 binding is independent of the degree of
integrin clustering, since PAC1 Fab fragments also recognise the high affinity state;
however, PAC1 Fab binding does not generate intracellular tyrosine phosporylation
(Abrams et al., 1994). Using PAC1 binding as a marker for integrin activation, it has
been shown that allbp3 can be activated by multiple platelet agonists such as thrombin,
ADP, adrenaline and thromboxane A2 (Shattil et al., 1998). Activation does not rest on
biochemical changes to the ligand binding site, since the chemical structure remains
identical between the activated and suppressed states (Yan and Smith, 2000). However,
43
there is now good evidence that conformational changes occur on activation, witnessed
by an increase in resonance energy transfer seen between fluorochromes labelling the
allb and P3 subunits, suggesting a closer proximity of the labels (Sims et al., 1991).
The mechanisms of this conformational change, together with the cellular triggers that
govern them, are now being elucidated.
It has become clear that the interaction of the a and |3 cytoplasmic domains is central to
the regulation of activation (O'Toole et al., 1994). In the membrane proximal regions of
all a and most P subunits there are conserved amino acid sequences, GFFKR and LLv-
iHDR respectively (Figure 1.2). Deletion of these regions activates integrins,
independently of cell type or physiological signalling pathways, suggesting that this
"hinge" region acts as a structural constraint that normally locks integrins into a default
state of low affinity (Crowe et al., 1994;0'Toole et al., 1994). This may be due to
charge interactions between the a and P subunits whose membrane proximal regions lie
closely associated with each other (Lu et al., 2001). For allbp3, a salt bridge is
QQC \
proposed between allb Arg and P3 Asp (Hughes et al., 1996). Using a lipid vesicle
model, Vinogradova et al. have shown that the allb cytoplasmic domain adopts a closed
formation with its COOH-terminal acidic region, but mutations inducing activation of
allbp3 open this closed conformation (Vinogradova et al., 2000). At present, studies








Figure 1.2: Membrane-proximal region and cytoplasmic tail of integrin heterodimers
The cytoplasmic tail region starts with the first charged lysine (K) residue adjacent to the transmembrane
domain. The highly conserved membrane-proximal residues (red shading) form a putative "hinge" region,
maintaining a low affinity default state. Additional conserved regions in the P integrin tail, such as the NPXY
and NPXF motifs (green shading), act as important binding regions for cytoskeletal and regulatory proteins.
Highly conserved amino acid residues are shown in capital letters; lower case letters represent residues
conserved in three or more subunits; - = non-conserved residue/gap; O = hydroxylated residue; n and O
represent apolar and polar residues, respectively. (From Hughes et al., 1996.)
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which may be due to different methodologies (Ginsberg et al., 2001;Li et al.,
2001b;Weljie et al., 2002).
The cytoplasmic interactions are transduced to the extracellular domains via the
transmembrane domain. The transmembrane domain begins after an extracellular
proline residue. There then follows a stretch of hydrophobic residues, culminating in a
positively charged amino acid, arginine or lysine. This is generally followed by a short
stretch of hydrophobic residues, so that the K/R is flanked by hydrophobic regions - this
is felt to be the beginning of the cytoplasmic domain (Williams et al., 1994). It is likely
that the 4-6 residue hydrophobic stretch just COOH-terminal to the conserved K/R is
membrane-embedded, at least in some integrin subunits such as a2, a5, pi and p2
(Armulik et al., 1999). Changes in the hydrophobicity of this region, such as are seen in
some activating mutations (O'Toole et al., 1994;Hughes et al., 1996), may alter the
length of the transmembrane domain itself in a "piston-like" motion, with resultant
conformational changes in the extracellular domain (Williams et al., 1994;Liddington,
2002). In this context, it is noteworthy that there are proteins known to bind to integrin
cytoplasmic tails, such as talin and cytohesin-1, and that cytohesin-1 binds to p2 integrin
at the conserved hydrophobic region (Nagel et al., 1998). The intracellular signals
thought to regulate integrin activation will be described in more detail below.
In the extracellular domain, three major regions have been implicated in ligand binding.
In the a subunit these are the P propeller, whose upper surface contains a ligand-binding
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site (Xiong et al., 2002) and, in many a subunits, the I domain, with its MIDAS motif
(Lee et al., 1995b). Finally, P subunits also contain a MIDAS motif predicted to be part
of an I-like domain (Lee et al., 1995b) and demonstrated in the crystal structure of avp3
(Xiong et al., 2002). Studying the way collagen binds to a2pl, Emsley et al. have
described how conformational changes in the a2 I domain are induced by ligand
binding. A 10A shift in the COOH-terminal helix of the I domain allows a strong bond
2+
to be formed between the Mg of the MIDAS motif and a glutamic acid in collagen
(Emsley et al., 2000). Similar conformational changes probably underpin affinity
regulation. Loftus et al. have proposed a model for integrin activation in platelets in
which the I-domain-like region of p3 is incapable of binding ligand in resting platelets,
but occludes the ligand binding site of the allb subunit. Activation then causes a
conformational change in the P3 I-domain-like region, exposing its ligand binding site,
and causing unmasking of the allb binding site (Loftus and Liddington, 1997) (Figure
1.3). Following the publication of the crystal structure of avP3 (Xiong et al.,
2001;Xiong et al., 2002), Liddington et al. have suggested that following activation,
initial ligand binding is to the exposed MIDAS domain of the p I-like domain.
Occupancy itself activates integrins with structural changes (Du et al., 1993). These
conformational changes result in a loosening of contacts between the p I-like domain
and the a subunit propeller and a separating of the head pieces of the a and P subunits.
This supports other work suggesting that the activated state requires separation of the




Figure 1.3: Schematic of high affinity binding in integrin allbp3
Schematic diagram demonstrating an overhead view of integrin allbp3 in the low affinity {above) and high
affinity states {below). In the low affinity state the p-propeller of the a subunit contains divalent cations (Q)
and ligand binding sites ( )that are partially masked by the overlying p subunit. Platelet activation results in
inside-out signals that cause conformational changes, such that the P3 I domain ligand binding site becomes
exposed and the orientation of the p and a subunits alters, exposing the binding sites on the a subunit for high





With the two head pieces separated, the ligand binding epitopes become fully exposed
and ligand binding affinity becomes maximised.
1.11.3 Inside-out signalling
A limited number of proteins have been demonstrated to influence integrin affinity. In
itself, integrin affinity modulation is best measured by binding of soluble ligand, such as
fibronectin, or ligand-mimetic antibodies such as PAC1, in order to distinguish it from
avidity changes (Hughes and Pfaff, 1998).
G-protein-coupled receptorpathways
In platelets, the affinity of the ocIIb(33 integrin has been shown to be upregulated by
ADP, thrombin, collagen and adrenaline (Bennett and Vilaire, 1979), which bind to G-
protein-coupled receptors. Several important signalling cascades may result from this.
One is the activation of phospholipase Cp by the activated a subunit of Gq. This results
in hydrolysis of phosphatidylinositol and the generation of diacylglycerol and IP3;
platelets in mice that are Gaq null fail to aggregate in response to thrombin, ADP or
thromboxane A2 agonists (Offermanns et al., 1997). The link between the generation of
IP3 and diacylglycerol and integrin activation remains unclear. IP3 stimulates a rise in
intracellular Ca2+, although this is not sufficient for activation (Shattil and Brass, 1987),
whilst diacylglycerol stimulates activation through protein kinase C (Shattil et al., 1992).
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G-protein-coupled receptors also activate a number of nonreceptor protein tyrosine
kinases, such as Src, Syk and Pyk2 (Jackson et al., 1996;Raja et al., 1997). Tyrosine
phosphorylation or dephosphorylation events are likely to be important in inside-out
signalling, since tyrosine kinase inhibitors inhibit fibrinogen binding in platelets,
whereas protein tyrosine phosphatase inhibitors enhance platelet activation (Jackson et
al., 1996). One key target for tyrosine kinases might be phosphoinositide 3-kinase,
which phosphorylates PI(4)P and PI(4,5)P2 to PI (3,4)P2 and PI(3,4,5)P3 respectively. PI
3-kinase can be co-immunoprecipitated with the protein tyrosine kinases Src and Syk in
activated platelets (Rittenhouse, 1996). Inhibition of PI 3-kinase reduces platelet
aggregation and allb(33 activation in response to agonists (Rittenhouse, 1996;Zhang et
al., 1996a), suggesting that PI 3-kinase is an activator of integrins, possibly via isoforms
of PKC that are found in platelets (Toker and Cantley, 1997). Other potential links
between PI 3-kinase and integrins include proteins that contain pleckstrin-homology
(PH) domains and are therefore targets for the PI 3-kinase product PI(3,4,5)P3, such as
cytohesin-1. Cytohesin-1 is known to interact with the P2 cytoplasmic domain of aLp2
(Kolanus et al., 1996) and PI 3-kinase activation is associated with recruitment of
cytohesin-1 to the plasma membrane where it may interact with the P2 cytoplasmic
domain (Nagel et al., 1998). However, in CHO cells PI 3-kinase does not appear to be
such a critical activator of integrins (Oertli et al., 2000) and it may be that PI 3-kinase is
more important for outside-in signalling than for affinity modulation.
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Ras proteins
Several members of the Ras superfamily of GTP-binding proteins have been shown to
play important roles in integrin affinity regulation. They are also key components of the
multitude of downstream signalling cascades for outside-in signalling (see below).
The ras gene was first identified in viral-induced rat sarcomas, from which the Harvey
and Kirsten strains of murine sarcoma retrovirus were isolated (HARVEY, 1964;Kindig
and Kirsten, 1967). The viral oncogenes were derived from normal 21kDa rat cellular
proteins, Harvey-Ras (H-Ras) and Kirsten-Ras (K-Ras) and the dominant oncogenes of
several human tumours were found to be mutant forms of the ras gene, homologous to
the viral W-ras and K-ras (Bos, 1989). N-Ras was later identified in a neuroblastoma
cell line (Shimizu et al., 1983). The ras genes are all highly conserved between species
and the promoter sequence suggests they are cellular housekeeping genes, each of
importance. The Ras proteins consist of 189 residues, of which 1-86 are identical and
87-164 are highly homologous; the terminal 25 residues represent the "hypervariable
domain", where the sequences diverge. The proteins bind guanine nucleotides and have
an intrinsic GTP-ase activity: they cycle between an active GTP-bound state and an
inactive GDP-bound state (Bourne et al., 1990). Since the vast majority of Ras within
the cell is in the inactive GDP-bound state (Scheele et al., 1995), activation results in
replacement of GDP by GTP, by means of guanine exchange factors (GEFs) such as
SOS (Quilliam et al., 1995). GTP is then hydrolysed back to GDP by the intrinsic
GTPase activity under the control of GTPase Activating Proteins (GAPs) that stimulate
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this hydrolysis. Whilst in the active GTP-bound state Ras triggers downstream events in
a variety of signalling pathways.
Using the chimeeric integrin aIIba6aP3pi in CHO cells, Hughes et al. identified H-Ras
and its effector kinase Raf-1 as key players in a pathway that suppressed integrin
activation without influencing integrin phosphorylation, mRNA translation or protein
synthesis (Hughes et al., 1997). This suppression also involved activation of the
ERK/MAP kinase pathway, although subsequent evidence has thrown doubt over the
necessity for ERK/MAPK activity for affinity modulation (Hughes et al., 2002). In
other cell lines, ectopic expression of a constitutively active H-Ras induced activation of
the a4pi and a5pl integrins, independent of MAPK activation, but dependent upon
phospholipase C activation (Shibayama et al., 1999;Liu et al., 1999b). Further, in
marrow-derived mast cells, H-Ras again activated a5pi, but in these cells activation was
dependent upon PI 3-kinase, being inhibited by wortmannin (Kinashi et al., 2000). It
seems likely, therefore, that H-Ras affinity modulation of integrins is dependent upon
the target integrin, the cell type and the upstream activators involved.
By contrast, the closely related Ras subfamily protein R-Ras, which has more than 50%
homology to H-Ras but also has a 26 amino acid N-terminal extension, has so far been
shown only to activate integrins. Zhang et al. showed that expression of activated R-Ras
converted cells that normally grew in suspension into highly adherent cells and
upregulated integrin-ligand binding (Zhang et al., 1996b). Since then, the mechanism by
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which R-Ras activates integrins has been sought. In CHO cells, Sethi et al. showed that
R-Ras did not directly activate integrins, but antagonized the effects of H-Ras
suppression in these cells (Sethi et al., 1999a). This antagonism did not appear to be
mediated through simple competition for the same downstream Raf pathway effectors,
although R-Ras and H-Ras can both bind Rafl, Ral-GDS and PI 3-kinase (Urano et al.,
1996;Marte et al., 1997;Rodriguez-Viciana et al., 1997). Mutational studies suggest that
despite the homology of their effector loop binding domains, R-Ras and H-Ras couple to
and activate their common effectors in different ways (Oertli et al., 2000). In addition,
R-Ras can stimulate PI 3-kinase activity, supporting other data that implicates PI 3-
kinase in integrin affinity activation (see above) (Marte et al., 1997;Marte and
Downward, 1997).
The small GTP-binding protein Rho may also play a role in integrin activation.
Inhibition of Rho by C3 exoenzyme blocks a4pi-dependent adhesion of lymphocytes
and aLP2-dependent adhesion of neutrophils to VCAM-1 and fibrinogen respectively
(Laudanna et al., 1996); however, in platelets, where C3 exoenzyme blocks platelet
aggregation in response to thrombin, no evidence has been found that this is through
allbp3 integrin affinity modulation and it has been suggested that Rho effects may
therefore be mediated through cytoskeletal regulation or avidity modulation, rather than
affinity modulation (Morii et al., 1992;Leng et al., 1998).
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Rap-1 is another member of the Ras family of small GTPases and recently this was
reported to activate LFA-1 integrin in a nonadherent, lymphoid cell line (Katagiri et al.,
2000). This activation involved changes in conformation, affinity and adhesion to
ICAM-1, but was not dependent upon PI 3-kinase activation.
CD98 and galectin-3
CD98 is a disulphide-linked 125 kDa heterodimeric membrane glycoprotein that is a
ubiquitously expressed cell surface antigen, highly conserved between species. Early
studies of peripheral blood T and B-lymphocytes implicated CD98 in the regulation of
cellular activation, but did not define a specific function (Haynes et al., 1981). It is
highly expressed in the foetus, but expression thereafter diminishes. In the adult,
however, CD98 appears to be upregulated in proliferating cell populations and
particularly in tumours (Warren et al., 1996;Diaz, Jr. and Fox, 1998).
CD98 has also been identified as a unique and highly specific regulator of integrin
affinity, using a cloning strategy based upon changes in integrin affinity to identify
potential modulators of integrin activation (Fenczik et al., 1997b). pi integrin-mediated
adhesion of the SCLC cell line H345 to fibronectin and laminin can be markedly
upregulated by cross-linking CD98 (Fenczik et al., 1997b). Other studies also implicate
CD98 in the regulation of integrin-mediated cell adhesion. In breast cancer cell lines,
a3pi-mediated adhesion to thrombospondin-1 was upregulated by cross-linking CD98
(Chandrasekaran et al., 1999b). In the promonocyte U937 cell line, attempts have been
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made to tease apart the interaction between CD98 and pi integrins in cell adhesion:
ligation of CD98 induced adhesion that was at least partly mediated through pi
integrins, since some pi integrin antibodies (but not all) were able to inhibit the effect
(Cho et al., 2001). In lymphocytes, CD98 ligation induced aLp2/ICAM-l mediated cell
adhesion via PI 3-kinase (Suga et al., 2001). There is therefore accumulating evidence
for an important role for CD98 in regulating integrin-mediated adhesion.
Putative ligands for CD98 include galectin-3, a member of a family of carbohydrate-
binding proteins. Using lysates from a murine macrophage cell line, Dong and Hughes
isolated a number of glycoproteins that bound to galectin-3, of which CD98 was one
(Dong and Hughes, 1997). Galectin-3 was initially described as the Mac-2 antigen,
when it was shown to be upregulated on murine peritoneal macrophages, specifically in
response to stimuli such as thioglycollate (Springer, 1981;Ho and Springer, 1982).
Galectin-3 is synthesized without a signal sequence and lacks a transmembrane
sequence, yet it is able to be secreted from the cytoplasm via pathway independent of the
endoplasmic reticulum and may be found at the cell surface (Sato et al., 1993).
Galectin-3 exists as a monomer and it has been shown to self-associate and form
polymers through interactions of either its N-terminal domain (Birdsall et al., 2001) or
its C-terminal domain (Yang et al., 1998), giving rise to a potential to cross-link CD98 at
the cell surface. Like CD98, galectin-3 is upregulated in T-lymphocytes in response to
mitogenic stimuli, such as 11-2, 11-4 or 11-7 (Joo et al., 2001). There is no clear evidence
directly linking galectin-3 to integrin affinity modulation, although early work noted that
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at relatively high concentrations galectin-3 inhibited adhesion and spreading of baby
hamster kidney cells to laminin, suggesting a possible influence on integrin function
(Sato and Hughes, 1992).
PEA-15
PEA-15 is a small death effector domain-containing protein that was isolated using a
cDNA expression cloning screen designed to isolate proteins able to reverse H-Ras-
mediated integrin suppression (Ramos et al., 1998). Interestingly it did this through a
pathway blocked by a dominant negative mutant of R-Ras, suggesting that R-Ras acts
downstream of PEA-15. Subsequently, PEA-15 has been shown to activate the MAPK
kinase and ERK pathway in a Ras-dependent manner, bypassing the usual anchorage
dependence of ERK activation (Ramos et al., 2000). This effect was independent of its
effect on integrin activation, but suggests that PEA-15 is able to protect against
apoptosis and to enhance Ras-ERK signalling, and may thus play an important role in
oncogenesis.
163-endonexin
P3-endonexin has been identified as a regulator of allbp3 integrin, the key platelet
integrin. It was initially identified in a yeast two-hybrid system as a novel protein that
bound p3 integrin cytoplasmic tails in a manner that was integrin subunit specific, since
it did not bind to allb, pi or P2 integrins (Shattil et al., 1995). CHO cells transfected
with p3-endonexin demonstrated an increase in PACl-aIIbp3 binding and increased
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fibrinogen-dependent aggregation (Kashiwagi et al., 1997). Again using a yeast two-
hybrid system, it has been shown that p3-endonexin binds to the p3 integrin cytoplasmic
domain through motifs located in the membrane-proximal and membrane-distal regions
of the P3 integrin tail (Eigenthaler et al., 1997). Experiments with chimaeric integrin
cytoplasmic tails suggest that these motifs are sufficient to confer specificity of binding
with p3-endonexin.
1.12 Cellular roles for integrins
An expanding number of roles are now understood to be dependent on integrins and it is
apparent that they are critical to key cellular processes, including cellular survival.
1.12.1 Adhesion
Cellular adhesion was the role in which integrins were initially identified in the 1980s
and ranges from adhesion of cell layers in Drosophila wing (Brown, 1994) to egg
fertilization, by interaction between a6pi on the oocyte and the sperm disintegrin
receptors (Almeida et al., 1995). Integrin-mediated adhesion occurs at an intercellular
level, but most prominently it occurs between cells and extracellular proteins - such as
fibrinogen in the case of thrombus formation - or components of the extracellular
matrix.
Cell-extracellular matrix interactions are critical for the survival and function of normal
epithelial cells. Not only does adhesion generate important cell survival signalling, but it
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permits a structural integrity between the ECM and the cell cytoskeleton which is critical
for biological roles such as cellular migration and cell growth. Adhesion occurs via
integrins at specialised sites called focal adhesions (FAs) or focal contacts (FCs). The
larger FAs are located at the ends of actin stress fibres; FCs are located at the tips of
extending filopodia and lamellipodia (Petit and Thiery, 2000). Both sites comprise a
number of molecules linking the cytoplasmic tails of ligand-bound integrin to the
underlying actin cytoskeleton. This protein complex is essential for integrin-mediated
signalling, both "inside-out" and "outside-in". It is also critical for the generation of
physical tension within the cell, without which cells are unable to migrate.
Lauffenburger and Horwitz (1996) argue that cell motility is a balance between
contractile forces pulling the cell forward over a surface and adhesive forces between the
cell and substratum. If the adhesive forces are too strong the cell becomes unable to
move, but if there is too little adhesion no tensile force can be generated to transmit to
the cytoskeleton and allow movement (Lauffenburger and Horwitz, 1996). These
models predict a bell-shaped curve for the rate of migration against the strength of cell
adhesion. Some credence is lent to this proposal, since it has been demonstrated that
high affinity integrin activity can impair cell migration at a given ligand concentration
(Palecek etal., 1997).
Formation of FAs follows ligand-induced integrin clustering and requires Rho activity
(Ridley and Hall, 1992;Hotchin and Hall, 1995). Actin-binding proteins such as talin,
filamin and a-actinin, together with focal adhesion kinase (FAK) form a complex with
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integrin cytoplasmic tails (Miyamoto et al., 1995a;Miyamoto et al., 1995b;Schaller et
al., 1992;Hanks et al., 1992). This induces FAK activation and autophosphorylation,
producing an SH2 binding domain capable of recruiting Src kinase (Schaller et al.,
1992;Schaller et al., 1999). Src kinase activity results in tyrosine phosphorylation of
FAK, inducing the formation of SH2 and SH3 binding sites for a variety of signalling
proteins, including pl30cas/crk (Vuori et al., 1996) and Grb2/SOS (Schlaepfer et al.,
1994;Wary et al., 1996), through which integrins influence fundamental cellular
behaviours such as cell cycle progression in response to mitogens (Giancotti and
Ruoslahti, 1999).
1.12.2 Migration and invasion
There is extensive evidence that integrins play a key role in cell migration. As discussed
above, they provide a key link to the actin cytoskeleton and the involvement of different
integrins in migration has been demonstrated in a number of cell types. Leucocyte
adhesion to epithelial cells via aLP2 (LFA-1) has already been discussed; there is also
strong evidence that other, non-P2 integrins, such as a4pi (VLA-4), a5pi (VLA-5) and
avP3, play a key role in the subsequent migration of leucocytes across the endothelium,
through extracellular matrix and on to sites of inflammation (Sixt et al., 2001;Burns et
al., 2001). In asthma a4pi also seems to be important for an eosinophilic migratory
response (Bocchino et al., 2000). Monocyte migration has been shown to be dependent
on a combination of Mac-1, aLp2 and a4pi, since blockade of these three effectively
inhibits monocyte accumulation at inflammatory sites (Issekutz, 1995).
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Integrins play a key role in embryonic development, in a manner that is likely to be
exquisitely timed and regulated. Administration of RGD peptides or monoclonal
antibodies directed against avpi integrins disrupts migration of avian cranial neural
crest cells (Bronner-Fraser, 1985;Darribere et al., 1990), whereas truncal neural crest
cell migration appears to be dependent more on avp3 and avp5 (Delannet et al., 1994).
The pi integrins are also implicated in migration of retinal ganglion cells (Cann et al.,
1996), oligodendrocytes (Milner et al., 1996) and glioma cells (Friedlander et al., 1996).
These events represent controlled invasion, but integrins are equally implicated in
invasion in disease states, such as neoplasia (see below).
1.12.3 Cellular proliferation and differentiation
There is considerable evidence that integrins are important in cellular proliferation.
Optimal growth factor signalling in many cell lines is only seen in adherent cells
(Khwaja et al., 1997;Short et al., 1998), whilst Bohmer et al. have reported that in
human fibroblasts adhesion is required throughout most of the G1 phase when mitogen
stimulation occurs (Bohmer et al., 1996). Extracellular matrix adhesion increases the
number of PDGF receptors by blocking their ubiquitin-dependent degradation (Baron
and Schwartz, 2000). Some integrins physically associate with growth factor receptors,
such as the PDGF, insulin and VEGF receptors with avP3, or pi integrins with the EGF
receptor (Giancotti and Ruoslahti, 1999). T cell proliferation has been shown to result
from cross-linking of a4pi, a5pi and a6pi (Davis et al., 1990;Shimizu et al., 1990);
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for thymocytes, a3(31 and a6pi are costimulatory for anti-CD3-induced proliferation
(Chang et al., 1995). These proliferative responses are specific to the integrin
heterodimer and are not universal: for example, the piC and plD cytoplasmic domain
splice-variants appear to be inhibitory to proliferation (Meredith, Jr. et al., 1995;Belkin
and Retta, 1998;Meredith, Jr. et al., 1999).
Integrin-mediated effects on the cell cycle are mediated through the plethora of outside-
in signalling pathways that are regulated by integrin-ligand binding. Although complex
and not yet fully understood, some signalling cascades linking integrins to the cell cycle
machinery have been established. These include stimulation of focal adhesion kinase
(FAK), pl30cas and paxillin, phosphoinositide 5-kinase and the Na+/H+ antiporter
(Schwartz et al., 1995). Integrin and growth factor receptor signalling results in
upregulation of cyclin-Dl and downregulation of Cdk-2 inhibitors (Fang et al.,
1996;Roovers and Assoian, 2000). Of these pathways, FAK signalling is most clearly
understood and has been shown to be required for cell cycle progression through G1
phase, in part by activating Jun kinase (Oktay et al., 1999). Integrin-mediated FAK
activation may also potentiate growth factor signalling by impinging on other pathways
such as the ERK/MAP kinase cascade (Renshaw et al., 1999). It seems likely that
sustained ERK signalling as a result of integrin and growth factor stimulation is
necessary for upregulation of cyclin D1 expression (Roovers and Assoian, 2000). It has
also been shown that PI 3-kinase is necessary for expression and stability of cyclin D1
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and integrins are known to regulate PI 3-kinase activity (Gille and Downward,
1999;Takuwa et al., 1999).
Whilst most integrins appear to promote cell proliferation, there are areas where this has
been found not to be the case and where integrin- or matrix-specific effects are seen. For
example, elevated a6(31 levels in myoblasts inhibit ERK and promote withdrawal from
the cell cycle and differentiation (Sastry et al., 1999). In fibroblasts and endothelial
cells, a2pi stimulation does not promote proliferation either (Wary et al., 1996),
although this may be a cell-specific effect, since it has been shown to promote mammary
epithelial tube formation (Zutter et al., 1999).
Cellular adhesion has been shown to be important in tissue morphogenesis, with changes
in cellular phenotype associated with changing integrin expression patterns. Disruption
of the cell-ECM interactions results in disrupted tissue development and has been shown
in a variety of contexts, including submandibular gland (Kadoya et al., 1995), kidneys
(Wada et al., 1996), mammary epithelium (Streuli et al., 1991) and myoblast
differentiation (Sastry et al., 1996).
1.12.4 Anoikis and programmed cell death
Programmed cell death, or apoptosis, has been described since the early 1980s. The key
features are a massive destruction of DNA by intranucleosomal cleavage, with
condensation of chromatin and nuclear fragmentation (Hengartner, 2000). In vivo,
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apoptotic cells are rapidly recognised and phagocytosed, thereby minimising the release
of harmful intracellular proteases and bystander damage. A variety of signals, including
intracellular stress and receptor-mediated signals, feed into the evolutionarily conserved
caspase family of cysteine-proteases; these converge on the "final common pathway"
involving activation of caspase-3 and its downstream effectors. The subject has been
extensively reviewed and an overview will be given here (Kaufmann and Hengartner,
2001;Assuncao and Linden, 2004).
The three major pathways leading to caspase-dependent apoptosis are illustrated in
Figure 1.4. (i) The death receptor pathway involves cell surface receptors, such as
Fas/CD95, whose ligation promotes the binding of adaptor molecules and then binding
and cleavage of procaspase-8 (Budihardjo et al., 1999). Activated caspase-8 then
directly cleaves and activates procaspase-3, or it may cleave the Bcl-2 family protein
Bid, to stimulate the mitochondrial pathway to apoptosis. (ii) In the mitochondrial
pathway, Bcl-2 family cytoplasmic proteins such as Bax and Bak translocate to and
insert into the mitochondrial membrane, promoting release of cytochrome c (Burlacu,
2003). This promotes the assembly of Apaf-1 and procaspase-9 into the apotposome,
which is then capable of cleaving and activating procaspase-3. Mitochondrial
cytochrome c release may occur as a result of DNA damage, (iii) A third pathway
involves regulation of anti-apoptotic proteins such as Inhibitor of Apoptosis Protein
(IAP), which normally bind to and inhibit active caspases-3, -7 and -9 (Salvesen and




Figure 1.4: Pathways regulating caspases in apoptosis
Figure summarising the three major pathways regulating leading to caspase-3 activation. The death receptor
pathway is initiated by activation of a number of cell surface death receptors, such as Fas/CD95, tumour necrosis
factor-a receptor 1, and death receptors 4 and 5. Activated caspase-8 provides a link with mitochondrial
pathways, by cleaving Bid. The truncated C-terminal fragment of Bid (bid) interacts with other Bcl-2 family
proteins to promote the release of cytochrome c (c) into the cytoplasm; here it forms a tetrameric complex with
procaspase-9, the apoptosome. Both the apoptosome and caspase-8 activate caspase-3, triggering apoptosis. A
second mitochondrial pathway arises by the release of SMAC, which sequesters inhibitor of apoptosis proteins
(IAPs), thus promoting caspase-3 cleavage. Adapted from Kaufman SH (2001) and Abraham MC (2004).
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through activity of SMAC/Diablo ("Second Mitochondrial Activator of Caspases"),
which itself is released from the mitochondria.
Caspase-independent pathways to programmed cell death also exist, since caspase
inhibition does not always block programmed cell death with apoptotic morphology
(Mateo et al., 1999;Assefa et al., 2000). Proteins that mediate these alternative cell
death pathways include apoptosis-inducing factor (Joza et al., 2001), endonuclease G (Li
et al., 2001a) and leucocyte elastase inhibitor-DNase II (Torriglia et al., 1999).
It has been recognised that cells require constant stimulation form their environment to
suppress their constitutive apoptotic pathway, since almost all cells (in a mouse model)
can be induced to undergo apoptosis (Weil et al., 1996). This environmental stimulation
may take the form of soluble factors, cell-cell contact or cell-ECM interactions, where it
has been termed "anoikis". ECM-dependent growth, or anchorage-dependence, has
important developmental functions, such as allowing the generation of hollowed-out
canals, like the vertebrate semicircular canals (Coucouvanis and Martin, 1995;Fekete et
al., 1997), and in preventing the survival of cells in an inappropriate environment. The
signals regulating anchorage dependence are mediated through integrins at the focal
adhesions and are intimately related to those that regulate cell proliferation, described
above. Activated FAK supports anchorage-independent cell survival, since transfection
of constitutively activated FAK rescues epithelial cell lines from anoikis (Frisch et al.,
1996), as do protein tyrosine phosphatase inhibitors such as vanadate (Meredith, Jr. et
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al., 1993). PI 3-kinase activation appears to be an important component of the cell
survival signal in many cell types (Khwaja et al., 1997) and other groups have suggested
that in some cell lines an increase in Bcl-2 expression upon attachment to fibronectin is
critical (Zhang et al., 1995;Frisch et al., 1996). In mammary epithelial cells pi-
mediated adhesion to ECM suppresses activity of caspase-1 (or interleukin-1 -converting
enzyme, ICE), providing a direct link to inhibition of the apoptosis pathway (Boudreau
et al., 1995).
More recently, it has been proposed that, whilst integrin-mediated cell signalling may
indeed promote survival, an alternative would be that unoccupied integrins transmit
signals that promote anoikis - signals that must be actively switched off to promote
survival (Schwartz, 2001). It has already been observed that unoccupied a5pi in non¬
adherent cells has a dominant effect inhibiting growth and cell survival (Giancotti and
Ruoslahti, 1990;Varner et al., 1995); in addition, by promoting a5pi transcription, the
CDK inhibitor INK4a sensitises cells to anoikis when the ligand is unavailable (Plath et
al., 2000).
1.13 Outside-in signalling
The complexities of outside-in integrin-mediated cell signalling and the integration of
the roles described above are incompletely understood. It is unclear why there should be
so much apparent redundancy in a system that finds at least eight integrins able to bind
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to fibronectin, or five to bind laminin; and it is unclear how different integrins, with no
intrinsic enzymatic activity themselves, activate specific cellular signalling pathways
resulting in diverse cellular responses. Signalling is centred upon the focal adhesion
complexes to which an array of signalling proteins is recruited. The major pathways are
outlined below.
Focal adhesion kinase
It has long been recognised that focal adhesion kinase (FAK) localises with integrins at
FAs (Schaller et al., 1992). Elegant studies using monovalent ligand or non-inhibitory
antibodies have highlighted the early role of FAK in integrin signalling (Miyamoto et
al., 1995b). Integrin occupation by monovalent ligand was able to induce integrin
redistribution in the plasma membrane, but no major signalling events; occupation by
non-inhibitory mAbs aggregated integrins and led to accumulation of FAK and tensin,
but not maximal signalling. Only the combined stimuli of integrin ligand occupancy,
plus integrin aggregation were sufficient to promote complete signalling complexes, able
to synergise with growth factor signalling (Miyamoto et al., 1996).
Engagement of integrins induces auto-phosphorylation of FAK on tyrosine-397 and
activation of FAK tyrosine kinase activity (Huang et al., 1993). A cascade of signalling
events is then unleashed, by tyrosine and serine phosphorylation of a number of proteins
such as paxillin and tenascin, by FAK or its mediators (Richardson and Parsons, 1995).
A number of important linking proteins are now implicated in events downstream from
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FAK phosphorylation. Fibronectin binding in 3T3 fibroblasts induces FAK to complex
with the tyrosine kinase Src, the adaptor protein Grb2 and the nucleotide exchange factor
SoS (Schaller and Parsons, 1994;Schlaepfer et al., 1994). This results in activation of
the ERK pathway and provides a link between integrin signalling and the Ras/ERK
pathway. In v-Src-transformed NIH3T3 cells, the association of v-Src, Grb2 and Sos
with FAK is independent of cell adhesion to fibronectin and may be important in the
acquisition of anchorage-independent growth.
More recently, FAK has been shown to associate with pl30Cas, a highly phosphorylated
protein isolated in vSrc- and vCrk-transformed cells (Sakai et al., 1994). Together with
human enhancer of filamentation-1 (HEF1) and embryonal Fyn substrate (Efs), pl30Cas
makes up the Cas (Crk-associated substrate) family of proteins, which have multiple
interaction domains and appear to act as docking proteins for SH2-domain-containing
proteins. Cyclical alteration between phosphorylated and dephosphorylated states would
permit the Cas proteins to modulate the stable assembly of such signalling complexes
(O'Neill et al., 2000).
Ras/ERKpathways
Ras (H-Ras, K-Ras and N-Ras) plays a pivotal role in control of cell growth and
differentiation. It is the downstream effector for receptor tyrosine kinases such as
epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) and is
classically involved in promoting mitogenic signalling via activation of Raf, MEK
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(MAPK/ERK kinase) and ERK (extracellular signal-regulated kinase, or mitogen-
activated protein kinase/MAPK) (Avruch et al., 1994). As described above, it is also
directly linked to FAK signalling, by the Grb2 adaptor protein and subsequent
recruitment of its GEF SoS. Maximal ERK pathway stimulation seems also to depend
upon phosphorylation of the She adaptor protein at the FAK-Src complex, as well as
397involvement of the PI 3-kinase pathway, since mutation of the FAK Tyr
autophosphorylation site disrupts binding of both the She SH2-domain and the p85 SH2-
domain, and in each case reduces ERK signalling (Schlaepfer and Hunter, 1998).
An increasing number of downstream Ras effectors have been identified, which merely
includes the classical pathway of Ras-Raf-MEK-ERK. Downstream events in the
pathway include translocation of ERK to the nucleus, where it phosphorylates nuclear
transcription factors such as Elkl, c-Myc, TCF and Jun. Other Ras effector pathways
include PI 3-kinase and Ral-guanosine exchange factors (Ral-GEFs), such as Ral
guanine nucleotide dissociation stimulator (RalGDS), Ral-GDS-like 1/2 (Rgll/2) and
RalGDS-like factor (Rlf). The major pathways are summarised in Figure 1.5. Both
Ras and its downstream effector Raf are capable of oncogenic transformation in some
cells, but activated Ras G12V effector mutants with differential binding to the major
downstream effectors have demonstrated that the transforming potential of the various
Ras pathways varies and that they may be synergistic (White et al., 1995).
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Figure 1.5: Ras signalling pathways.
Activated, GTP-bound Ras interacts with a number of effector proteins, as illustrated. The classical Ras-Raf-
MEK-ERK pathway results in activation of a number of transcription factors, such as ELK1, RSK and Jun,
involved in transcription and cell-cycle progression. PI 3-kinase links Ras directly with cell survival signalling
via PKB and inhibition of the pro-apoptotic factor BAD, but also with cytoskeletal signalling events via Rac
Activation of the RAL-GEF proteins such as RAL-GDS controls Ral activity and transcription factors like
Forkhead. Phospholipase Cs activation catalyses PI 4,5-bisphophate into diacylglycerol and inositol
triphosphate, activating PKC and mobilising intracellular calcium.
Key. PLCs, phospholipase Cs; p70S6K, p70 ribosomal S6 kinase, PDK1, phosphatidylinositol trisphosphate-
dependent kinase 1, PLA2, phospholipase A2; PLD; phospholipase D; RSK, p90 ribosomal S6 kinase, GSK3,
glycogen synthase kinase 3; TCF, ternary complex factor; ELK-1, ETS(E26 transformation specific)-like gene
1;PKC, protein kinase C; PKB, protein kinase B.
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PI 3-kinase
Through its p85a regulatory subunit, PI 3-kinase has been shown to associate with
activated FAK and to be activated by this association (Chen et al., 1996). PI 3-kinase
also interacts reciprocally with Ras, as described above (Rodriguez-Viciana et al., 1994).
PI 3-kinase activity appears to be essential for actin-cytoskeletal rearrangements and cell
survival in Ras-induced transformation (Kauffmann-Zeh et al., 1997;Rodriguez-Viciana
et al., 1997;Matsuguchi and Kraft, 1998). These effects are mediated by the
phosphorylated lipid products of PI 3-kinase, which can regulate many protein targets.
Of these, protein kinase B (PKB, also known as AKT) phosphorylates glycogen synthase
• • / S6Kkinase 3 (Cross et al., 1995) and indirectly activates p70 S6 kinase (p70 ) (Burgenng
and Coffer, 1995); it also protects against apoptosis in a number of cell systems
including protecting against anoikis in epithelial cells (Khwaja et al., 1997). This
appears to be through regulation of the apoptosis machinery at multiple points, with
inhibition of pro-apoptotic factors BAD, caspase-9 and NF-/cB (Datta et al., 1999).
Given this protective role in cell survival it is unsurprising to find that PKB is
constitutively activated in a number of human tumours, including lung cancers, both in
vivo (Bellacosa et al., 1995) and in vitro (Moore et al., 1998).
Rho pathways
Rho has been implicated in downstream signalling for both cell cycle regulation and FA
assembly. Treatment of Swiss 3T3 cells with lysophosphatidic acid induces Rho-
mediated FA assembly in an ECM-dependent manner; in this setting it was concluded
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that Rho was necessary for FA formation and subsequent integrin signalling (Hotchin
and Hall, 1995). In the same cell type, Rho activity is also required for integrin-
mediated activation of ERK (Renshaw et al., 1996). In suspended cells, activation of
endogenous Rho can also lead to ERK activation, partially mimicking the effects of
adhesion (Renshaw et al., 1996), which is intriguing since Rho is the target for
nucleotide exchange of the oncogenes dbl and Ibc (Toksoz and Williams, 1994). It has
been demonstrated that dbl and Ibc can induce anchorage-independent but serum-
dependent growth in fibroblasts (Schwartz et al., 1996), which may therefore be a result
of constitutive Rho-mediated signalling. The downstream effectors of the Rho pathway
have not been confirmed, but are likely to include a series of Rho-activated
serine/threonine kinases (Ishizaki et al., 1996).
Integrin-linked kinase
Integrin-linked kinase (ILK) was identified by a yeast two-hybrid screen as a protein
able to interact with the cytoplasmic domain not only of pi integrin (Hannigan et al.,
1996), but can also P2 and P3 subunits. ILK appears to have an important role in
anchoring actin filaments of the cytoskeleton to cell matrix contact sites, which may
modulate the physical strength of the connection to the ECM as well as cell signalling at
these sites (Wu and Dedhar, 2001). Overexpression of ILK in epithelial cells results in
activation of PKB and glycogen synthase kinase 3 (Persad et al., 2001a;Persad et al.,
2001b), with resultant activation of the transcription factor AP-1, thus providing a direct
link influencing gene expression (Dedhar, 2000). One of the consequences of
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constitutive activation, or overexpression, of ILK in mammalian cells is suppression of
anoikis, through suppression of the apoptosis protease caspase-3 (Persad et al., 2000).
1.14 Integrins and disease
The importance of integrins to the organism as a whole is emphasised by the effects of
complete loss of some integrin subunits, as seen in knockout studies. For example, pi
knockout mice, with the loss of 10 heterodimers, die in utero (Fassler and Meyer, 1995)
and knockouts of pi-associated a subunits show similar embryonic lethality, with the
exception of al. In addition, a number of rare diseases have now been pinpointed to
specific aberrations in integrin function.
Glanzmann's thrombasthenia is an autosomal recessive disorder characterized by
excessive gum bleeding or menorrhagia. The fault lies in the platelet integrin allbp3,
with loss of functional integrin at the platelet surface and consequent loss of platelet
aggregation (Hogg and Bates, 2000). Mutations are recognised in either subunit
(Newman et al., 1991). Conversely, understanding of integrin-mediated platelet
aggregation has led to the development of specific allbp3 inhibitors (GpIIb-IIIa
inhibitors), which are used clinically to induce a Glanzmann's thrombasthenia-like state
and have been shown to reduce the risk of clot formation in acute coronary syndromes
and following coronary artery stenting.
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As has been noted above, leucocyte adhesion deficiency-1 is a disease characterized by
recurrent soft tissue infections. The molecular basis for this is a loss of |32 integrin
expression, with loss of an array of p2 heterodimers, including LFA-1 and Mac-1.
Without these key cell-ECM protein links, neutrophils are unable to extravasate and
migrate to sites of injury (Anderson and Springer, 1987).
Given their role in cellular migration and adhesion, it is unsurprising that integrins are
important in the function of the cells of the immune system. This cellular recruitment
may be beneficial, such as neutrophils responding to infection; or it may prove harmful,
for example, where eosinophils are recruited to an allergenic stimulus, in a process
mediated through a4pi and ICAM-1 on bronchial epithelium and p2 integrins on the
eosinophils (Hillis and MacLeod, 1996). Integrins are now also implicated in
atherosclerosis, since the development of atherosclerotic plaques, with a local influx ofT
lymphocytes and monocytes, is a P2-dependent process (Mine et al., 2002).
1.14.1 Integrins and neoplasia
Just as they are key regulators of cellular adhesion and migration, and of cellular
proliferation and survival, so the corollary is that integrin dysfunction has been
implicated in neoplasia, where cells escape the normal bounds that control these
functions. Two cardinal features of neoplasia are the ability to proliferate free of normal
mitogenic stimuli, witnessed in vitro as serum-independent growth, and the ability to
escape anoikis, anchorage-independent growth. The development of anchorage
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independence has been associated with integrin dysregulation in many tumours (Varner
and Cheresh, 1996). In mammary tumours, higher grade tumours exhibit increasingly
aberrant integrin expression in both in vitro models and in vivo (Koukoulis et al.,
1991;Howlett et al., 1995). Such effects are cell- and integrin-specific: in vitro work
shows that blocking P1 integrins can cause reversion to a non-transformed phenotype in
a model of breast cancer development, whilst blocking anti-P4 or anti-a.6 antibodies
promote neoplasia (Weaver et al., 1997). In CHO cells overexpression of a5pi
inhibited tumour growth (Giancotti and Ruoslahti, 1990) and increased av expression or
P3 expression has been associated with the development ofmalignant melanoma, both in
vivo and in vitro (Albelda et al., 1990;Mitjans et al., 1995). It is unclear exactly how
these changes in integrin profile result in the development of neoplasia and invasive
growth, but it is likely to be a many-facetted problem. Signalling proteins known to be
regulated in part through integrins, in particular PI 3-kinase, have been shown to be
constitutively elevated in tumour cells, including small cell lung cancer (Moore et al.,
1998) - and would be expected to promote cellular proliferation. In addition, there is
some suggestion that tumour invasiveness is enhanced by matrix metalloproteinases and
that integrins can induce expression of these proteins (Seftor et al., 1992;Varner and
Cheresh, 1996). More recent work in colon cancer cell lines has shown that higher cell
density induces avP6 expression in a PKC-dependent manner, which in turn induces
gelatinase B secretion and degredation of the local extracellular matrix (Niu et al.,
2001); in this model, therefore, cancer cell growth is driven in part by the induced
expression of av(36. This integrin has been implicated in tumour invasion in head and
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neck squamous cell carcinomas as well, by upregulating matrix metalloproteinases-9 and
-2 (Thomas et al., 2001).
1.15 Aims of this thesis
Cancer cells therefore show evidence of abnormal integrin regulation, with profound
effects on cellular behaviour. Constitutive activation of integrin-mediated pathways is
likely to be fundamental in the acquisition of serum-independent and anchorage-
independent growth, the hallmarks of neoplasia. Furthermore, integrin-mediated
adhesion is important in the development of chemoresistance in cancer cell lines (Sethi
et al., 1999b), probably mediated through the PI 3-kinase pathway (Brognard et al.,
2001;Schmidt et al., 2002), and in cellular migration and the development of metastasis.
These two behavioural features of lung cancer - the development of chemoresistance
and ofmetastasis - are most directly responsible for its high mortality.
The primary aim of this thesis, therefore, was to determine how integrins were regulated,
in order to try and modulate these two fundamental processes. It has been shown that
CD98 stimulates adhesion in SCLC and that small GTP-binding proteins of the Ras
family regulate integrin function and therefore I addressed the following questions:
1. How does CD98 regulate integrin function and what are the functional
consequences?
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2. In what way is galectin-3, a natural ligand of CD98, related to lung cancer
phenotype?
3. How does R-Ras mediate reversal of integrin suppression?






The following reagents were purchased from Life Technologies (Paisley, UK):
Dulbecco's Modified Eagles Medium (DMEM); Hanks' buffered salt solution (HBSS);
penicillin; streptomycin; dialysed foetal bovine serum (FBS); BCA protein reagent; L-
glutamine; 30% albumin (w/v); non-essential amino acids; 30%(w/v) acrylamide/bis
solution; LipofectAMINE™ Plus reagent. The following were purchased from
Calbiochem-Novabiochem Corporation (Nottingham, UK): wortmannin, LY294002.
The following were purchased from Amersham Life Science Ltd. (Cheshire, UK):
Hybond C nitrocellulose membrane, enhanced chemiluminescence (ECL) reagent,
32
[y "PjATP. Unless otherwise stated, all chemicals were purchased from Sigma
Chemical Company (Dorset, UK).
Primary antibodies
PAC1 antibody (IgG2a) was a generous gift from Dr. S. Shattil (Scripps Research
Institute, La Jolla, USA). Anti-galectin-3 antibody (B2C10) was a generous gift from
Dr. F.T. Liu (University of California, Sacramento, USA). TS2/16 (IgGi) and 4F2
(IgG2a) were cultured in-house (see Section 2.2).
The following primary antibodies were purchased as indicated:
Antibody Target Isotype Source
SC-7095 CD98 Goat polyclonal Santa Cruz Biotechnology
RDI CD98 CabG CD98 Goat polyclonal Research Diagnostics Inc.
C-14 ERK2 Rabbit polyclonal Santa Cruz Biotechnology
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4B4 (31 integrin IgG, Coulter Immunology
18 pi integrin IgGi Transduction Laboratories
K20/K20-FITC pi integrin IgG2a DAKO
CD71 (L01.1) CD71 IgG2a Becton Dickinson
A-17 FAK Rabbit polyclonal Santa Cruz Biotechnology
P1B5 a.3 integrin IgG, Chemicon International, Inc.
Santa Cruz Biotechnology (Santa Cruz, California, USA); Upstate Biotechnology (Lake
Placid, USA); Coulter Immunology (Hialeah, USA); Transduction Laboratories
(Lexington, USA); Becton Dickinson (Erembodegem, Belgium); Chemicon
International, Inc. (Temecula, California, USA).
Secondary antibodies
All anti-species specific horseradish peroxidase-conjugated secondary antibodies were
purchased from DAKO (Bucks, UK). For immunofluorescence studies, all anti-species
specific and anti-FITC specific ALEXArM-conjugated secondary fluorochromes were
purchased from Molecular Probes (Leiden, The Netherlands).
DNA constructs were obtained as follows: Tac-a5 (permission from Dr. S.E. LaFlamme,
Centre for Cell Biology and Cancer Research, NY, USA); pDCR-H-Ras G12V
(permission from Dr. M.H. Wigler, Cold Spring Harbor Laboratory, NY, USA) and
pSG5-R-Ras G38V (permission from Prof. J. Downward, ICRF, London, UK) were
provided by Dr. M.H. Ginsberg (Scripps Research Institute, La Jolla, USA) and have
been described previously (LaFlamme et al., 1992;White et al., 1995;Wennstrom and
Downward, 1999;Oertli et al., 2000).
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The human promonocytic leukaemia cell line U937 H4 was obtained from the UK
Human Genome Mapping Project Resource Centre (Cambridge, UK).
Tissue sections for immunohistochemical studies were obtained from archival samples
from University of Edinburgh, Department of Pathology files.
2.2 Production of 4F2 monoclonal antibody
The hybridoma cell lines for the monoclonal antibodies 4F2 (C13) and TS2/16 (Hb-243)
were purchased from the American Type Tissue Culture Collection and cultured in-
house in DMEM containing 15%FBS, 50IU/ml penicillin, 50IU/ml streptomycin and
5/xg/ml L-glutamine and OPI media supplement. Secreted antibody was purified using
protein-A affinity chromatography (Amersham, Pharmacia, Uppsala, Sweden).
2.3 Cell culture
Chinese hamster ovary (CHO) cell lines
The aP-py CHO cell line was a generous gift from Dr. Mark Ginsberg (Scripps Institute,
La Jolla, California, USA). These cells stably express a chimaeric integrin comprising
aIIba6aP3pi, of which the extracellular domain is represented by allbp3 (Hughes et
al., 1997). Expression of the chimeric integrin is maintained through G418 selection and
its expression is driven by the polyoma T antigen. The aP-py cell line was cultured in
DMEM, supplemented with 10%(v/v) FBS (heat inactivated at 57°C for 1 hour),
l%(v/v) non-essential amino acids, G418 antibiotic (400/xg/ml) (Promega), 50IU/ml
penicillin and 50IU/ml streptomycin. Cells were passaged on reaching confluence,
every three to five days. Beyond a passage number of 12, fresh stocks were utilized.
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Small cell lung cancer (SCLC) cell lines
SCLC cell lines NCI-H69, NCI-H345 and NCI-H510 were purchased from the
American Type Tissue Culture Collection (Rockville, Maryland, USA). These cell lines
have been well characterized (Carney et al., 1985a;Carney et al., 1985b).
All SCLC cell lines were cultured in Rosewell Park Memorial Institute Medium 1640
(RPMI 1640) containing 25mM HEPES supplemented with 10% (v/v) heat-inactivated
FBS, 50IU/ml penicillin and 50IU/ml streptomycin. Cells were grown in 25-50mls
medium in 75cm flasks. Cells were passaged every four to five days and passage
numbers of greater than forty were discarded. Prior to experimentation, cells were
washed in HBSS and cultured in quiescent medium, comprising RPMI 1640 containing
25mM HEPES, 0.25% (w/v) BSA, 50IU/ml penicillin and 50IU/ml streptomycin.
Macrophages
Human peripheral leukocytes were isolated using discontinuous density centrifugation
through Percoll gradients (Szefler et al., 1987;Dransfield et al., 1994). Whole blood was
obtained by venepuncture using 19 gauge needles (Sarstedt UK), from healthy
volunteers on no current drug therapies. Volunteers were screened to ensure that they
did not have elevated eosinophil levels, by flow cytometry and light microscopic
assessment of cytocentrifuge preparations stained with haematoxylin/eosin according to
previous protocols (Ward et al., 1999). Purity was assessed by flow cytometry using 20
microlitre samples of isolated cell suspensions, to assess the composition of each
preparation with respect to individual leukocyte populations. Flow cytometric scatter
profiles were used to gauge percentages of monocytes and lymphocytes, before
proceeding to further monocyte purification. This was performed by using in vitro
adhesion to tissue culture plastic. For adhesion-mediated purification, cells were allowed
to adhere to tissue culture plastic (Falcon or BioWhittaker, UK), at a concentration of
4x106 per ml for one hour in warm Iscove's medium without serum at 37°C/5%C02.
Non-adherent cells were then removed by circumferential washing of cell culture wells
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three times with cation replete PBS, using sterile plastic pastettes. Further cell culture
occurred in Iscove's supplemented with 10% autologous serum.
2.4 Transformation of!?, coli
TOP10/P3 competent stocks were purchased from Invitrogen (Groningen, The
Netherlands). Frozen aliquots of cells were thawed on ice and 25mM p-mercaptoethanol
(final concentration) was added for 10 minutes prior to addition ofDNA. DNA (l-10ng)
was gently mixed with the cells and allowed to rest for 30 minutes at 4°C. Cells were
heat-shocked at 42°C in a thermomixer (Eppendorf, Cambridge, UK) for one minute and
returned to 4°C for a further two minutes. Transformed cells were allowed to grow by
addition of antibiotic-free SOC media for 60 minutes at 37°C (225rpm in a
thermomixer), prior to spreading on appropriate antibiotic selection plates and
incubating overnight at 37°C. Individual colonies were picked into LB broth containing
appropriate antibiotic selection and grown overnight for DNA purification and
restriction enzyme digest verification.
2.5 DNA purification
Small scale (1-10ml) DNA purifications were performed using Wizard SV Miniprep kits
(Promega) according to the manufacturers' instructions. Diagnostic restriction enzyme
digests were performed with appropriate restriction enzymes (Promega) and resolved on
1% agarose (Seakem, Rockland, Maine, USA) gels containing 0.3jag/ml ethidium
bromide to enable UV visualization.
Large scale (100-500ml) DNA purifications were performed using the Qiagen
Endotoxin Free Maxiprep kit (Qiagen, Crawley, UK) according to the manufacturers'
instructions. For low copy plasmids, Qiagen Midiprep kits were used, with their low
copy number plasmid protocol. Purified DNA was checked with diagnostic restriction
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enzyme digests and quantified using a Pharmacia Biotech Ultrospec 2000UV
spectrophotometer (Amersham Pharmacia Biotech, Amersham, UK)
2.6 Cellular transfection
Transient transfections of ap-py and CH0-K1 cells were performed with
LipofectAMINE™ Plus reagent as described by Chen et al. (Chen et al., 1994). Cells
were seeded at a density to achieve 50% confluency overnight in 100mm or 60mm
dishes (Corning, High Wycombe, UK). Purified DNA was placed in 5ml BD Falcon
tubes (Becton Dickinson, Oxford, UK) in a volume ranging from 1—40^tl. The DNA was
pre-complexed with 110/d of the Plus reagent mixture (comprising Plus reagent
0.25%(v/v) diluted in DMEM containing l%(v/v) non-essential amino acids) and gently
mixed. After a 15 minute incubation at room temperature, 110/xl of LipofectAMINE1M
mixture (comprising LipofectAMINE™ 0.25%(v/v) diluted in DMEM containing
l%(v/v) non-essential amino acids) was added and incubated for a further 15 minutes at
room temperature. The mixture was then made up to a total volume of 4ml with pre-
warmed DMEM containing l%(v/v) non-essential amino acids and placed onto the
washed cells. Cells were cultured for five hours at 37°C, before addition of complete
media (4ml), containing 10% FCS. After 24 hours, media containing DNA was
removed and replaced with fresh complete media. For experiments where protein kinase
activities were to be assessed, the transfection media was replaced with quiescent media.
Cells were assessed 48 hours after transfection, either for lysis and SDS-PAGE analysis,
or for integrin affinity determination.
2.7 Cell lysis
Cells were washed with ice cold PBS and lysed in buffer containing 50mM HEPES pH
7.4, 0.3M NaCl, 1.5mM MgCL2, 1.2mM EDTA, 0.5% Triton X-100, 20mM p-
glycerophosphate, lOOmM sodium fluoride, lOmM sodium pyrophoshphate, ImM
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sodium vanadate, 0.5mM dithiothreitol. One Complete™ protease inhibitor tablet
(Boehringer Mannheim, Lewes, UK) was added per 50ml of lysis buffer. Lysates were
clarified by centrifugation at 13,000rpm for 10 minutes at 4°C and analysed for protein
concentration. Samples were heated in sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer at 99°C for 10 minutes (See 2.9 for buffer
composition).
2.8 Assay of protein concentration
Protein concentrations of lysates were quantified using a BCA protein assay (Pierce, IL,
USA). Samples were diluted 1:5 or 1:10 in dPLO and 10/xl incubated with 200/xl of test
solution for 30 minutes at 37°C in 96-well plates. Plates were read using an automated
plate reader (MRX microplate reader, Dynatech, Chantilly, USA). Samples were
assayed in triplicate and graded against a standard curve (0.1-0.5mg/ml) using bovine
serum albumin.
2.9 SDS Page and Western blotting
Samples were resolved on SDS polyacrylamide gels using a vertical electrophoresis tank
Biorad Mini Protean II system (Biorad, Hemel Hempstead, UK). Samples were
electrophoresed at 80-150volts using electrophoresis buffer for 1-2 hours, adjacent to
pre-stained molecular weight markers (Life Technologies, Paisley, Glasgow). For
optimal protein separation, 8% gels were used for 60-120kDa proteins, 10% gels for 40-
70kDa and 12% gels for lO^-OkDa proteins.
Proteins were transferred onto Hybond C nitrocellulose membranes in a methanol-based
transfer buffer at lOOvolts for 60-90 minutes, in a Mini Protean II blotting tank (Biorad,
UK). Protein loading was confirmed by staining with 1% Ponceau S for 5 minutes to
visualize protein bands. Non-specific binding sites were blocked by incubation with
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PBS-Tween 20 containing 5% non-fat dried milk powder for 1 hour at room
temperature. Membranes were probed with appropriate antibodies diluted in PBS-
Tween 20 containing 5% non-fat dried milk powder overnight at 4°C. They were then
washed vigorously in PBS-Tween 20 for 1 hour, before exposure to appropriate species-
specific horseradish peroxidase-conjugated (HRP) secondary antibodies for 1 hour,
diluted in PBS-Tween 20 containing 5% non-fat dried milk powder. Membranes were
then washed further in PBS-Tween 20 and immunoreactive bands identified using
enchanced chemiluminescence (ECL) according to the manufacturer's instructions. For
assessment of phosphorylated proteins, blocking and subsequent incubation steps were
carried out using 3% albumin in PBS.
Buffers
1 x SDS-PAGE sample buffer
50mM Tris-HCl, 10%(v/v) glycerol, 2%(v/v) SDS, 0.1%(v/v) bromophenol blue,
10%(v/v) P-mercaptoethanol, pH 6.8.
SDS polyacrylamide gel
Separating Gel: 0.375M Tris base (pH 8.8), 0.1%(v/v) SDS, 8-12%(v/v) acrylamide,
0.1%(v/v) ammonium persulphate, 0.02%(v/v) TEMED.
Stacking Gel: 0.13M Tris base (pH 6.8), 0.15%(v/v) SDS, 4.6%(v/v) acrylamide,
0.1 l%(v/v) ammonium persulphate, 0.02%(v/v) TEMED.
Gel electrophoresis buffer
50mM Tris base, 250mM glycine, 0.1%(v/v) SDS.
Transfer buffer
210mM glycine, 24.7mM Tris base, 20%(v/v) methanol.
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PBS-Tween 20 Wash buffer
PBS containing 0.2%(v/v) Tween 20
2.10 Flow cytometric assessment of antigen expression
Aliquots of 5xl05 cells were washed in PBS and resuspended in 50—100/xl of PBS,
containing either primary antibody or an isotype control antibody. Primary antibody
incubation was for 30 minutes at room temperature, all subsequent steps being carried
out at 4°C. After primary antibody incubation, cells were washed in PBS and then
incubated with appropriate species-specific FITC- or PE-conjugated secondary antibody
for a further 30 minutes in the dark. Samples were then washed again in ice-cold PBS
and resuspended in 500/d PBS for analysis by flow cytometry on a FACS-Caliber
(Becton, Dickinson, Erembodegem, Belgium). A minimum of 5000 cells were analysed
per condition.
2.11 Integrin affinity determination by flow cytometry
The integrin affinity status of transfected aP-py cells was assessed by three-colour flow
cytometry, 48 hours after transfection, using the PAC1 antibody to label activated anbP3.
Cells were transfected as described in 2.6 with test 0-10/tg DNA, as well as 2/ig Tac-a5
transfection reporter construct. Transfected cells were trypsinised and resuspended in a
total volume of 50/xl containing 0.4%(v/v) PAC1 ascites in FIEPES/NaCl buffer
(comprising 20mM HEPES, 140mM NaCl, 1.8mM CaCh, ImM MgCh and 2mg/ml
glucose) for 30 minutes. For each sample, internal controls were performed containg
either 5mM EDTA (for maximal integrin suppression) or 100/xM MnCh (for maximal
integrin activation). Cells were washed in cold PBS and all subsequent steps were
carried out at 4°C. Samples were incubated in 50/d DMEM containing 4%(v/v) anti-
mouse IgM-FITC (Biosource, Nivelles, Belgium) for 30 minutes in the dark. They were
washed again and incubated finally in 50/xl DMEM containing 2%(v/v) anti-Tac-R-
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phycoerythrin (R-PE) (DAKO, Ely, UK). Cells were then washed and resuspended in
cold PBS. Immediately prior to analysis on a FACS-Caliber flow cytometer, ToPro3
(Molecular Probes, Leiden, The Netherlands) was added to a final concentration of 1/xM
per sample, to permit live/dead cell by analysis of FL-4 fluorescence.
Data analysis
Live/dead cell analysis was performed using FL4 fluorescence to gate out dead (FL-4
positive) cells. For the live cell population, PAC1 binding was assessed in the most
highly transfected cells. The integrin Activation Index (AI) was calculated as follows, as
described by Hughes et al. (Hughes et al., 1997):
Activation Index (%) AI = (Fn - Fi) / (Fa - Fi) x 100
F»: Geometric mean fluorescence intensity (MFI) of PAC1 binding to native integrin
Fp MFI of PAC1 binding in the presence of 5mM EDTA, i.e. maximally suppressed
Fa: MFI of PAC1 binding in the presence of lOOjuM MnC^, i.e. maximally activated
2.12 Co-immunoprecipitation
Cells (30 x 106) were washed with Hanks' buffered salt solution, before being lysed
using 20mM HEPES, 150mM NaCl, 2mM MgCh, 0.5mM CaCh, 1% 3-[(3-cholamido-
propyl)dimethylammonio]propanesulfonate, and Complete protease inhibitor cocktail
(Roche Applied Science, Mannheim, Germany). All steps were subsequently performed
at 4°C. Lysates were clarified by centrifugation at 13,000rpm. To remove non-specific
contaminants, lysates were then incubated with 30/d of albumin-agarose (Sigma-
Aldrich) for 30 mins. After further centrifugation, the residual lysates were incubated
overnight with 2/xg of either 4F2, mouse anti-human CD71 as a negative control
antibody, mouse anti-pi integrin (K20), or a mouse IgGi negative control antibody
(DAKO, Bucks, UK). Incubation with Protein G agarose (50/xl) was used to precipitate
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the antibodies over 1 hour. Agarose beads were then washed twice in 20mM HEPES,
150mM NaCl, 2mM MgCl2 and 0.5mM CaCl2 before being boiled with SDS-PAGE
sample buffer. Samples were run on 10% Sepharose gel and transferred to nitrocellulose
membrane (Amersham Biosciences UK, Bucks, UK). After blocking with 5% nonfat
milk, Western blots were probed with antibody to pi integrin (Transduction
Laboratories, Lexington, KY) and a secondary anti-mouse horseradish peroxidase
conjugate (DAKO, Bucks, UK). Visualization was by enhanced chemiluminescence.
2.13 PI 3-kinase activity assay
Cultures of SCLC cells were washed twice in HBSS, resuspended in quiescent medium
and incubated at 37°C for 24 hours. The following day the cells were washed twice in
HBSS at 37°C and disaggregated by gentle passage through a 21-gauge needle. They
were then counted and aliquotted into 6-well plates (Costar, Cambridge, USA), using 10
x 105 cells per point. Cells equilibrated for 1 hour at 37°C before addition of agonist or
antagonist. Following addition of the agent, plates were transferred to a water/ice bath
(4°C), the cells were aspirated and centrifuged at 3000xg for 1 minute. The supernatant
was aspirated and the cells lysed by addition of 250/d of ice-cold lysis buffer (50mM
HEPES (pH 7.4), 15mM NaCl, 1.5mM MgCl2, ImM EGTA, lOmM sodium
pyrophosphate, lOOmM sodium fluoride, 10%(v/v) glycerol, l%(v/v) Triton X-100,
0.5mM dithiothreitol, ImM sodium orthovanadate, 50/xM 4-2-aminoethyl-
benzenesulfonyl fluoride, 5/xg/ml leupeptin, 20/xg/ml aprotinin, and 10 /xg/ml soybean
trypsin inhibitor) to the cells and to any residual cells in the 6-well plate. After a
minimum thirty minutes' lysis at 4°C, the plate and eppendorf lysates were amalgamated
and then clarified by centrigugation at 13,000xg for 10 minutes. The protein
concentration of each assay point lysate was then assessed and samples were
equilibrated for protein, -500fig per assay point.
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Equilibrated samples were incubated with 1/xg of anti-p85-SH3 PI 3-kinase antibody
overnight at 4°C. The following day, 30/xl of goat anti-mouse IgG agarose beads,
washed in lysis buffer, were added for a further 2 hours. The beads were then pelleted
and washed twice with lysis buffer, once with a high salt buffer containing lOOmM Tris-
HC1 and 500mM LiCl (pH 7.6) and twice with a solution containing 200mM HEPES,
40mM MgCb and 600mM NaCl (pH 7.4). PI 3-kinase assays were performed in a final
volume of 200/xl containing 50mM HEPES (pH 7.4), lOmM MgCl2, 150mM NaCl,
[y32P]ATP (5/xCi, 5000Ci/mmol), 50/xM ATP, and 0.5mg/ml sonicated
phosphatidylinositol: phosphatidylserine (3:1, w/w). Reactions were carried out for 10
minutes at 37°C and terminated by adding 750/xl of chloroform:methanol:0.1M HC1
(40:80:1, v/v/v). Phase partition was carried out by adding 250/xl chloroform and 250/d
0.1M HC1. After centrifugation, the lower phase was washed twice with synthetic upper
phase (methanol: 1M HCkchloroform, 48:47:3, v/v/v), dried in a Speedivac and
resupended in 30/xl chloroform, prior to separation of the lipids by thin layer
chromatography (TLC). 3'-phosphorylated lipids were identified by autoradiography
using Kodak "X-OMAT" film. Radioactivity was quantified by liquid scintillation
counting using "Flo-Scint IV" (Packard, Biosciences, Groningen, The Netherlands) and
a Packard 1900 TR liquid scintillation analyzer.
2.14 Adhesion assay
96 well plates (Costar) were coated with 100/xl of 10/xg/ml laminin (Life Technologies)
overnight at 4°C and blocked with lmg/ml BSA (1 hour at 25°C). SCLC cells were
washed twice in RPMI 1640 and quiesced overnight in quiescent media. 200/xl of cells
(2xl05/ml) were added to the wells in the presence or absence of 4F2 (20/xg/ml),
function-blocking (31 antibody 4B4 (1:100) (Coulter Immunology), function-blocking
a3 antibody P1B5 (l:100)(Chemicon International), or 2mM EDTA. After 1 hour of
incubation at 37°C, non-adherent cells were removed by gentle washing with PBS and
adherent cells were fixed with 100% methanol. For control wells, plates were
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centrifuged for 2 minutes at lOOOrpm and the supernatant was aspirated; all cells were
then fixed with 100% methanol. Following fixation, cells were stained with 1%
methylene blue. Plates were washed with distilled water, lOOpl of 0.1M HC1 was added
to each well and the absorbance of the resulting solution was measured at 630 nM on a
plate reader (Dynatech Technologies, Chantilly, Virginia). Each condition was assayed
in triplicate. Adhesion was expressed as a percentage of maximum possible adhesion,
represented by the control wells in which all cells had been centrifuged and fixed.
2.15 Immunohistochemistry
Tissue
Archival tissue samples of lung tumours were obtained from University of Edinburgh
Department of Pathology files (1997-2001) and consisted of human lung biopsy samples
taken by bronchoscopy, percutaneous biopsy or thoracic surgery. Control slides were of
normal lung taken from non-involved lobes of lung cancer cases. Samples had been
fixed in 4% paraformaldehyde and embedded in paraffin wax.
Immunohistochemistry
°
3-5pm sections were dried on to slides overnight at 37 C. For immunohistochemistry,
sections underwent deparaffinization in xylene, followed by antigen unmasking in
Vector Unmasking Solution (1:500) (Vector Laboratories, UK) for 3x5 minutes at 99 C.
Immunohistochemistry was performed following the DAKO Techmate protocol (DAKO
Ltd., UK), using the indirect streptavidin-biotin method. The primary antibodies used
were goat polyclonal antibody to CD98 (SC-7095, Santa Cruz, California, USA) at
1:100 dilution and mouse monoclonal antibody to galectin-3 (gift, Dr. F.T. Liu) at 1:400
dilution. Negative control sections were incubated in carrier solution only. Positive
control sections were taken from reactive lymph nodes. The immunostained sections
were counterstained with haematoxylin.
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Scoring
Sections were assessed together by standard light microscopy by two assessors (the
author and a pathology registrar) and independently by a third, a consultant pathologist.
Where differences were identified, the cases were settled by conference.
Immunoreactivity for CD98 and galectin-3 was scored semi-quantitatively in areas of
tumour: (a) for percentage of cells staining (absent = 0; < 20% = 1; 20-80% = 2; > 80%
= 3); and (b) for strength of staining (absent = 0; weak = 1; moderate = 2; strong = 3).
The cellular localization of CD98 and galectin-3, whether nuclear, cytoplasmic or
membranous, was noted. The distribution of CD98 and galectin-3 in other cell types
(interstitial and alveolar macrophages, lymphocytes, fibroblasts, bronchial epithelium,
vascular endothelium and mesothelium) was also documented for all sections, where
present.
Statistical analysis
Median scores for (a) percentage of cells staining and (b) strength of staining were
compared between groups. Since the number of possible outcomes for each sample was
limited (0 - 3), the distribution of data was assumed to be non-Gaussian, so that non-
parametric analysis was required: the Kruskal-Wallis test looked for significant variation
between group medians, with post hoc between-group comparison by Dunn's Multiple
Comparison Test.
2.16 Immunofluorescence
The following primary antibodies were used: 4F2 conjugated with ALEXA™-Fluor 568
(Molecular Probes, Leiden, The Netherlands) (designated 4F2-AR), K20-FITC (DAKO,
Glostrup, Denmark), 4B4 (Beckman Coulter, Fullerton, CA), TS2/16 conjugated with
FITC (Sigma-Aldrich)(designated T2/16-FITC)) and CD71-FITC (BD Biosciences).
The following secondary and tertiary antibodies were used: to amplify the FITC signal,
ALEXA™-Fluor 488 rabbit anti-fluorescein and ALEXA™-Fluor 488 goat anti-rabbit
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IgG (Molecular Probes); to localize 4B4, ALEXA™-Fluor 488 goat anti-mouse IgG
(Molecular Probes). Mouse IgGi and IgG2a antibodies directed against Aspergillus niger
glucose oxidase (DAKO) were used as negative controls.
To assess the native state of CD98 and pi integrin, SCLC cells were plated onto glass
coverslips and fixed with 3% paraformaldehyde. Formaldehyde groups were quenched
by immersing the coverslips in 50mM NH4CI for 10 minutes. Nonspecific binding sites
were then blocked using 0.2% fish skin gelatin in PBS. Cells were then incubated
sequentially with: (i) 4F2-AR and K20-FITC or IgGl and IgG2a negative control
antibodies; (ii) secondary ALEXA™-Fluor 488 rabbit anti-fluorescein; and (iii) tertiary
ALEXA™-Fluor 488 goat anti-rabbit IgG. To assess the effect of cross-linking CD98
with mAb 4F2, primary antibody incubation with 4F2-AR and K20-FITC was carried
out prior to fixation. Secondary and tertiary antibody labeling was carried out as above.
To assess the effect of pi integrin function-stimulating or function-blocking antibodies,
cells were incubated with TS2/16-FITC or 4B4, respectively, before fixation and
subsequent secondary and tertiary antibody labeling. In these latter experiments
incubation with 4F2-AR was performed last of all, after secondary and tertiary labeling
of the pi integrin. As a further negative control, localization of 4F2-AR and pi integrin
was compared with that of the transferrin receptor (CD71), by using an isotype-matched
(IgG2a) mouse anti-human CD71 antibody (CD71-FITC). In all experiments cells were
gently washed twice with PBS between steps. Finally, cells were mounted from distilled
water in Mowiol. Confocal microscopy was performed with a TCS NT confocal
microscope system (Leica, Heidelberg, Germany) and image analysis was performed
using TCS NT software (Eeica).
2.17 Library amplification
The mammalian cDNA expression library H4 was obtained from the Human Genome
Mapping Project (Cambridge, UK). This library was extracted from human
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promonocytic leukaemia U937 cells, activated with phorbol 12-myristate 13-acetate.
The library had been cloned into the pCDM8 vector (Invitrogen, Groningen, The
Netherlands), which contains a CMV promoter and the polyoma origin of replication
(that facilitates replication in ap-py cells). Insert sizes were greater than 500bp and
cloned non-directionally. Library cDNA was transformed into TOP10/P3 E. Coli strains
as described and the transformed cells grown overnight at 37°C on 25x25 cm LB-Agar
plates (Corning, High Wycombe, UK), containing ampicillin 50/xg/ml and tetracycline
10/xg/ml for selection. Transformations were repeated six times to obtain sufficient
colonies to provide enough DNA to cover the quoted complexity of the library by a
factor of 10. Colonies were scraped from the incubation plates into antibiotic-free LB
broth and DNA was purified from the culture using the Qiagen Midiprep kit. Purified
DNA was quantified by UV spectrophotometry and confirmed to contain vector and
library fragments by Xho 1 restriction enzyme digestion. DNA from individual
preparations was pooled for use in the genetic screen
2.18 Library screening and sorting
Transfection of ap-py cells was performed in 100mm tissue culture dishes, according to
the protocol described above. In total, 19 plates were transfected with DNA: pCDM8
control (4/xg), H-Ras G12V (3/xg), and 17 plates with H4 library DNA (4/xg). All plates
also received 2/xg Tac-as reporter construct.
After 48 hours integrin affinity was assessed by flow cytometry as described above,
adjusted for volume. Sixteen library-transfected plates were trypsinised and resuspended
in a total of 1.35ml HEPES/NaCl buffer. They were divided into 6 cell suspensions of
cells (6x225/xl) and were incubated with 25/xl of PAC1 ascites fluid to give a final
concentration of 0.4%(v/v). Cells were washed with cold PBS and incubated at 4°C with
250/xl DMEM containing 4%(v/v) anti-mouse IgM FITC. After further washing, cells
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were incubated with 250/d DMEM containing 2%(v/v) anti-Tac-PE. Cells were finally
washed and resuspended in cold PBS at a concentration of 2xl06/ml.
Cell sorting was carried out on a FACSVantage cell sorter (Becton Dickinson) with a
100/xm flow nozzle. Prior to cell sorting 7-AAD (Molecular Probes, Leiden, The
Netherlands) was added to a final concentration of 20ng/ml as a live/dead marker. Gates
were set up using 7-AAD-negative (live) and 7-AAD-positive (dead) populations; in
addition, by using cells transfected with pCDM8 and Ras G12V, gates were set for
transfected cells (Tac-positive) and cells with high integrin activation (PAC1-positive).
Cells were sorted to collect those with high integrin activation status.
Following sorting, cells were subject to HIRT extraction of plasmid DNA (Hirt, 1967).
They were transferred to 1.5ml eppendorfs, centrifuged at lOOOrpm for 10 minutes and
resuspended in 400/rl of lysis solution (0.6% SDS(w/v) and lOmM EDTA). After a 20
minute incubation at room temperature, 100/xl 5mM NaCl was added and the mixture
incubated overnight at 4°C. Lysates were then clarified by centrifugation at 13,000rpm
for 10 minutes, then subjected to two cycles of phenol/chloroform purification
(lysate:phenol/chloroform, 1:1). DNA within the aqueous phase was subjected to
ethanol precipitation with 20fig of glycogen (Boehringer Mannheim, Lewes, UK). DNA
resuspended in 100/xl dEEO was precipitated with 3M sodium acetate 10%(v/v) and
300%(v/v) ethanol by centrifugation at 13,000rpm for 20 minutes. The DNA pellet was
washed in 70% ethanol and resuspended in a final volume of 8/xl dEEO.
DNA was digested overnight with 10 units Dpnl restriction enzyme at 37°C and then
used to transform TOP10/P3 cells as described. Individual colonies were assessed for
the presence of the H4 library pCDM8 vector by PCR. Positive colonies were grown
individually for transformation into aP-py cells and re-screened in pools of ten for their
effect on integrin affinity status.
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2.19 Polymerase chain reaction (PCR)
To determine whether colonies of bacteria carried the pCDM8 vector, initially samples
were cultured in 5mls of LB broth under ampicillin (50/ig/ml) and tetracycline (10/rg/ml)
restriction. cDNA were then obtained by Miniprep, as described in Section 2.5, and
subjected to PCR. In a 50/xl aliquot, the following components were added:
Reagent Final concentration Volume for 50/nl
Sterile deionised water - 30
lOx PCR buffer lx 5
2mM dNTP mix 0.2mM of each 5
lOmM Forward primer 0.2mM 1
lOmM Reverse primer 0.2mM 1
Taq DNA polymerase 1 unit/50/d 1
25mM MgCl2 2.5mM 5
Template DNA Variable 2
Samples were kept on ice until the final addition of Taq DNA polymerase, then
transferred to a thermomixer for incubation. All PCR regimes went through the same
sequence of steps: initial denaturation, denaturation, primer annealing, extension and a
final extending phase. Where large numbers of bacterial colonies needed to be screened,
a "master mix" of reagents was prepared and aliquotted into a 96-well PCR plate, with a
total volume of 25/xl per sample. Samples were then taken directly from the bacterial
colonies and added to individual wells prior to PCR.
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2.20 Statistical analysis
Unless otherwise stated, data was assumed to follow a Gaussian distribution and
statistical analysis was performed using one-way analysis of variance (ANOVA) and
post hoc analysis by Newman-Keuls Multiple Comparison Test.
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Chapter 3
Associations between CD98 and |31 Integrin
3.1 Introduction
CD98 is a disulphide-linked 125 kDa heterodimeric membrane glycoprotein composed
of a glycosylated 80 kDa heavy chain and a non-glycosylated 48 kDa light chain. It is a
ubiquitously expressed cell surface antigen that is highly conserved between species.
Early studies of peripheral blood T and B-lymphocytes implicated CD98 in the
regulation of cellular activation, but did not define a specific function for this antigen
(Haynes et al., 1981;Gerrard et al., 1984). Expressed at low levels on the surface of
quiescent cells, CD98 is quickly induced following cellular activation (Suomalainen,
1986). It is rapidly upregulated early in transition from GO to G1 phase and remains at
elevated levels until the cell cycle is complete. CD98 is strongly expressed on adherent
human embryonic and newborn fibroblasts but expression gradually diminishes from
100% to 1% on fibroblasts from normal adults (Azzarone et al., 1984;Azzarone et al.,
1986). CD98 expression is reconstituted to high levels on sarcomatous cell lines
(Azzarone et al., 1985); moreover, overexpression of CD98 in NIH3T3 cells results in
transformation (Hara et al., 1999). These expression patterns suggest that the function
of CD98 is coupled to cellular activation, though a definitive role and mechanism of
action have not been ascribed.
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Six CD98 light chains have been identified, all of which are associated with L-type
amino acid transport activity (Mannion et al., 1998) (Kanai et al., 1998) (Torrents et al.,
1998) (Estevez et al., 1998) (Mastroberardino et al., 1998) (Pfeiffer et al., 1999)
(Pfeiffer et al., 1998;Tsurudome et al., 1999). CD98 heavy chain has been shown to
control delivery of the L-amino acid transporter (LAT-2) transporter protein to the
membrane in a Xenopus oocyte model system (Pineda et al., 1999;Rossier et al., 1999).
LAT-2 is predominantly expressed in renal proximal tubules. It has been proposed that
the CD98-LAT-2 heterodimer is important in amino acid transport in kidney proximal
tubules, whereas CD98-LAT-1 is involved with cellular amino acid uptake, reflected in
the more widespread distribution of LAT-1.
There appears to be only a single heavy chain and recent evidence implicates this in an
association with integrins. CD98 has been identified as a unique and highly specific
regulator of integrin affinity, using a cloning strategy based upon changes in integrin
affinity to identify potential modulators of integrin activation (Fenczik et al., 1997a). It
has been shown that pi integrin-mediated adhesion of the SCLC cell line H345 to
fibronectin and laminin can be markedly upregulated by cross-linking CD98. In
addition, CD98 has been shown to stimulate adhesion of breast cancer cells to laminin
via the integrin a3pl. Other studies also implicate CD98 in the regulation of integrin-
mediated cell adhesion (Chandrasekaran et al., 1999a). CD98 may also act together with
pi integrins during T-cell co-stimulation (Warren et al., 2000).
98
Monocytes/macrophages are a key cell type in the control of inflammatory processes and
CD98 has a critical role in the functional reprogramming ofmonocyte behaviour. Anti-
CD98 monoclonal antibody promotes monocyte-monocyte interactions that ultimately
lead to polykaryon (multinucleated giant cell) formation, a phenotype associated with
chronic inflammatory conditions. Compelling evidence also exists for a connection
between CD98 and virus-induced cell fusion. Antibodies to the heavy chain of CD98
promote cell fusion induced by Newcastle disease virus and by the gpl60 envelope
glycoprotein of human immunodeficiency virus (Okamoto et al., 1997;Ohta et al.,
1994;Suga et al., 1997). Thus, mounting evidence suggests that CD98 may be important
in cancer, inflammation and viral disease through its effects on cellular activation and
integrin-mediated adhesion.
Both intracellular signalling via CD98 and the cytoplasmic tail of CD98 appear to be
crucial for its action (Tabata et al., 1997). CD98 that lacks either a cytoplasmic domain
or the unpaired cysteine in the extracellular domain disrupts virus-induced cell fusion
and does not inhibit Tac-(31 suppression of integrin affinity (Fenczik et al., 2001).
Tyrosine kinase activation may be an early signal transduction pathway activated by
CD98. Tyrosine kinase inhibitors such as genistein and herbimycin inhibit CD98
activity in haematopoietic cells and cell fusion mediated by HIV gpl60 (Warren et al.,
1996;Tabata et al., 1997). In this context, the phosphoinositide 3-kinase (PI 3-kinase)
family of enzymes may also be influenced by CD98, acting as they do as a biochemical
link between the phosphoinositide pathway and proteins with tyrosine kinase activity.
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Evidence also suggests that CD98 is involved in the regulation of intracellular calcium
concentration [Ca2+] through the Na+/Ca2+ exchanger: this has been assessed in skeletal
muscle, myocytes, parathyroid cells and lymphocytes and its effect seems to be cell type
specific (Michalak et al., 1986;Posillico et al., 1987;Freidman etal., 1994).
The understanding of the mechanisms and biological relevance of CD98 function may
have far-reaching practical applications. Blocking CD98 activity in tumour cells may be
one route to preventing tumour progression and modulating cancer metastasis. Analysis
of the mechanisms by which CD98 regulates virus-induced cell fusion may result in the
development of novel anti-viral compounds. In addition, if inflammatory cells use
CD98 to stimulate activation and adhesion at sites of tissue injury, then agents that
inhibit CD98 activity may result in the development of novel anti-inflammatory
compounds.
3.2 CD98 is highly expressed by SCLC
To confirm that experimental SCLC cell lines expressed CD98, these cell lines were
analysed by flow cytometry and Western blot for CD98 protein expression. For flow
cytometry, aliquots of 5 x 106 cells were first washed in PBS, then incubated with the
monoclonal antibody 4F2, or an isotype-matched control, at a concentration of 20/xg/ml,
as described in "Materials and Methods". Secondary labelling was performed with a
goat anti-mouse F(ab)2-FITC, prior to flow cytometric analysis. The mean fluorescence
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exhibited with 4F2 relative to that with isotype-matched control represented CD98
expression levels. The results, shown in Figure 3.1 (upper panel), confirmed that the
SCLC lines H69, H345 and H510 all expressed high levels of CD98 (mean fluorescence
ratio relative to control ± SEM: 49.8 ±20.6; 41.2 ± 4.9; 44.0 ± 24.0 respectively), in
contrast to low levels ofbinding seen with Swiss 3T3 cells (3.0 ± 2.0) or bovine tracheal
smooth muscle cells (1.0 ± 0).
In separate experiments, CD98 expression by SCLC was confirmed in Western blot
analysis of whole cell lysates. Control cell lines used were Cos-7 cells, which normally
express CD98 at moderate levels; in addition, these were transfected with cDNA for
human CD98. Lysates were equilibrated for protein and Western blots probed for the
presence of CD98 with goat polyclonal antibody directed against CD98 (SC-7095).
Figure 3.1 (lower panel) shows that in H69, H345 and H510 cells a protein band was
observed at -85 kDa, corresponding to the heavy chain of CD98 and also observed in the
transfected Cos-7 cells; it was observed at lower levels in native Cos-7 cells. These data
support the thesis that CD98 was highly expressed in SCLC experimental lines.
3.3 Co-immunoprecipitation of CD98 with pi integrins
3.3.1 Initial experiments and modifications
Establishing satisfactory conditions for co-immunoprecipitation of pi integrin and CD98
was extremely difficult. Initial pilot experiments with H69 and H345 SCLC cells
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Figure 3.1: SCLC strongly express CD98.
Upper panel: Expression of CD98 in H69, H345 and H510 SCLC cell lines, assessed by flow
cytometry. Cell lines were incubated with 4F2 (20pg/ml) or isotype-matched control, followed by
secondary anti-mouse FITC. CD98 expression is shown as a ratio of fluorescence compared to
controls, for each cell line. Comparisons were made with other cell lines, bovine tracheal smooth
muscle (BTSM) and mouse Swiss 3T3.
Lower panel: Western blot of CD98 expression by H69, H345 and H510 SCLC lines. Lysates were
equilibrated for protein and probed with goat anti-CD98 (SC-7095). Simian Cos-7 cells transfected
with CD98 (Cos-7CD9g) were used as positive control and expressed moderate levels of CD98 in their
native state.
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suggested that although both cell lines expressed pi integrin, as has previously been
shown (Hirasawa et al., 1994;Falcioni et al., 1994), this was in relatively low quantities
compared with cells with extensive cytoplasm and greater surface area. Human
macrophages derived from donors expressed high amounts of both CD98 and pi
integrin, but even with these, inconsistent results were obtained. It was necessary to
establish a control cell line into which cDNA for human CD98 could be transfected.
From these cells, CD98 would then be immunoprecipitated and its association with pi
integrin assessed. Amongst easily transfectable cell lines, Cos-7 (simian) and A549
(human) were shown to express pi integrin strongly, along with other proteins of
potential interest, the p85 subunit of PI 3-kinase and FAK (Figure 3.2, upper panel).
By contrast, our other commonly used cell line, CHO-K1 cells, did not appear to express
pi integrin strongly (Figure 3.2, lower panel); this may in part be a species problem
with the antibody used for probing the Western blot. Cos-7 cells were therefore used for
further studies.
Cos-7 cells were cultured in 60mm culture dishes and transfected at a concentration of
approximately 5 x 105 cells/plate, using the standard LipofectAMINE technique as
described in "Materials and Methods". Satisfactory transfection was demonstrated in
two ways. Firstly, at harvest, cells were lysed in lOOjtrl MAPK lysis buffer and,
following clarification and protein assay, 30/rg of cellular protein was run out on
Western blot and probed for CD98 expression with the goat polyclonal antibody SC-
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Figure 3.2: Cos-7 cells, but not CHO-K1 cells, strongly express pi integrin, p85 and FAK.
Western blots demonstrating expression of relevant target proteins of potential interest in Cos-7 cells
(iupper panel) and CHO-K1 cells (lower panel). Whole cell lysates, equilibrated for protein, were
probed with antibodies directed against pi integrin, p85 and focal adhesion kinase (FAK) and
compared with human A549 cells and A431 cells (manufacturer's positive control). Cos-7 and
CFIO-K1 cells were of interest as easily transfectable cell lines, but CHO-K1 cells clearly did not





















Figure 3.3: Successful transfection of Cos-7 cells with cDNA for CD98.
(a) Lysates from untransfected cells (lanes 1 and 2) or cells transfected with CD98 {lanes 3 and 4) (30yig protein
per lane) were probed with SC-7095 goat anti-CD98 and secondary anti-goat biotin.
(b) Cos-7 cells transfected with CD98 were incubated with carrier {dotted line; mean fluorescence 6.2 arbitrary
units), IgG2a control antibody (20pg/ml) {dashed line; 6.8 AU) or 4F2 (20pg/ml) {solid line, grey infill; less
transfected 109.2 AU, highly transfected2531.4 AU), then secondary anti-mouse FITC. Untransfected cells also
bound 4F2 {solid line; 566 A U).
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endogenous CD98 (lanes 1 and 2), whilst transfected cells express very high levels
{lanes 2 and 4). Secondly, cells were trypsinised at harvest and expression of CD98
assessed by flow cytometry using 4F2 monoclonal antibody (20/rg/ml), Figure 3.3b
demonstrates that, although untransfected Cos-7 cells express moderately high levels of
CD98, following transfection there is a population of transfected cells that express CD98
to extremely high levels. Thus, by two different methods, and with two different CD98-
specific antibodies, it was clearly demonstrated that Cos-7 cells were successfully
transfected with, and expressed, CD98.
To assess whether CD98 and pi integrin co-immunoprecipitated, transfected Cos-7 cells
were incubated with 4F2 (20/xg/ml) for 10 minutes at 37°C. Cells were washed twice in
ice-cold HBSS and lysed with MAPK lysis buffer, as described in "Materials and
Methods". Following clarification of the lysates, the 4F2 antibody was
immunoprecipitated using Protein G agarose beads. These were washed gently in lysis
buffer, before being boiled in reducing sample buffer. Samples were then subject to
Western blotting and probed for the presence of pi integrin, but this was not observed
(Figure 3.4). This could have been for a number of reasons: (i) CD98 and pi integrins
did not co-immunoprecipitate; (ii) they did co-immunoprecipitate, but the pi integrins
were lost in the assay; (iii) or, the CD98 was never immunoprecipitated in the first place.
Co-immunoprecipitation experiments are highly sensitive to buffer conditions and it was








Figure 3.4: pi integrin was not co-immunoprecipitated with CD98 in transfected Cos-7 cells.
Cos-7 cells transfected with CD98 (Cos-7CD9g), or controls (Cos-7) were incubated with 4F2 (20pg/ml), lysed and
CD98 immunoprecipitated with protein G agarose beads. Beads were boiled in lx sample buffer and probed for the
presence of pi integrin with mouse anti-pl mAb and secondary goat anti-mouse biotin. Cos-7 and A431 whole cell
lysates, which express pi integrin strongly, were used as positive controls.
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loss of co-localising proteins during the assay. Therefore, a CHAPS/deoxycholate-
based, non-reducing lysis buffer was adopted (see "Materials and Methods"). With this
adaptation to the protocol, it was first shown that CD98 was being successfully pulled
out by 4F2 and Protein G agarose (Figure 3.5a); secondly, pi integrin was co-
immunoprecipitated with CD98, since it was isolated on Western blot in those samples
treated with 4F2, but not in those treated with an IgG2a negative control antibody
(Figure 3.5b). This suggested that, in transfected Cos-7 cells at least, CD98 and pi
integrin co-immunoprecipitated.
3.3.2 CD98 and pi integrin co-immunoprecipitate in human macrophages
In order to assess whether CD98 and pi integrin co-immunoprecipitated in untransfected
cell types, human macrophages were first studied, since they are known to express both
proteins to high levels. Peripheral blood monocytes were kindly donated by colleagues,
isolated by discontinuous density centrifugation through Percoll gradients as described
in "Materials and Methods" (Szefler et al., 1987;Dransfield et al., 1994) and matured
into macrophages by culture for 5-7 days. On day 5-7 of culture, macrophages were
washed twice in HBSS, before lysis in CHAPS/deoxycholate buffer. Following protein
assay and clarification, immunoprecipitation was performed by overnight incubation at
4°C with 2fig of either 4F2 or IgG2a isotype control antibody, together with Protein G
agarose. Figure 3.6 shows that pi integrin was co-immunoprecipitated by 4F2 (lane 2),
but not by the IgG2a isotype control (lane 1); in addition, the pi integrin band was not
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Figure 3.5: CD98 and (31 integrin co-immunoprecipitate in CD98-transfected Cos-7 cells.
(a) Probing with SC-7095 goat anti-CD98, CD98 is immunoprecipitated by 4F2 (20pg/ml) from untransfected cells
(Cos-7) and cells transfected with CD98 (Cos-lam)(lanes 1 & 3), but not from transfected cells with an isotype
IgG2a control antibody (lane 2).
(b) Probing with mouse anti-pl mAb, (31 integrin is co-immunoprecipitated from transfected cells (Cos-7CD9g),
when CD98 is immunoprecipitated by 4F2 (lanes 6 & 7), but not by carrier (lanes 2 & 3) or control IgG2a control
antibody (lanes 4 & 5). The co-immunoprecipitation of (31 integrin from untransfected cells (lane I) is more




Figure 3.6: CD98 and (31 integrin co-immunoprecipitate in human macrophages.
Probing with mouse anti-(31 mAb, (31 integrin is identified in immunoprecipitates from human
macrophages when immunoprecipitated with 4F2 (2pg) {lane 2), but not with an isotype IgG2a
control antibody {lane 1). Whole cell lysates demonstrate that (31 integrin expressed in human
macrophages {lane 4) runs slightly heavier than in A431 cells {lane 5); no equivalent weight protein
is identified when "pure" 4F2 mAb (2pg) is run out on the Western blot {lane 3). Results
representative of three experiments.
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sample buffer and run on the Western blot (lane 3). Thus, CD98 and pi integrin were
observed to co-immunoprecipitate in human macrophages.
3.3.3 CD98 and pi integrin co-immunoprecipitate in H69 SCLC
In addition to human macrophages, SCLC cells were assessed for evidence of a physical
association between CD98 and pi integrin. Attempts to confirm this association using
the conditions described above for macrophages were fruitless - no definite co-
immunoprecipitation was observed. However, another group published evidence
suggesting that pi integrin and CD98 did co-imunoprecipitate in polarised cells (Merlin
et al., 2001), using a different CHAPS-based lysis buffer. In addition, because of the
low cytoplasm/nucleus ratio of SCLC, large numbers of SCLC were used for these
experiments.
Thus, using 30 x 106 cells per point, H69 SCLC were lysed with the new lysis buffer.
Lysates were clarified and incubated overnight at 4°C with precipitating antibodies,
which were then pulled down with Protein G agarose as before. Following boiling in
reducing sample buffer, samples were run out on Western blot and probed for the
presence of either CD98 or pi integrin. Figure 3.7a shows clearly that CD98 was
isolated by precipitation with 4F2 as expected (lane 3). Figure 3.7b shows that pi
integrin was isolated by both the pi-specific antibody K20 (lane 3) and by 4F2 (lane 1);
however, it was not immunoprecipitated by an IgG2a monoclonal antibody directed
against CD71 (lane 2). CD71 is the cell surface transmembrane receptor for transferrin,
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Figure 3.7: CD98 and (31 integrin co-immunoprecipitate in H69 SCLC cells.
(a) Probing with SC-7095 goat anti-CD98, CD98 is immunoprecipitated by 4F2 (2pg) from H69 SCLC, but
not by mouse anti-(31 (K20, 2pg, lane 1) or an isotype IgG, control antibody (lane 2).
(b) Probing with mouse anti-(31 mAb, (31 integrin is immunoprecipitated from H69 SCLC cells by mouse
anti-pl (K20, 2pg, lane 3) and co-immunoprecipitated by 4F2 (2pg), but not by control IgG2a antibody
against CD71 (lane 2) or negative IgG, control antibody (lane 4).
(c) Probing with anti-CD71 antibody, a protein of approximately llOkDa is isolated by immunoprecipitation
with anti-CD71 antibody (lane 1), but not by control IgG2a antibody (lane 2).
Results representative of three experiments.
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which is strongly expressed by SCLC; this antibody was thus an excellent isotype
control to use for comparison with the IgG2a monoclonal antibody 4F2 directed against
CD98, also a transmembrane protein. Figure 3.7c shows that when probed for the
presence of CD71, a protein band was isolated at approximately the correct molecular
weight for CD71 in the lane with antibody against CD71 (lane 1), but not in the presence
of an IgG2a isotype control (lane 2). This suggested that the CD71 antibody was specific
and was indeed successfully pulling out the transferrin receptor CD71.
Taken together these results suggested that |31 integrin and CD98 did indeed co-
immunoprecipitate in SCLC H69 cells, as they had been shown to do in both human
macrophages and transfected Cos-7 cells.
3.4 Confocal microscopy of CD98 and (31 integrin
Although the co-immunoprecipitation experiments above suggested that CD98 and (31
integrin are physically associated, these data are fraught with interpretational difficulties,
due to the biochemical constraints that exist in such experiments. Confocal microscopy
was therefore used as a complementary technique to validate or refute these results, i.e.
whether or not CD98 and pi integrins co-localise. The proteins of interest were labelled
with protein-specific antibodies, which were then localised by the use of fluorophores,
attached either to secondary antibodies or directly conjugated to the primary antibodies.
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3.4.1 Early experiments
The objective of these studies was to assess CD98 and (31 integrin in intact, native cells,
specifically SCLC; as strong expressers of both target proteins, human macrophages
were also used. The establishment of reproducible experimental conditions to accurately
assess antibody binding and thence co-localisation was fraught with technical and
interpretational difficulty. An experienced observer was essential in interpretation and
the expert technical assistance ofDr. Linda Sharp was greatly appreciated.
Experiments followed a broadly similar design, as described in "Materials and
Methods". After washing in PBS, cells were fixed to a glass slide or coverslip, using 3%
paraformaldehyde (PFA). Aldehyde groups were quenched with 50mM NH4CI and
blocking of non-specific binding was performed using 10% sheep serum/0.2% fish skin
2_j_ 2+ • •
gelatin in Ca /Mg -free PBS. Cells were permeabilised with 0.1% Triton in
2+ 2d"Ca /Mg -free PBS. Cells were then incubated with primary antibodies directed against
CD98 and (31 integrin, followed by appropriate species-specific secondary antibodies.
Because of the necessity to prevent cross-reactivity between the secondary fluorophores
and primary antibodies, the primary antibodies needed to be raised in different species.
The primary antibodies used initially were a mouse monoclonal directed against (31
integrin (8E3) and a goat polyclonal against CD98 (SC-7095). The secondary
fluorophores were donkey anti-goat Alexa Fluor™ 568 (AlexaRed) and goat anti-mouse
Alexa Fluor™ 488 (AlexaGreen). A number ofproblems were encountered.
114
(a) In the earliest experiments SCLC H69 cells, after washing in PBS, were
deposited onto slides by cytospin at 300rpm, prior to fixation with 3% paraformaldehyde
(PFA). Aldehyde groups were then quenched with 50mM NH4CI and blocking of non¬
specific binding, primary and secondary antibody incubations were performed as
described in "Materials and Methods". However, it was observed that cells examined in
this way were both somewhat flattened and accompanied by a large quantity of cellular
debris and/or residual serum. This resulted in messy, non-specific staining which was
felt to be unrepresentative of the situation in viable, intact cells (Figure 3.8a). Cytospin
preparations were therefore abandoned.
(b) As an alternative method of adhering cells to slides in preparation for
immunofluorescence, slides or coverslips were coated with laminin (10/xg/ml) for two
hours. Excess laminin was removed by gentle washing with PBS, before cells were
plated out and allowed to adhere. Fixation, blocking and antibody incubations were
performed as above. However, with both macrophages and SCLC cells, the presence of
laminin gave rise to an unacceptably high level of non-specific antibody binding to the
laminin (Figure 3.8b). Therefore the use of laminin in these experiments was also
abandoned.
(c) It was clearly demonstrated that the use of 10% sheep serum as part of the
blocking step resulted in increased non-specific binding of the secondary fluorophore
donkey anti-goat AlexaRed. As illustrated in Figure 3.8c, cells blocked in 0.2% fish
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Figure 3.8: (a) Cytospin preparation produces excessive debris (both slides).
Typical appearances of cells, plus profuse cellular debris and serum proteins following cytospin preparation.
(The cells were labelled with 4F2 (20pg/ml). followed by goat anti-mouse Alexa Fluor™ 568, then FITC-
conjugated mouse anti-pi antibodies.)
Latninin Glass
Figure 3.8: (b) Plating cells on laminin results in more background staining.
Macrophages plated onto laminin (lOpg/ml) or straight onto glass were incubated with antibodies against pi
integrin, then labelled with secondary Alexa Fluor 488. Plating cells onto laminin resulted in higher background
staining and less specific staining of cells.
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10% sheep serum No sheep serum
Figure 3.8: (c) Sheep serum block strongly binds secondary antibody fluorophore.
H69 SCLC were blocked in 0.2% fish skin gelatin in PBS, with or without 10% sheep serum. Incubation was
with donkey anti-goat Alexa Fluor™ 568. To localise the cells, nuclei were labelled with To-Pro-3 (lpM)
(filtered out in the left hand slide).
Goat CD98
Goat (31
Goat CD98 + peptide block
Goat (31 + peptide block
Goat CD98 + 4F2
Goat (31 + 4F2
Figure 3.8: (d) Unconjugated primary goat antibodies lead to poor specificity of staining.
H69 cells incubated with goat polyclonal antibody against CD98 exhibited poor specificity of staining, even if co-
incubated with a peptide block (upper panel, red). By contrast, the monoclonal antibody 4F2, with secondary
Alexa Fluor 488 labelling (green), exhibits highly specific staining of CD98. Similar results are demonstrated with
goat primary antibody against (51 integrin (bottom panel, red).
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skin gelatin alone exhibited negligible cellular or background fluorescence following
incubation with donkey anti-goat AlexaRed alone, whereas cells blocked with 10%
sheep serum/0.2% fish skin gelatin in Ca2+/Mg2+-free PBS exhibited high levels of
diffuse fluorescence, rendering meaningful interpretation impossible. The use of sheep
serum was, therefore, excluded, with no apparent increase in non-specific antibody
binding.
(d) Finally, it was also concluded that indirect immunofluorescence, i.e. the use of
unconjugated primary antibodies - by necessity of different species - with appropriate
species-specific secondary fluorophores, led to unacceptable levels of cross-reactivity
between the secondary fluorophores and primary antibodies (Figure 3.8d). It was
therefore decided to abandon the use of these unconjugated primary antibodies as far as
possible and to turn to pre-conjugated primary antibodies against CD98 and pi integrin.
3.4.2 Conjugation of 4F2 with Alexa Fluor™ 568
The two key mouse monoclonal antibodies used for further studies were 4F2 and K20.
4F2 was synthesised as described in "Materials and Methods". To conjugate this with
the Alexa Fluor™ 568 fluorophore, the Alexa Fluor™ 568 Protein Labelling Kit from
Molecular Probes was used. Following the manufacturer's instructions, a conjugate of
4F2 and Alexa Fluor™ 568 was synthesised, designated "4F2-AR", with a labelling ratio
of 3.2 moles of dye per mole of protein. 4F2-AR was used in subsequent
immunofluorescence experiments at a concentration of 20/xg/ml.
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3.4.3 Titration of (31 integrin labelling
The antibody K20 (DAKO) is accepted internationally as a specific mouse monoclonal
directed against (31 integrin. For use in immunofluorescence, the pre-conjugated product
K20-FITC (DAKO) was used. Fluorescein isothyocyanate (FITC) can itself be used for
immunofluorescence, but bleaches far more rapidly under laser excitation than the more
stable Alexa Fluor™ fluorophores. In addition, conjugation of FITC to K20 was in a
low ratio (approximately 1:1), resulting in weak, albeit specific fluorescence when used
alone, even at concentrations of 1/10 (10/rg/ml). Figure 3.9 shows that in F169 SCLC
this signal could be amplified by use of secondary and tertiary labelling, using rabbit
anti-FITC Alexa Fluor™ 488 (1:400) and donkey anti-rabbit Alexa Fluor™ 488 (1:200)
respectively, with no significant increase in non-specific labelling.
3.4.4 CD98 and (31 integrin co-localise in human macrophages
To assess whether CD98 and pi integrin co-localise in macrophages, monocytes were
isolated from peripheral blood and cultured as described above. On days 5-7 they were
harvested by trypsinisation, then allowed to settle onto coverslips in serum-free Iscove's
medium for 4 hours. Cells were washed twice with HBSS and incubated with primary
antibodies 4F2-AR (20/rg/ml), K20-FITC (1/10) or IgGi isotype control antibody in
HBSS for 15 minutes at 37°C. The cells were then washed twice in HBSS at 4°C and
2+ 2+
fixation, quenching of aldehydes and blocking with 0.2% fish skin gelatin in Ca /Mg -
free PBS was performed as above. Incubations with secondary and tertiary antibodies
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K20-FITC alone K20-FITC +
secondary anti-FITC +
anti-rabbit Alexa Fluor 488™
Figure 3.9: Amplification of pi integrin signal.
H69 SCLC cells were probed with K20-FITC (1/10), directed against pi integrin, with or without
secondary/tertiary amplification. Amplification was with secondary rabbit anti-FITC Alexa Fluor 488™ (1:400)
and tertiary anti-rabbit Alexa Fluor 488™ (1:200).
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2+ 2+
were performed in 0.2% fish skin gelatin in Ca /Mg -free PBS. For the isotype control
antibody, secondary labelling was with goat anti-mouse Alexa Fluor 488™ (1:200).
Figure 3.10 shows that under these conditions, whilst there was no significant binding of
IgGi isotype control antibody, there was specific binding of 4F2-AR and K20-FITC. In
addition there was clear evidence of overlap of the immunofluorescence signals,
indicating that CD98 and pi integrin co-localise in human macrophages.
3.4.5 CD98 and pi integrin co-localise in H69 SCLC
Using a similar design, H69 SCLC were first washed in HBSS twice and incubated
overnight in quiescent medium. They were then disaggregated by gentle passage
through a 21-gauge needle, washed again and incubated in eppendorfs with primary
antibodies in HBSS at 37°C. Following primary incubation, cells were washed twice in
HBSS at 4°C then resuspended in 20-30/xl of HBSS to be placed as a droplet on a
coverslip. Fixation, quenching, blocking and secondary/tertiary incubations were
performed as before. Figure 3.11 shows that, as with macrophages, 4F2-AR and K20-
FITC bound specifically and that the two signals frequently, but not universally, co-
localised. This suggested that CD98 and pi integrin co-localised in H69 SCLC.
3.4.6 CD98 and pi integrin co-localisation is independent of activation state
To assess whether this co-localisation was dependent on whether pi integrin was in the
suppressed or activated state, the proteins were interrogated using pi integrin-inhibiting











anti-rabbit Alexa Fluor 488™
Figure 3.10: CD98 and (31 integrin co-localise in human macrophages.
Macrophages were probed with 4F2-AR or K20-FITC, directed against CD98 and pi integrin respectively.
Amplification of the FITC signal was with secondary rabbit anti-FITC Alexa Fluor 488rM and tertiary anti-rabbit
Alexa Fluor 488™. A mouse isotype control IgG, antibody did not bind to macrophages and there was no cross-
reactivity between 4F2-AR and the secondary/tertiary AlexaFluor 488™ antibodies (upper panel). Where CD98




IgG, control secondary anti-FlTC +
anti-rabbit Alexa Fluor 488™




anti-rabbit Alexa Fluor 488™
Figure 3.11: CD98 and (31 integrin co-localise in human SCLC H69 cells.
H69 SCLC cells were probed with 4F2-AR or K20-FITC, directed against CD98 and (31 integrin respectively.
Amplification of the FITC signal was with secondary rabbit anti-FITC Alexa Fluor 488IM and tertiary anti-rabbit
Alexa Fluor 488™. A mouse isotype control IgG, antibody did not bind to SCLC and there was no cross-
reactivity between 4F2-AR and the secondary/tertiary AlexaFluor 488™ antibodies (upper panel). Where CD98
and P1 integrin co-localised, the overlay image produced a gold signal (lower two panels). Representative of at
least three experiments.
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function-blocking antibody 4B4 (Coulter Immunology) suggested that a concentration of
1/30 - 1/100 was optimal for immunofluorescence studies (data not shown). Since this
was a mouse antibody like 4F2-AR, care was taken that all incubations with 4B4 and
secondary goat anti-mouse AlexaGreen were performed prior to incubation with 4F2-AR
(which was therefore the last incubation), to prevent any cross-reactivity. Figure 3.12a
shows that when SCLC were incubated with the pi integrin function-blocking antibody
4B4, the pi integrin and CD98 signals continued to exhibit co-localisation.
The pi integrin-stimulating antibody TS2/16 was produced in-house by culture of the
appropriate hybridoma and subsequent immunoglobulin purification, as described in
"Materials and Methods". This was conjugated to the fluorophore FITC and titration
experiments confirmed that a concentration of 1/50 (4/rg/ml) was optimal for
immunofluorescence, using using rabbit anti-FITC Alexa Fluor™ 488 and donkey anti-
rabbit Alexa Fluor™ 488. Again, since TS2/16 is a mouse monoclonal antibody,
incubation with 4F2-AR was performed as the final incubation to prevent any cross-
reactivity. Figure 3.12b shows that when SCLC were incubated with the pi integrin-
stimulating antibody TS2/16, the pi integrin and CD98 signals continued to exhibit co-
localisation.
By contrast, when SCLC were incubated with CD71-FITC, a pre-conjugated mouse
IgG2a antibody directed against the cell surface transferrin receptor, there was no clear
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Distance along Line A
Figure 3.12a: CD98 and pi integrin are constitutively co-localized.
H69 SCLC cells were probed with the pi integrin-inhibiting antibody 4B4 (1/30) or IgG, and
IgG,a isotype controls (not shown), followed by secondary goat anti-mouse Alexa Fluor
488™. CD98 was then isolated with 4F2-AR. The fluorescence of the individual signals
along Line A (Overlay image) indicates that there is a high degree of co-localization between















Distance along Line B
Figure 3.12b: CD98 and (31 integrin are constitutively co-localized.
H69 SCLC cells were probed with the pre-conjugated |31 integrin-stimulating antibody
TS2/16-FITC (1/10) or IgGj isotype control (not shown), followed by secondary and tertiary
amplification. CD98 was then isolated with 4F2-AR. The fluorescence of the individual
signals along Line B (Overlay image) indicates that there is a high degree of co-localization
between CD98 and (31 integrin {graph). The scale bar represents 10pm. Representative of
three experiments.
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evidence of overlap between the fluorescence signals for the transferrin receptor and
CD98 (Figure 3.13).
Taken together, these experiments suggested that not only were CD98 and pi integrins
co-localised at the cell surface, but that this physical association was independent of the
activation status of the pi integrin. In addition, it was a physical association specific to
these two proteins, since it was not seen with another cell surface protein, the transferrin
receptor, which is highly expressed by SCLC (EC50 of 1.4 pg/ml to H69 SCLC cells).
3.5 Functional effects of cross-linking CD98
3.5.1 Cross-linking CD98 with 4F2 stimulates PI 3-kinase
The cytoplasmic tail of CD98 appears to be critical for its action and there is evidence to
suggest that CD98 is involved in the regulation of intracellular signalling (Tabata et al.,
1997). The effect of cross-linking CD98 on intracellular signalling was therefore
examined. To specifically examine the effect of cross-linking CD98 the monoclonal
antibody to the heavy chain of CD98 (4F2) was used. 4F2 did not stimulate
mobilization of intracellular [Ca2+] in fura-2 loaded SCLC cells (Dr. R.C. Rintoul,
personal communication). Since PI 3-kinase plays a key role in integrin activation,
cellular activation and transformation the effect of 4F2 on PI 3-kinase activity in SCLC
cells was examined. PI 3-kinase activity from p85a immunoprecipitates was measured
as described in "Materials and Methods". The identity of the PI(3)P has previously been
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CD98 CD71 Overlay
Figure 3.13: CD98 and CD71 are not co-localized.
H69 SCLC cells were probed with the pre-conjugated CD71 antibody CD71-FITC (1/2).
CD98 was then isolated with 4F2-AR (20pg/ml). The fluorescence of the individual signals
along Line C (Overlay image) indicates that there is no significant co-localization between
CD98 and CD71 (graph). The scale bar represents 10pm. Representative of three
experiments.
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confirmed by monomethylamine deacylation and HPLC analysis, using a SAX 5 column
and (NH4)2HP04 gradient and authentic tritiated standards as markers (Dr. R.C. Rintoul,
PhD thesis). Figure 3.14 {upper graph) shows that following 10 minutes' incubation,
4F2 (20/xg/ml) caused a significant increase in PI 3-kinase activity relative to basal
levels (mean fold increase ± SEM = 1.60 ± 0.17). PI 3-kinase activation by 4F2 could
be blocked by pre-incubation with the PI 3-kinase inhibitor wortmannin (lOOnM) (0.43 ±
0.14). The IgG2a isotype control antibody against the CD71 transferrin receptor
(10/xg/ml) did not stimulate PI 3-kinase activity relative to baseline levels, at either 5
minutes (1.04 ± 0.05) or 10 minutes (1.03 ± 0.12). Figure 3.14 {lower graph) shows
further that there is a timecourse of PI 3-kinase activation by 4F2, increasing above
baseline at 2 minutes (mean fold increase ± SEM = 1.46 ± 0.23) and 5 minutes (2.49 ±
0.46) and dropping back by 20 minutes (1.73 ± 0.38) (courtesy Dr. R.C. Rintoul). In
addition, monovalent Fab'-4F2 fragments (20/xg/ml) had no effect on PI 3-kinase
activity (0.95 ± 0.01) and were able to block the effect of intact antibody 4F2 (0.83 ±
0.03). It has separately been demonstrated that although the monovalent Fab'-4F2
fragments on their own had no effect on PI 3-kinase activation, cross-linking them by the
addition of anti-mouse Fab' antibodies reproduced 4F2-mediated PI 3-kinase activation.
These data confirm that cross-linking of CD98 is required for PI 3-kinase activation.
Moreover, this is a specific effect of incubation with 4F2, since neither saturating
concentrations of negative control IgG2a antibodies, nor an IgG2a antibody (10/xg/ml) to
the CD71 transferrin receptor, had any effect on PI3-kinase activity.
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Figure 3.14: Cross-linking CD98 activates PI 3-kinase.
Upper graph. Quiescent H69 SCLC cells were incubated with 4F2 (20pg/ml) for 10 minutes,
in the presence or absence of wortmannin (Wm), or with anti-CD71 antibody (lOpg/ml) for
5 or 10 minutes. PI 3-kinase activity was then assayed. Results are the mean +/- SEM of
three experiments. (*** p < 0.001 relative to Basal.)
Lower graph. Quiescent H69 SCLC cells were incubated with 4F2 (20pg/ml) for varying
times, or with Fab'-4F2 (20pg/ml) with and without 4F2, or an isotype IgG2a control
antibody. Results are the mean +/- SEM of three experiments. (Courtesy Dr. R.C. Rintoul.)
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3.5.2 Cross-linking CD98 with 4F2 promotes pi-dependent cell adhesion
To further examine the functional effects of cross-linking CD98, particularly relating to
interactions with p 1 integrins, the influence of cross-linking CD98 on cell adhesion was
assessed. Using a 96-well plate, coated with a layer of laminin (lOjug/ml), quiescent
H69 SCLC were first disaggregated and counted, then incubated for an hour at a
concentration of 1 x 105/ml, in the presence or absence of 4F2 (20/ig/ml), with EDTA or
specific integrin function-blocking antibodies. Non-adherent cells were then gently
washed off and adherent cells fixed and stained with 1% methylene blue. The number of
cells remaining was thus proportional to the strength of methylene blue staining.
Comparing the number of adherent cells with the maximum possible (if all cells were
fixed in the well, 100% control) and the number of cells adherent to untreated plastic
alone, Figure 3.15 demonstrates that although laminin increased adhesion relative to
plastic alone, this was not statistically significant. However, incubation with 4F2
resulted in significantly increased cellular adhesion (mean % adhesion ± SEM = 70% ±
13.5), compared to either plastic (28.7% ± 10.1) (p < 0.01) or laminin alone (41.8% ±
5.0) (p < 0.05). This increased adhesion with 4F2 was strikingly reduced by the
presence of 2mM EDTA (22% ± 5.0), the pi integrin function-blocking mAb 4B4
(1/100) (32.5% ± 9.4) or the a3 integrin function-blocking mAb P1B5 (1/100) (48.3% ±
5.0), none of which exhibited adhesion significantly differing from that achieved on
plastic alone. These results suggested that one of the functional effects of cross-linking
CD98 was to stimulate a3pl integrin-dependent cellular adhesion.
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Figure 3.15: Cross-linking CD98 stimulates integrin-mediated adhesion .
Quiescent H69 SCLC cells were allowed to settle for 1 hour in 96-well plates coated with or
without laminin, in the presence of 4F2 (20pg/ml). In addition to 4F2, incubations were also
performed in the presence of EDTA (2mM), pi integrin function-blocking antibody 4B4
(1:100), or a3 integrin function-blocking antibody P1B5 (1:100). Adhesion was quantified as
described in "Materials and Methods" and expressed as a percentage of maximum possible
adhesion (defined as 100%, with all cells centrifuged into the well). Results shown are the




This chapter presents the results of a number of studies directed at investigating the role
of CD98 in modulating pi integrins. CD98 is a transmembrane protein widely
expressed in the foetus and in activated cells and the specificity of this link to pi
integrins was thrown into light when it was demonstrated that CD98 was specifically
able to rescue pi integrins from dominant suppression by piA integrin tails (Fenczik et
al., 1997a). However, the physical and molecular bases of this link are still unclear.
The most immediate question is whether CD98 and pi integrins are linked by direct
association, or by an indirect signalling cascade. Having established that CD98 was
highly expressed by SCLC cell lines, this chapter presents substantial evidence that the
two proteins are physically associated in the cell membrane. Co-immunoprecipitation
experiments demonstrated that pi integrin could be co-immunoprecipitated with CD98
from a number of cell lines: these included Cos-7 cells transfected with CD98, human
macrophages derived from whole blood and the human H69 SCLC cell line. In
validation of these experiments, confocal microscopy was used to visualise the two
target proteins, in both human macrophages and H69 SCLC cells. In both cell types,
CD98 and pi integrins were co-localised. Importantly, in neither confocal nor co-
immunoprecipitation experiments was CD98 seen to be associated with another cell
surface protein, the transferrin receptor (CD71). This suggests that the association with
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pi integrin was a specific association and did not occur simply because the two proteins
were both expressed in the cell membrane.
Finally, this chapter presents results investigating the functional effects of cross-linking
CD98 with the monoclonal antibody 4F2 in SCLC cells. Cross-linking CD98 stimulated
intracellular signalling through PI 3-kinase, whose activity was upregulated by 4F2, but
not by monovalent Fab'-4F2 or antibodies against CD71. In addition, 4F2 stimulated
increased integrin-dependent SCLC cell adhesion to laminin. These findings suggest an
integral role for CD98 in events taking place at the cell membrane, with influence over
downstream cellular functions.
Reviewing these findings, it was unsurprising to find that CD98 was highly expressed in
our SCLC lines. This is entirely in keeping with other work published by other groups
(Nikolova et al., 1998;Pedersen et al., 2001;Azzarone et al., 1985), demonstrating that
CD98 is upregulated in cancerous cells, both in vivo and in vitro. Indeed, high CD98
expression was observed in other transformed cell lines, such as CCD19-LU and human
bronchial epithelial cells (HBE-16) (data not shown), both of which are cell lines
transformed with SV40. Earlier work has shown that transfection with CD98 is
sufficient to induce cellular transformation (Hara et al., 1999;Shishido et al., 2000).
Thus increased CD98 expression correlates with the transformed phenotype. In part this
may reflect the fact that CD98 is involved in amino acid transport regulation, since all
six of the light chain proteins so far described have been shown to be homologous to
134
y+L and L-type amino acid transport proteins (Mannion et al., 1998) (Kanai et al., 1998)
(Torrents et al., 1998;Estevez et al., 1998;Mastroberardino et al., 1998;Pfeiffer et al.,
1998;Pfeiffer et al., 1999;Tsurudome et al., 1999). It makes biological sense that a
transformed cell, with higher levels of cell cycle activity, should have increased
transporter systems in place to permit this - such systems might be expected to be
necessary to sustain transformation. This indeed appears to be the case, since
transformation of BALB 3T3 cells by CD98 required its association with the light chain
and mutations preventing this association removed its transformational ability (Shishido
et al., 2000). Whether increased expression of CD98 heavy chain is to be explained in
this way, or whether it has influence on the transformation process in other ways is
currently unclear.
What has become apparent is that CD98 is intimately linked with pi integrins. The co-
immunoprecipitation experiments presented in this chapter were technically difficult and
may be criticised in their interpretation because they were highly dependent upon the
conditions under which immunoprecipitation took place. Multiple unsuccessful attempts
to co-immunoprecipitate CD98 and pi integrin preceded successful experiments and
these seemed at least in part due to the more stringent effects of the MAPK lysis buffer
used initially. Although a CHAPS/deoxycholate lysis buffer was then effective in co-
immunoprecipitation from both transfected Cos-7 cells and normal human macrophages,
it was unsuccessful for SCLC, for which further modification of the lysis buffer and
experimental conditions was required. These adjustments indicate that the molecular
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bond between CD98 and pi integrin is sufficiently weak as to be lost under more
stringent lysis conditions, but also that other conditions such as cell numbers are critical
in such experiments. Using cell lines such as H69 SCLC, which are small and have a
relatively large nucleus and small cytoplasm/cell surface area, even though CD98 and pi
are both highly expressed, increasing the cell numbers was critical in raising the
sensitivity of the assay. These co-immunoprecipitation experiments, therefore, were
both cell type-dependent and sensitive to assay conditions and hence open to simple
criticism - the very conditions that permit co-immunoprecipitation may be producing a
false positive result. However, the finding that CD71 did not co-immunoprecipitate with
pi integrins suggests that conditions were not so lax that any protein in the cell
membrane would be co-immunoprecipitated.
Under these circumstances, the complementary data provided by confocal microscopy
has been supportive. Initial experiments highlighted the difficulties of trying to cope
with cross-reactivity between different primary and secondary antibodies and results
were strikingly more specific using conjugated primary antibodies. Confocal
microscopy then supplied powerful data supporting the co-localisation of CD98 and pi
integrin, including whether it was constitutive or dependent upon integrin activation
state, by use of integrin function-stimulating and -blocking antibodies. This had not
been assessed before. Limitations include that the cells were assessed only at one point
in time, for which they were fixed in paraformaldehyde, so a true assessment of changes
in CD98-integrin association was not possible. To do this would require real-time
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imaging in live cells during pi integrin-dependent processes, such as
adhesion/deadhesion, together with a more refined imaging analysis, such as fluorescent
resonance energy transfer.
Importantly, the findings also agree with other in vitro data emerging on the relationship
between CD98 and pi integrin. Zent et al. have shown that CD98 binds to the
cytoplasmic domain of integrin piA and P3, but very poorly to the muscle-specific
variant piD or the leucocyte-specific p7 (Zent et al., 2000). It is interesting to note that
very mild detergent conditions were required (0.05% Triton X-100), correlating with
experience described here. In addition, binding of CD98 in this system correlated with
the ability to complement dominant suppression, since it was far less effective at
reversing suppression induced by Tac-piD or Tac-p7. By mutational analysis, it was
observed that the last seven residues of the piA tail were necessary for this interaction
and that part of the importance of the CD98-pl integrin interaction was a participation in
the polarisation and regulation of amino acid transporters.
This has been further supported in two whole cell systems. Merlin et al. have shown
that in polarized intestinal epithelial cells, CD98 is co-localised with pi integrin (Merlin
et al., 2001) on the basolateral cell membrane. This group have suggested that since
overexpression of CD98 disrupts the normal pi integrin surface distribution and actin
cytoskeleton re-organisation, CD98 may be intimately involved in pi-related cell
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signalling, although this may have been an artefact of overexpression in this system.
Using rhabdomyosarcoma and fibrosarcoma cells, Kolesnikova et al. have recently
shown that CD98 constitutively associates with a2pi, a3pi, a5pi and a6pi integrins,
but not a4pi, suggesting that the integrin a chain does contribute to the specificity of
this interaction (Kolesnikova et al., 2001). This study used reciprocal
immunoprecipitation and since EDTA did not influence the association, it supports the
present data that it was a constitutive interaction, pi integrin and CD98 were associated
in low density "light membrane" fractions on a sucrose gradient, not in the dense
fractions containing most of the pi integrin - this would be consistent with an
interaction in the context of "lipid rafts" in the cell membrane, which may prove
important for signalling. Interestingly, this group also reported that the presence of the
light chain modified the targeting ofCD98 to the lipid fraction.
Earlier studies had suggested that at least some of the functional effects of CD98, such
as homotypic cell aggregation, were mediated through tyrosine kinase activation
(Warren et al., 1996;Tabata et al., 1997). Since PI 3-kinase is a major downstream
target of receptors with intrinsic or associated tyrosine kinase activity, it was therefore
unsurprising to find that cross-linking CD98 stimulated PI 3-kinase activity. This work
has been extended in our group: it has been shown that cross-linking CD98 activates
protein kinase B, the key downstream effector of PI 3-kinase, as well as MAP kinase.
This pattern of signalling is in keeping with an integrin-mediated signalling pathway and
subsequently CD98 signalling has been shown to be pi integrin and FAK-dependent
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(Rintoul et al., 2002). The signalling function of CD98 heavy chain and the amino acid
transport function of the light chain seem to be mutually independent, since cross-linking
CD98 with 4F2 had no effect on amino acid uptake and the amino acid transport
blocking agent BCH had no effect on CD98 signalling. These features are in keeping
with an earlier finding by Fenczik's group that distinct regions of CD98 are responsible
for amino acid transport and integrin-related interactions (Fenczik et al., 2001). Using
chimaeric CD98/CD69 proteins, the extracellular domain of CD98 heavy chain was
identified as important for amino acid transport, whereas the cytoplasmic and
transmembrane domains were required for its effects on integrin function.
In summary, this chapter has provided evidence of a physical association of CD98 with
pi integrins and of downstream effects of cross-linking CD98, both in cell signalling
and cell behaviour. These findings are increasingly supported by a literature that
suggests a direct involvement of CD98 in pi integrin signalling, which is distinct from
its role in amino acid transport. This picture of a multifunction molecule gives credence
to the finding of CD98 upregulation in transformed cell systems, such as lung cancer.
139
Chapter 4
CD98 and Galectin-3 Expression in Human Lung Disease
4.1 Introduction
Lung carcinoma is categorised broadly by histology into small cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC). SCLC almost invariably present with
widespread metastatic disease and, despite initial response to chemotherapy, the tumours
relapse and become resistant to further chemotherapy. By contrast, NSCLC are less
likely to have metastasised at presentation, but are relatively insensitive to
chemotherapy. About 10-14% of cases of SCLC exhibit areas of NSCLC morphology;
these mixed tumours have both a poorer response to treatment and poorer survival
(Fushimi et al., 1996).
Chapter 3 has presented evidence strongly supporting a role for CD98 as a protein
intimately involved in the modulation of integrin function and with a potential for
promoting oncogenic transformation. Most of the earlier work has been in vitro and
there has been relatively little work looking at CD98 expression in vivo. Broadly
speaking, both lines of investigation have suggested that tumours exhibit increased
expression of CD98 compared with non-tumour tissue. Papetti et al. described increased
CD98 expression in a variety of tumour cell lines as well as paraffin-embedded sctions
of prostate cancer; treatment with an antibody to CD98 resulted in growth inhibition
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(Papetti and Herman, 2001). In squamous cell laryngeal carcinoma, a histological study
observed increased CD98 expression only in those tumours showing metastatic
behaviour (Esteban et al., 1990). Transfection of the epidermal growth factor (EGF)
receptor negative SCLC cell line, GLC3, with mutant EGF receptor resulted in
upregulation of CD98 expression (Pedersen et al., 2001). However, in leukaemia, higher
CD98 levels have been associated with improved outcomes, with more prolonged
periods of remission in both adults and children (Taskov et al., 1996;Nikolova et al.,
1998). In lung disease, including lung cancer, there have been no histological studies
examining CD98. Given its potential role in neoplasia, it was decided that an
assessment of CD98 expression should be undertaken in a series of routine pathological
sections, including a range of lung cancers.
As previously discussed in Chapter 1, Dong and Hughes identified galectin-3 as a ligand
for CD98 (Dong and Hughes, 1997). Galectin-3 is a (3-galactoside binding protein of
~30kD which is expressed in a variety of cells, including cells of the
monocyte/macrophage lineage and epithelial cells (Hughes, 1994;Barondes et al.,
1994b). Galectin-3 consists of a carboxyl-terminal carbohydrate binding domain, a
repetitive collagen-like sequence and a functionally distinct amino-terminal domain
(Barondes et al., 1994a;Gong et al., 1999). It exists as a monomer but can self-associate
and form polymers through interactions of either its N-terminal domain (Birdsall et al.,
2001) or its C-terminal domain (Yang et al., 1998), giving rise to a potential to cross¬
link proteins at the cell surface. Histologically, the role of galectin-3 in malignant
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transformation is controversial. Upregulation of galectin-3 expression has been
observed in thyroid, gastric, pancreatic and head and neck malignancies (Schaffert et al.,
1998;Baldus et al., 2000;Cvejic et al., 2000;Honjo et al., 2000), but other studies have
found down-regulation of galectin-3 in ovarian and breast cancers (Castronovo et al.,
1996;van den Brule et al., 1996a), and conflicting results have been obtained in colonic
carcinomas (Lotz et al., 1993;Bresalier et al., 1998). This may reflect cell type
specificity and the influence of galectin-3 on tumour cell behaviour. To date there have
been no immunohistochemical studies comparing galectin-3 expression in lung cancers,
although recently Yoshimura et al. have described differential expression between SCLC
and NSCLC when measured by reverse transcription-polymerase chain reaction
(Yoshimura et al., 2003).
4.2. Assessment of 4F2 for immunohistochemistry
Earlier studies had been performed using the mouse monoclonal antibody 4F2 directed
against CD98 in immunohistochemistry studies (Rintoul, PhD thesis, 2002). However,
staining on these samples was considered poor, with high background staining, and the
samples themselves were old, historical samples from the University of Edinburgh
Department of Pathology files. It was deemed necessary to reassess the accuracy of 4F2
for use in immunohistochemical studies.
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4.2.1 4F2 is an unreliable antibody for immunohistochemistry
Five recent biopsy samples, embedded in paraffin wax, were confirmed to have SCLC
by a consultant pathologist, Dr. Donald Salter. Samples were treated with methanol:
acetone (1:1, v/v) at -20°C for 20 mins, then permeabilised with 0.1% Triton X-100 in
PBS for 5 mins, before being washed in PBS twice for 5 mins. They were then blocked
with 10% normal rabbit serum in PBS for 30 mins at r/t and then incubated with 4F2
(135/xg/ml) for 30 mins at r/t. Subsequent washes and secondary staining was performed
using the indirect streptavidin-biotin method as described in "Materials and Methods".
Assessment of these sections revealed that 4F2 staining was universally poor (Figure
4.1). This included areas of inflammation which, being rich in CD98-rich
polymorphonucleocytes and macrophages, would be expected to be strongly positive
internal controls. This suggested that the antigen was not being recognised by the
antibody. This could be because the epitope had been masked by fixation and not
successfully retrieved, or because the antibody was not applicable for this technique.
However, no external positive control was utilised. It was concluded that no comment
could be made about CD98 expression in these specimens using this technique and that a
positive control slide was essential.
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(a) (b)
x 400 x 200
(c) (d)
x 400 x 400
Figure 4.1: 4F2 produces poor results in historical paraffin-embedded specimens.
Historical, paraffin-embedded specimens of SCLC were probed with 4F2 (135pg/ml) or carrier
solution, then by secondary rabbit anti-mouse HRP. followed by DAB substrate. Negative control
samples showed no binding (a), but test samples shown at lower power (b) or higher power (c and d)
exhibited a high degree of non-specific binding of 4F2 to background proteins.
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4.2.2 Polyclonal and monoclonal antibodies against CD98 may be used in frozen
section samples
As positive controls, two different cell samples were taken: (a) frozen sections of lymph
nodes infiltrated by lymphoma; (b) CHO cells transfected with the expression vector for
CD98-COOH. Untransfected CHO cells, which express low levels of CD98, were used
as negative controls. CHO cells were transfected according to standard protocol with
2/xg cDNA for CD98-COOH per 10cm dish. At 48 hours they were harvested, being
trypsinized and allowed to re-adhere for 4 hours on glass slides. Cells were then fixed
with 3% paraformaldehyde for 20 mins at r/t, and aldehydes quenched with 50mM
NH4CI for 10 mins. All samples were then subject to the same immunohistochemical
staining protocol as in "Materials and Methods", including a peroxidase block (0.5%
H2O2 in H2O for 10 mins). Three different antibodies were used directed against CD98:
4F2 mouse monoclonal; SC-7095 goat polyclonal; RDI-CD98 CabG goat polyclonal.
All samples showed positive staining with either of the commercial goat polyclonal
antibodies (Figure 4.2). This included untransfected CHO cells, although these were
markedly less positive than transfected CHO-CD98 cells. Using 4F2 mouse monoclonal
as the primary antibody, untransfected CHO cells appeared negative, but CHO-CD98
cells remained strongly positive, as were lymphoma sections. Thus all antibodies appear
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Figure 4.2: Monoclonal and polyclonal antibodies to CD98 in frozen section
CHO cells, either untransfected (UT) or transfected with CD98 (TR), and sections of frozen human
lymph node (LN) were exposed to increasing concentrations of (a) monoclonal 4F2 or polyclonal
antibodies: (b) SC-7095; or (c) RDI CD98 CabG (RDI). Appropriate secondary antibodies were used
and negative controls were exposed to carrier alone during primary incubations.
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In order to confirm successful transfection of CD98 into CHO cells, an associated pilot
experiment was performed in which transfected CHO-CD98 cells were harvested and
assessed for CD98 expression by flow cytometry using 4F2, as described in "Materials
and Methods". The use of 4F2 in flow cytometry has previously been well established
as a marker of CD98 expression. In transfected CHO-CD98 cells 4F2 bound strongly
(mean fluorescence 46.2 AU), in contrast to the fluorescence seen with either an isotype
control antibody or carrier solution (3.4 and 3.1 AU respectively); however,
untransfected CHO cells exhibited no increase in 4F2 binding (mean fluorescence 2.7
AU) over isotype or carrier controls (2.6 and 2.4 AU respectively) (data not shown).
This confirmed that CHO cells used as positive controls in immunohistochemical studies
were capable of high levels of detectable CD98 expression following transfection, but
expressed negligible amounts of CD98 in the native state.
4.2.3 4F2 is ineffective in paraffin-embedded histology sections
No improvement in specificity of staining in frozen sections was observed by pre-
adsorbing the primary antibodies in 20% human/20% rabbit serum (data not shown).
The potential use of 4F2 was therefore reassessed in paraffin-embedded sections of
lymph nodes involved by lymphoma, since these would be the type of test sample used.
Standard immunohistochemical technique was followed using incremental doses of 4F2.
Antigen retrieval was performed either with Vector Unmasking Solution or with ImM
EDTA pH8. Figure 4.3 demonstrates that, despite containing clearly visible germinal
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Figure 4.3: 4F2 is not useful in paraffin-embedded histology sections.
Parrafin-embedded sections of human lymph node, known to be involved with lymphoma, were prepared
using two different standard methods of antigen retrieval, either the proprietary Vector™ Unmasking
Solution or ImM EDTA pH8. Immunohistochemistry was performed with incremental concentrations of
4F2 (100 - 500p.g/ml). No clear antigen specificity was achieved with either antigen retrieval regimen,
and the non-specific background signal was high. All sections are shown at x400 magnification.
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From this set of experiments it was concluded that 4F2 could be used in frozen sections
or paraformaldehyde-fixed cells, or with live cells in flow cytometry, as elsewhere in
this thesis. However, the absence of staining in paraffin-embedded positive control
tissue sections, despite standard antigen retrieval techniques and high doses, implied that
4F2 was unsuitable as a primary antibody under these conditions. 4F2 was therefore
abandoned for further immunohistochemical studies and the commercial polyclonal
antibody SC-7095 assessed for further use.
4.2.4 Titration of SC-7095
Paraffin-embedded lymph node control sections were used to assess the sensitivity of the
goat polyclonal SC-7095 in detecting CD98 under a standard immunohistochemical
protocol with two different standard antigen unmasking conditions. A dose-response
study was then performed using the DAKO Techmate system to optimize the antibody
concentration to be used, since future studies would use this system to process multiple
slides. Figure 4.4 shows that SC-7095 localized clearly to the germinal centers of
lymph nodes, with the clearest results seen using Vector Unmasking Solution; an
optimal dilution of 1:100 was identified under these conditions. Negative control
samples were probed using carrier solution only in place of primary antibody, but with
appropriate biotinylated secondary rabbit anti-goat as for the test samples. These
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Figure 4.4: Titration of SC-7095 anti-CD98 antibody in paraffin-embedded histology sections.
Parrafin-embedded sections of human lymph node, known to be involved with lymphoma, were prepared
using Vector™ Unmasking Solution. Immunohistochemistry was performed with incremental
concentrations of the goat polyclonal anti-CD98 antibody SC-7095 (1/1600 - 1/25). A clear, specific
signal was observed, picking out membranous expression of CD98 by proliferating lymphocytes in lymph
node germinal centres (arrowed). With increasing antibody concentration, decreasing specificity of
staining was observed. All sections are shown at x200 magnification.
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4.2.5 Assessment and titration of mAb B2C10 against galectin-3
It was first confirmed that the mouse monoclonal antibody B2C10 (gift, Dr. F.T. Liu),
raised against galectin-3, demonstrated immunoreactivity against the appropriate target
protein. This antibody has previously been well described and was initially shown to
recognize the amino-terminal of galectin-3 (Liu et al., 1996). E.coli were transformed
with cDNA encoding hamster galectin-3 according to standard protocol as described in
"Materials and Methods". E.coli were then cultured and selected for carriage of the
correct plasmid by antibiotic selection. Individual colonies were then boiled in lx lysis
buffer, run on SDS-PAGE and probed with B2C10 for expression of galectin-3. B2C10
isolated a protein of molecular weight ~30kD from transformed cells (data not shown).
This would correspond well with the predicted expression of galectin-3 and confirmed
that B2C10 was directed against galectin-3.
B2C10 was titrated using the DAKO Techmate system and with a standard protocol. As
above, lymph node sections provided appropriate positive control samples. Figure 4.5
shows that compared with negative controls (diluent only), B2C10 specifically localized
to germinal centers, with galectin-3 expression by macrophages. An optimal signal was





Figure 4.5: Titration of anti-galectin-3 antibody B2C10 in paraffin-embedded histology sections.
Titration of B2C10 in lymphoma-involved human lymph node paraffin sections. Immunohistochemistry
was performed with incremental concentrations of B2C10 (1/1600 - 1/200). A clear, specific signal was
observed, picking out expression of galectin-3 by macrophages {arrowed). With high antibody
concentration, decreased specificity of staining was observed. All sections are shown at x200
magnification.
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4.3 Test sections involving human lung neoplasms
To assess the expression of CD98 and galectin-3 in normal and pathological processes in
the lung, a broad cross-section of lung biopsy and lung resection samples was identified
from the University of Edinburgh Department of Pathology files. Samples dated from
the period 1997-2001 and were pathology specimens identified from routine clinical
practice. Control samples of normal lung were taken from non-involved lobes of lung
cancer cases. All samples had been fixed in 4% paraformaldehyde and embedded in
paraffin wax.
For immunohistochemistry, 3-5/xm sections were dried on to slides overnight at 37°C.
They then underwent deparaffinization in xylene, followed by antigen unmasking in
Vector Unmasking Solution (1:500) for 3x5 minutes at 99 C. Immunohistochemistry
was performed following the DAKO Techmate protocol, using the indirect streptavidin-
biotin method as described in "Material and Methods". The primary antibodies used
were goat polyclonal antibody to CD98 (SC-7095) at 1:100 dilution and mouse
monoclonal antibody to galectin-3 (B2C10) at 1:400 dilution. Negative control sections
were incubated in carrier solution only. Positive control sections were taken from
reactive lymph nodes; in addition, other cell types within the same sections (especially
macrophages) acted as internal positive controls. The immunostained sections were
counterstained with haematoxylin.
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Sections were assessed together by standard light microscopy by the author and Dr.
Monaghan, a pathologist with a specialist interest in respiratory disease, and
independently by a third (Dr. Salter, consultant respiratory pathologist). Where
differences were identified, cases were settled by conference. Immunoreactivity for
CD98 and galectin-3 was scored semi-quantitatively in areas of tumour: (a) for
percentage of cells staining (absent = 0; < 20% = 1; 20-80% = 2; > 80% = 3) and (b) for
strength of staining (absent = 0; weak = 1; moderate = 2; strong = 3). The cellular
localization of CD98 and galectin-3, whether nuclear, cytoplasmic or membranous, was
noted. The distribution of CD98 and galectin-3 in other cell types (interstitial and
alveolar macrophages, lymphocytes, fibroblasts, bronchial epithelium, vascular
endothelium and mesothelium) was also documented for all sections, where present.
A total of 115 samples were studied, represented in Table 4a. These covered the major
subtypes of bronchogenic carcinoma, mesothelioma, carcinoid and a variety of
inflammatory conditions. The expression of CD98 and galectin-3 observed in each
group was as described below.
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Table 4a: Samples studiedfor CD98 and galectin-3 expression
Lung condition Samplenumber
Normal 5















mixed cell type (1)
Interstitial pulmonary fibrosis 4
Sarcoidosis 4
Bronchiolitis obliterans organizing s
pneumonia (BOOP)
U
Extrinsic allergic alveolitis 5
Langerhans cell histiocytosis 5
4.3.1 Normal Lung
All CD98 expression was membranous. It was expressed at moderate levels by both
tissue macrophages and alveolar macrophages, and weakly by type II pneumocytes and
bronchial epithelium. Otherwise, CD98 expression was absent in normal lung (Figure
4.6a), with no expression identified to any degree by type I pneumocytes, endothelium,




Figure 4.6(a): CD98 expression in normal lung.
Low (x200) and high (x400) power views demonstrating characteristic CD98 expression
in normal lung. Expression is identified in bronchial epithelium (BE), macrophages




Figure 4.6(b): Galectin-3 expression in normal lung.
Low (x200) and high (x400) power views demonstrating characteristic CD98 expression
in normal lung. Expression is identified in bronchial epithelium (BE), macrophages
(MP), type I and II pneumocytes (P1/2) and vascular endothelium (VE). Mesothelial
cells and fibroblasts were also positive (not demonstrated on this section).
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In normal lung, bronchial epithelium expressed galectin-3 moderately to strongly; tissue
and alveolar macrophages expressed it strongly. There was weak/moderate galectin-3
expression by type II pneumocytes and weak expression by type I pneumocytes,
mesothelial cells, interstitial fibroblasts and vascular endothelium (Figure 4.6b).
These general observations of CD98 and galectin-3 expression in normal lung held true
for non-involved lung in all subsequent sections.
4.3.2 Squamous cell carcinoma
CD98 expression was membranous and was expressed in 25 of the 26 squamous cell
carcinoma specimens. Strength of expression was moderate / strong (mean score = 2.42)
by the majority of cells (mean score = 2.87). CD98 expression exhibited a degree of
"zoning", in that it was most strongly expressed in the basal layer cells of carcinomas,
diminishing with distance from the basement membrane (Figure 4.7a). In addition, in
the most well differentiated squamous cell carcinomas, which exhibited areas of
keratinization, CD98 expression was noted to diminish within keratin pearls. Overall,
CD98 expression by squamous cell carcinomas was significantly different from that
exhibited by both adenocarcinomas and carcinoid tumours (p<0.001).
Galectin-3 expression was predominantly cytoplasmic and nuclear, and was seen in the
majority of cases (20/25). Overall, strength of expression was moderate (mean score =






Figure 4.7(a): CD98 expression in squamous cell carcinoma.
Low (xlOO) and high (x400) power views demonstrating characteristic CD98 expression
in squamous cell carcinoma. Expression was greatest in basal layers, diminishing with
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Figure 4.7(b): Galectin-3 expression in squamous cell carcinoma.
Low (xlOO) and high (x400) power views demonstrating characteristic galectin-3
expression in squamous cell carcinoma. Expression was greatest towards areas of












Figure 4.7(c): Complementary expression of CD98 and galectin-3 in squamous cell carcinoma.
Intermediate (x200) power views of paired samples of well-differentiated squamous cell carcinoma.
CD98 expression tends to diminish within keratin pearls, whereas galectin-3 expression is upregulatcd
in these regions.
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differential expression between well and poorly differentiated carcinomas, with higher
expression in well-differentiated carcinomas (mean score = 2.06) and weaker expression
in poorly differentiated samples (mean score = 1.43), but this did not achieve
significance. Zoning was also evident in the pattern of galectin-3 expression (Figure
4.7b), but by contrast with CD98, galectin-3 was increasingly expressed by tumour cells
towards areas of central necrosis and within keratin pearls, such that CD98 and galectin-
3 expression appeared complementary (Figure 4.7c). Overall, galectin-3 expression by
squamous cell carcinomas was significantly different from that exhibited by SCLC and
carcinoid tumours (p<0.01).
Thus, in squamous cell carcinomas, CD98 expression was broadly upregulated, with a
tendency to reduced expression in the more differentiated, keratinised areas. By
contrast, galectin-3, although highly expressed, tended to be highest in the most well
differentiated samples.
4.3.3 Adenocarcinoma
Of 22 specimens, 20 adenocarcinomas expressed CD98 in a membranous pattern to
varying levels (mean strength score = 1.32), and by the majority of tumour cells in each
sample (mean score = 2.53) (Figure 4.8a). CD98 expression by adenocarcinomas was
significantly different from expression by SCLC (p<0.05) and significantly different





Figure 4.8(a): CD98 expression in adenocarcinoma.
Intermediate (x200) and high (x400) power views demonstrating characteristic




Figure 4.8(b): Galectin-3 expression in adenocarcinoma.
High (x400) power views demonstrating characteristic galectin-3 expression in
adenocarcinoma. Bronchoalveolar cell carcinomas sometimes exhibited a classical
lepidic growth pattern (upper panel). Galectin-3 expression was observed in nuclear
(N), cytoplasmic (C) and membranous (M) compartments (lower panel).
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The strength of galectin-3 expression by adenocarcinomas was moderate to high (mean
score = 2.36) and in all cases expression was seen in the majority of cancerous cells
(mean score = 3). Galectin-3 was again expressed in a predominantly cytoplasmic and
nuclear pattern (Figure 4.8b). There was no discernible difference between well and
poorly differentiated adenocarcinomas. Overall, galectin-3 expression by
adenocarcinomas was significantly different from galectin-3 expression by SCLC and
carcinoid tumours (p<0.001).
Therefore, in adenocarcinomas, CD98 and galectin-3 are both highly expressed.
4.3.4 Small cell carcinoma
One case of SCLC represented a tumour sample taken post-chemotherapy. This was
considered separately from all the other SCLC cases, which were taken pre-
chemotherapy. All these small cell carcinomas expressed CD98 in a membranous
pattern, the majority to high levels (mean score = 2.23) and by the majority of the
carcinoma cells in each sample (mean score = 2.85) (Figure 4.9a). This was
significantly different from CD98 expression observed in both adenocarcinomas
(p<0.05) and carcinoid tumours (p<0.01).
Galectin-3 expression was negative in the majority (13/18) of SCLC cases (mean
strength score = 0.28) (Figure 4.9b). Of the five that exhibited any galectin-3




Figure 4.9(a): CD98 expression in small cell carcinoma.
Low (xlOO) and high (x400) power views demonstrating characteristic membranous








Figure 4.9(b): Galectin-3 expression in small cell carcinoma.
Intermediate (x200) and high (x400) power views demonstrating characteristic galectin-3
expression in SCLC. Internal controls include macrophages (MP) and bronchial epithelium
(BE).
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expression by SCLC was significantly different from that observed in squamous cell
carcinomas (p<0.01) and significantly different from adenocarcinomas (p<0.001).
In SCLC, therefore, although CD98 expression is uniformly high, galectin-3 expression
is absent or only at very low levels. This is in contrast to the situation seen in NSCLC.
One case of SCLC represented a mixed tumour. Within this, the areas of small cell
phenotype were negative for galectin-3, whilst areas of squamoid differentiation
exhibited high galectin-3 expression (Figure 4.10). This suggests that galectin-3 may be
useful in histological assessment of such mixed tumours, by clearly discriminating
between SCLC and NSCLC populations within the tumour.
A further case of SCLC was identified that differed from all others in that, for clinical
reasons, the biopsy had been obtained after a full course of treatment with
chemotherapy. This was the only post-chemotherapy sample examined. Although there
was no difference in CD98 expression from other SCLC cases, all malignant cells in this
sample exhibited very strong galectin-3 expression, which contrasted markedly with all
other SCLC cases (Figure 4.11). This was reproducible on repeated immunostaining.
4.3.5 Carcinoid tumour
CD98 expression by carcinoid tumours was focally weak, where present at all (mean





Figure 4.10: Galectin-3 expression in a mixed tumour.
Intermediate (x200) and high (x400) power views of a mixed tumour, in which areas of
small cell phenotype (SCLC) exhibit low/absent galectin-3 expression, in contrast to areas







Figure 4.11: CD98 and galectin-3 expression in small cell carcinoma post-chemotherapy.
Intermediate (x200) and high (x400) power views of a SCLC sample, taken following chemotherapy. CD98
expression is membranous (upper panel); in contrast to other SCLC samples, galectin-3 expression is
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Figure 4.12: CD98 and galectin-3 expression in carcinoid tumour.
High (x400) power views of carcinoid tumour. CD98 expression was minimal or absent (a)
and galectin-3 expression was absent (b). Macrophages (MP) and vascular endothelial cells
(V) acted as internal positive controls for immunohistochemistry in this highly vascular tumour.
171
seen in SCLC (p<0.01) and significantly different from squamous cell carcinomas
(pO.OOl).
Galectin-3 expression by carcinoid tumour cells was negative in all cases (mean score =
0) (Figure 4.12b). This is significantly different from galectin-3 expression by
squamous cell carcinomas (p<0.01) and significantly different from adenocarcinomas
(p<0.001).
Thus, despite a neuroendocrine origin like SCLC, carcinoid tumours have a different
CD98 / galectin-3 phenotype.
4.3.6 Small cell lung cancer exhibits different galectin-3 expression compared
with non-small cell carcinoma
All types of aggressive lung tumour exhibited upregulated expression of CD98 to a
varying degree. However, comparing galectin-3 expression between the different
phenotypes of bronchogenic tumours, it was clear that there was a striking difference
between SCLC and NSCLC. Whereas all NSCLC phenotypes expressed galectin-3
moderately or strongly, SCLC tumours expressed galectin-3 only very weakly, if at all.
Carcinoid tumours expressed neither protein to significant levels. Figure 4.13
summarises the strengths of expression of CD98 and galectin-3 exhibited by the









Figure 4.13: CD98 and galectin-3 expression by bronchogenic tumours.
Graphical summary of the relative strengths of (a) CD98 expression and (b) galectin-3
expression of squamous cell carcinoma, adenocarcinoma, SCLC and carcinoid tumour.
Bars represent the mean +/- standard error.
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4.3.7 Mesothelioma
Eleven mesothelioma samples were studied, ofwhich 9 were of epithelioid subtype, one
of spindle cell subtype and one of mixed cell type. There was no apparent difference
between the different cell types in either CD98 or galectin-3 expression. CD98
expression by mesothelioma cells was weak / moderate (mean expression score = 1 ±
0.2); of those tumours expressing CD98, a variable percentage of tumour cells were
expressing the protein (mean percentage score = 2 ± 0.3) (Figure 4.14a).
Galectin-3 expression by mesotheliomas was weak / moderate (mean expression score =
1.2 ± 0.3), although in those tumours expressing galectin-3, the majority of cells did so
(mean percentage score = 2.9 ± 0.1) (Figure 4.14b).
4.4 Test sections involving inflammatory lung conditions
Tumour cells were not present in the majority of these samples. Assessment of these
sections therefore focused on the cells making up the inflammatory interstitium.
4.4.1 Idiopathic pulmonary fibrosis
Interstitial cells in IPF were not prominent in our histology sections. Those that were
present expressed no CD98, but expressed galectin-3 to weak levels (mean score = 0.75




Figure 4.14: CD98 and galectin-3 expression in malignant mesothelioma.
(a) CD98 expression was membranous, but only weak/moderate in tumour cells (M).
(b) Galectin-3 expression was largely cytoplasmic and weak/moderate. Vascular endothelial cells acted
as a positive internal control (VE).
























Figure 4.15: CD98 and galectin-3 expression in interstitial pulmonary Fibrosis.
No tumour cells were present in these sections and assessment was made of the cells that predominated in
the interstitial disease process.
(a) CD98 expression was largely absent, with no convincing expression by fibroblasts (F), the
predominant cells in the interstitium. Occasional macrophages (MP) acted as internal positive controls.
(b) Galectin-3 expression was largely cytoplasmic and weakly expressed by fibroblasts. Bronchial
epithelial cells (BE) expressed galectin-3 strongly in nuclear, cytoplasmic and membranous compartments
and acted as positive internal controls together with vascular endothelial cells.
Sections shown at x400 magnification.
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4.4.2 Sarcoidosis
The predominant interstitial changes seen in sarcoidosis were the presence of non-
caseating granulomas. In all cases the epithelioid giant cells that constituted the
granulomas expressed low levels of CD98 (mean score = 1 ± 0.0), whereas other
interstitial cells, namely fibroblasts, were negative for CD98. All granulomatous giant
cells expressed moderate levels of galectin-3 (mean score = 2 ± 0.0), but interstitial
fibroblasts were negative in 2 of the three samples and not seen in the third (Figure
4.16a and b).
4.4.3 Bronchiolitis obliterans organizing pneumonia (BOOP)
Interstitial cells were visualized in these sections, but did not express CD98 (mean score
= 0). In all sections, these interstitial fibroblasts expressed galectin-3 weakly (mean
score = 1 ± 0.0) (Figure 4.17a and b).
4.4.4 Extrinsic allergic alveolitis
Interstitial cells did not express CD98 in EAA, and expressed galectin-3 weakly in only
2 out of the five samples (mean score = 0.4 ± 0.2) (Figure 4.18a and b).
4.4.5 Langerhans cell histiocytosis
In Langerhans cell histiocytosis characteristic tumour cells were seen. In these samples
there was weak/moderate expression of CD98 by the tumour cells (mean score = 1.2 ±
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Figure 4.16: CD98 and galectin-3 expression in sarcoidosis.
No tumour cells were present in these sections and assessment was made of the cells that predominated in
the interstitial disease process.
(a) CD98 expression was generally absent from fibroblasts (F), the predominant cells in the interstitium.
However, non-caseating granulomas (G) with macrophages and multinucleated epithelioid giant cells
(EGC) demonstrated strong membranous CD98 expression.




Figure 4.17: CD98 and galectin-3 expression in bronchiolitis obliterans organising pneumonia.
No tumour cells were present in these sections and assessment was made of the cells that predominated in
the interstitial disease process.
(a) CD98 expression was absent from fibroblasts (F), the predominant cells in the interstitium.
Macrophages (MP) provided an internal positive control.
(b) Galectin-3 expression was present at low levels in fibroblasts, but there was strong expression by
macrophages.




Figure 4.18: CD98 and galectin-3 expression in extrinsic allergic alveolitis.
No tumour cells were present in these sections and assessment was made of the cells that predominated in
the interstitial disease process.
(a) CD98 expression was absent from fibroblasts (F), the predominant cells in the interstitium. Alveolar
macrophages (MP) provided an internal positive control.
(b) Galectin-3 expression was present at low levels in fibroblasts, but there was strong expression by
macrophages and moderate expression by type II pneumocytes (P2).
Sections shown at x400 magnification.
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expressed by tumour cells (mean score = 1.6 ± 0.5) but was expressed only weakly in the
interstitium of 1 out of four samples (Figure 4.19a and b).
4.5 Discussion
The aim of experiments described in this chapter was to establish the pattern of
expression of CD98 and its ligand, galectin-3, in a variety of lung conditions,
particularly lung tumours. The chapter describes initial difficulties in obtaining a true
assessment of CD98 expression in historical, paraffin-embedded lung tissue. It was
established that the monoclonal antibody 4F2, although excellent for fresh cell work, or
work on frozen sections, was inadequate for application in paraffin-embedded sections.
By contrast, the commercially available goat polyclonal antibody SC-7095 proved
excellent for this purpose and further work established appropriate concentrations for
this and for a monoclonal antibody against galectin-3. The most likely explanation for
the superiority of SC-7095 over 4F2 under these conditions would be the availability of
epitopes. Presumably the epitope for 4F2 is somehow destroyed in the paraffin
processing and are not recoverable, even with standard unmasking techniques as
described. The epitope for SC-7095 must clearly survive these processes.
The major thrust of the chapter thereafter describes a semi-quantitative
immunohistochemical assessment of the expression of CD98 and galectin-3 in a variety
of lung carcinomas, carcinoid tumours, mesotheliomas, inflammatory lung conditions
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Figure 4.19: CD98 and galeetin-3 expression in histiocytosis.
(a) CD98 expression was absent from fibroblasts (F). the predominant cells in the interstitium. The
Langerhans cells (LC) did not express CD98. Alveolar macrophages (MP) provided an internal positive
control.
(b) Galectin-3 expression was present at very low levels in fibroblasts (left panel)-, there was strong
expression by macrophages and moderate expression by vascular endothelial cells (VE). Langerhans cells
expressed galectin-3 to moderate levels (right panel).
Sections shown at x400 magnification.
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and normal controls. The key findings were: (i) in NSCLC, CD98 and galectin-3 were
highly expressed. In squamous cell carcinomas there appeared to be differential
expression of CD98 and galectin-3 between well- and poorly differentiated carcinomas,
such that increased CD98 expression was broadly associated with more poor
differentiation, whereas galectin-3 expression was maximal in better differentiated
tumours, (ii) In SCLC, by contrast, although CD98 was highly expressed, galectin-3
was very poorly expressed, (iii) Expression of CD98 and galectin-3 by carcinoid
tumours was very low or absent.
This pattern of CD98 and galectin-3 expression may be an important feature affecting
the different behaviours of these tumours, in particular chemoresistance and the
development of metastatic disease. As such, the assessment of galectin-3 expression
may be a useful diagnostic tool as well as a predictor of response to chemotherapy, and
may therefore be important in influencing patient treatment. Additionally, assessment of
galectin-3 expression may be of particular benefit in mixed tumours, where the response
to chemotherapy is otherwise difficult to predict.
As previously discussed, the finding that CD98 expression was upregulated in lung
carcinomas is in keeping with several studies showing that CD98 is upregulated in
actively proliferating cells. It is unsurprising that slow growing, less malignant
carcinoid tumours expressed only minimal CD98. There is a good correlation between
the level of CD98 expression seen here and the growth rates measured by the volume
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doubling time. Amongst lung carcinomas, SCLC and squamous cell carcinomas show
the highest rate of growth when measured by volume doubling time (Geddes,
1979;Hasegawa et al., 2000). In the present study, these were seen to express higher
levels of CD98 than the more slowly growing adenocarcinomas. Carcinoid tumours are
the slowest growing of the tumours studied and expressed the least amount of CD98.
Galectin-3 expression in lung tumours was examined because it has been identified as
the ligand counter-receptor for CD98 (Dong and Hughes, 1997). The striking finding
was that SCLC exhibited minimal or absent galectin-3 expression, in distinct contrast to
all NSCLC, which expressed significant amounts of galectin-3. Additionally, one SCLC
sample was histologically a mixed carcinoma. There was a clear distinction between
areas of SCLC phenotype, which were galectin-3 negative, and areas of NSCLC
phenotype, which expressed galectin-3 to high levels. This broadly supports the finding
of differential expression of galectin-3 between SCLC and NSCLC as a whole. It offers
the possibility that assessment of galectin-3 expression may be of use in differentiating
SCLC from NSCLC in small tissue samples, such as core biopsies or bronchial biopsies,
where confusion arises. In practice, however, this is not usually a problem, since there
already exists a broad range of markers allowing classification of lung tumours between
SCLC and NSCLC. Might galectin-3 expression be a useful cell marker in other ways?
Evidence from in vitro work suggests that galectin-3 may promote neoplastic
transformation. Honjo et al. introduced recombinant galectin-3 into null-expressing,
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non-tumourigenic BT-549 cells, resulting in the acquisition of anchorage-independent
growth, one of the hallmarks of tumourigenicity (Yoshii et al., 2002). In addition,
human breast carcinoma BT549 cells transfected with galectin-3 and treated with
genistein exhibit G2/M phase cell cycle arrest, but are protected against apoptosis, as
compared with non-transfected controls (Lin et al., 2000). Furthermore, in vitro,
galectin-3 has anti-apoptotic functions. In human breast carcinoma cells, galectin-3
overexpression protects against nitric oxide-induced apoptosis in a liver
ischaemia/reperfusion model (Moon et al., 2001), as well as apoptosis induced by a
variety of other stimuli, including loss of cell adhesion (Kim et al., 1999), staurosporine
and cisplatin (Matarrese et al., 2000;Matarresea et al., 2000). In T-cells, galectin-3
prevents apoptosis induced by anti-Fas-antibody (Yang et al., 1996). Interestingly,
galectin-3 shows significant homology to the anti-apoptotic protein Bcl-2 (Yang et al.,
1996). Overexpression studies in BT549 cells suggest that any anti-apoptotic effect of
galectin-3 is not mediated through changes in Bcl-2 expression, but may be via a
cysteine protease pathway (Akahani et al., 1997).
In vivo, increased galectin-3 expression has been associated with neoplastic progression
in a variety of tumours, including gastric (Baldus et al., 2000), pancreatic (Berberat et
al., 2001), colonic (Irimura et al., 1991) and thyroid (Cvejic et al., 1998;Cvejic et al.,
2000) carcinomas. However, other groups have reported contrasting evidence that
down-regulation of galectin-3 is associated with tumour progression in other tumour
groups, such as breast and ovarian cancers (Castronovo et al., 1996;van den Brule et al.,
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1996b). Studies have also tried to examine whether subcellular localization of galectin-3
varied with tumour progression: in squamous cell tongue carcinomas, for example,
galectin-3 expression was up-regulated during progression from normal to cancerous
states, but there was a loss of nuclear staining compared to normal mucosa (Honjo et al.,
2000). Lotz et al. found a similar loss of nuclear expression associated with progression
of colonic carcinoma, but this was in the context of an overall decrease in galectin-3
expression as measured by mRNA levels and immunohistochemistry (Lotz et al., 1993).
A role for galectin-3 in the development of neoplasia has thus so far been controversial
and the evidence seems to suggest that its role may be tumour-specific to some degree.
Recently another group has published evidence supporting the finding that galectin-3 is
differentially expressed in lung cancer. Yoshimura et al. reported overexpression of
galectin-3 in NSCLC by comparison to SCLC, when measured by reverse transcription-
polymerase chain reaction (Yoshimura et al., 2003). In their study, SCLC either failed
to express galectin-3, or did so at a very low level. Therefore, these two studies
complement each other, with a clear differential in galectin-3 expression between
NSCLC and SCLC, observed at both RNA and protein level.
No definite cellular function for galectin-3 has yet been ascribed. Localization has been
demonstrated in various cellular compartments, with clear nuclear and cytoplasmic
expression (Openo et al., 2000); membranous expression has been documented and there
is also evidence that galectin-3 may be actively secreted into the extracellular milieu
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(Cherayil et al., 1989;Sato and Hughes, 1994). Among its potential extracellular ligands
are the ECM proteins laminin and fibronectin. Within the cell, galectin-3 has been
reported to have activity as a pre-mRNA splicing factor (Dagher et al., 1995) in the
nucleus and to be a component of heterogeneous nuclear ribonuclear protein. If
promoting oncogenic transformation, therefore, galectin-3 may be acting at a nuclear or
cytoplasmic level by as yet unknown mechanisms.
Intriguingly, galectin-3 may be acting at the cell surface to cross-link CD98 and promote
integrin-like signalling and hence cell survival. The quaternary structure of recombinant
murine galectin-3 was recently described by sedimentation velocity and equilibrium
studies, and suggested that galectin-3 exists predominantly as a monomer (Morris et al.,
2004). However, other lines of evidence suggest that it may self-associate into
oligomeric units. Gel electrophoresis experiments have revealed dimers (Ochieng et al.,
1993), whilst the ability to promote haemagglutination (Frigeri et al., 1990) or to co¬
operatively bind to laminin (Massa et al., 1993) and IgE (Hsu et al., 1992) suggests a
protein functioning at a multivalent level. It may do this directly, through self-
association of its N-terminal domains (Birdsall et al., 2001), or it may do so by first
binding to ECM proteins that are abundant in the local milieu. Recent work suggests
galectin-3 can precipitate rapidly from a monomelic solution as pentamers, forming
heterogenous, disorganised, cross-linking complexes with multivalent carbohydrate
ligands (Ahmad et al., 2004). Against this, the majority of galectin-3 seen in samples in
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the present work was cytoplasmic or nuclear, although some membranous staining was
also identified, allowing for this possibility.
The cellular role of CD98 has already been discussed in Chapter 3. Its involvement in
integrin-related cell-signalling pathways raises the possibility that cross-linking CD98 by
its natural ligand may profoundly affect tumour sensitivity and the induction of
apoptosis by chemotherapeutic agents.
These studies therefore offer interesting insights into a possible role for galectin-3 in
lung cancer. It has long been known that SCLC is, at presentation, by far the most
chemosensitive histological subtype, whereas NSCLC adenocarcinomas and squamous
cell carcinomas have been regarded as relatively chemoresistant. This supports the
pattern of galectin-3 expression observed here, since galectin-3 negative SCLC might be
expected to undergo chemotherapy-induced apoptosis and exhibit a clinical response to
such chemotherapy. The galectin-3 positive NSCLC would be expected to be relatively
chemoresistant, and a tumour of mixed cell type to have an intermediate response.
Galectin-3 expression on initial diagnostic biopsy may therefore be of potential use as a
predictor of chemotherapeutic response in tumours, rather than simply as a discriminator
between SCLC and NSCLC.
In this context, the single sample of SCLC taken post-chemotherapy is intriguing, since
it was strongly positive for galectin-3, in contrast to all other SCLC specimens. Since
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relapsed SCLC is usually much more chemoresistant, this would be predicted from the
present study, although it does not inform any further on the role, if any, that galectin-3
might play in the development of that chemoresistance.
This chapter also describes CD98 expression and galectin-3 expression in other lung
conditions. These included tumours of non-bronchogenic origin - mesothelioma and
Langerhans cell histiocytosis - and a number of interstitial lung diseases. There has
been little research in these fields before involving either galectin-3 or CD98 and only
very general conclusions may be drawn.
Since both mesothelioma and Langerhans cell histiocytosis are proliferative diseases, it
was unsurprising to discover elevated CD98 expression in the tumour cells, as with
bronchogenic cancers. Galectin-3 was elevated to moderate levels by both tumours.
Following the discussion above, this would be in keeping with the low level of response
seen in these diseases to either chemotherapy or radiotherapy. However, the numbers in
these samples was low and there are no previous reports with which to compare these
results.
The remaining samples broadly fall into the category of "inflammatory lung diseases",
although it should be stated that for neither sarcoidosis, nor BOOP, nor IPF has the
pathological trigger been clearly identified. In sarcoidosis, the characteristic
pathological markers are non-caseating granulomata; in IPF there appears to be an
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abnormal proliferative response from fibroblasts in the interstitium; in BOOP a chronic
inflammatory cell infiltrate is found, with increased patchy fibrosis.
There is little direct evidence published on the role of CD98 in any of these diseases,
although a single report looking at a variety of interstitial lung diseases found elevated
CD98 expression by macrophages isolated from bronchoalveolar lavage fluid (Taylor et
al., 2000); along with other markers studied, this really goes no further than suggesting
that the macrophages in these diseases were activated by comparison with macrophages
from normal subjects. Given the chronic inflammatory response observed in these
diseases, macrophages would be expected to be present; however, the present study
found no striking CD98 expression elsewhere.
The role of galectin-3 is more interesting and evidence is now accumulating for a
significant part in the control of inflammation. Several groups have now shown that
galectin-3 is required for a normal inflammatory response. Colnot et al. found that
galectin-3-null mice demonstrated an attenuated inflammatory cell infiltrate following
peritoneal injection with thioglycollate, which was not due to increased apoptosis by the
granulocytes, nor to increased phagocytosis by macrophages (Colnot et al., 1998b). In a
similar model, these findings were associated with a reduced NF-kB response (Hsu et
al., 2000). Macrophages from these animals had abnormal cell spreading and were more
likely to undergo apoptosis. Conversely, gene therapy with the instillation of plasmid
DNA encoding galectin-3 has been shown to reduce an eosinophilic inflammation in a
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rat model of acute asthma, with a strong reduction in IL-5 mRNA levels (Del, V et al.,
2002). In addition, in vitro studies have shown that exogenous galectin-3 can both
stimulate superoxide production by neutrophils (Yamaoka et al., 1995) and promote the
adhesion of neutrophils to laminin, both by forming lectin bridges with the laminin and
by promoting other cell adhesion molecules (Kuwabara and Liu, 1996).
Taken together, these studies suggest that galectin-3 may play an important role in
control of inflammatory cell responses. In the present study, therefore, it was interesting
to observe that macrophages and epithelioid giant cells were universally strongly
positive for galectin-3 and also that there was a low-grade expression of galectin-3 by
interstitial fibroblasts in some sections.
In summary, this chapter has described important findings in the expression of CD98
and particularly galectin-3 in human lung carcinomas, with notable differences between
SCLC and NSCLC. These may suggest an important role clinically for assessment of
galectin-3 expression as a marker of chemoresistance and may direct further
investigation into the role of galectin-3 in cell survival.
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Chapter 5
Modulation of Integrin Activation Status:
R-Ras Reversal of Suppression
5.1 Introduction
One of the underlying aims of this thesis was to attempt to elucidate the mechanisms by
which integrin activation status may be modulated. "Integrin activation" represents the
end result of two distinct processes, affinity modulation and avidity modulation, as
discussed in Chapter 1. Studies undertaken here have been directed specifically at
investigating affinity modulation, which involves a conformational change in the
integrin as a direct result of intracellular signalling pathways, resulting in a change in the
binding affinity of the integrin towards its ligand (reviewed in (Huttenlocher et al.,
1995)).
Although the predominant integrins expressed on small cell lung cancer are those of the
pi family (Hirasawa et al., 1994;Falcioni et al., 1994), the most thoroughly investigated
integrin has been the platelet integrin allbp3 whose activation is required to permit
fibrinogen binding and clot formation. Research has been facilitated by the use of the
highly specific ligand-mimetic antibody PAC1, which recognises ligand-binding sites
within the activated (but not suppressed) allbp3 integrin (Shattil et al., 1985). It has
been shown that integrin-ligand binding is a divalant cation dependent process requiring
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calcium and magnesium, such that chelation of these ions with EDTA totally inhibits
PAC1 binding, whereas the presence ofmanganese ions increases the activation state of
integrins to a maximum (Gailit and Ruoslahti, 1988). Further studies were facilitated by
the use of a model system established in the Chinese hamster ovary cell line. O'Toole et
al. showed that expression of allbp3 in these cells failed to bind PAC1 even in the
presence of known activation stimuli, suggesting that the mechanisms required for
allbp3 regulation are absent in this cell line (O'Toole et al., 1990). However, if the
cytoplasmic domain of the integrin was substituted with a different alpha subunit and a
pi subunit cytoplasmic change, this permitted PAC1 binding. A stable cell line was
therefore established expressing the chimaeric integrin allba6p3pi (aP-py cells), in
which the extracellular domain of allbp3 is constitutively active. In 1997, Hughes et al.
published data reporting that an activated form of H-Ras (Ras G12V) inhibited PAC1
binding in a Raf-1 and MAP kinase dependent manner (Hughes et al., 1997). It has been
shown that the small GTP-binding protein R-Ras not only activates integrins, enhancing
cell adhesion, but it is able to reverse this H-Ras mediated integrin suppression (Zhang et
al., 1996b;Sethi et al., 1999a). However, the downstream effector pathways through
which R-Ras reversal occurs are not understood. Although it is recognised that R-Ras
and H-Ras can both bind the common effectors Rafl, Ral-GDS and PI 3-kinase (Urano
et al., 1996;Marte et al., 1997;Rodriguez-Viciana et al., 1997), Sethi et al. found that
these pathways were not involved in R-Ras reversal (Sethi et al., 1999a).
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The use of the aP-py CHO cell system has been established in our laboratory by Dr. Y.
Lad (PhD Thesis 2001). The present chapter examines early steps that were taken in
trying to identify possible cell signalling pathways that might be involved in integrin
affinity modulation, with a special interest in the mechanism of R-Ras reversal. In the
first instance the ap-py CHO cell system was established as a workable test system.
It was hypothesised that possible candidates for integrin modulation might then include
proteins involved in the regulation of the cell cycle. In the normal cell cycle, successive
waves of cyclins and cyclin-dependent kinases (Cdks) drive progression, acting in GO to
initiate S phase and in G2 to trigger mitosis (Coqueret, 2002). Expression levels of the
different cyclins vary individually across the cell cycle and are both highly regulated and
rate-limiting (reviewed in Coqueret (2002)). Following serum starvation cyclin D1 may
be induced early in the G1 phase in a growth factor-dependent manner, via the Ras-Raf-
MAPK-ERK pathway. Its role at this point consists mainly of an association with Cdk4
to initiate retinoblastoma protein (Rb) phosphorylation (Dowdy et al., 1993), relieving
histone deacetylase binding and thus allowing cyclin E/Cdk2 complexes access to their
targets, pushing the cell towards S phase. Using a different technique, following
asynchronous cells, cyclin D1 levels have been demonstrated to be low in S phase, but
elevated in G1 and G2 phases, the suggestion being that cyclin D1 initially rises in G2
and is then maintained through mitosis and Gl, until suppressed in S phase (Stacey,
2003). During mitosis, cells in culture are visibly observed to "round up", becoming
loosely attached to the underlying surface, enabling them to undergo cell division easily.
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Only following mitosis do they become strongly adherent once more. This suggests an
intimate relationship between the cell cycle and cell surface adhesion proteins such as
integrins and it was therefore hypothesized that cyclin D1 may be involved in the
promotion of integrin suppression running up to and during the mitotic phase.
An additional subject of investigation was CD98, which has been implicated in pi
integrin activation (see Chapter 3), together with a general approach to try and identify
pathways involved in mediating R-Ras reversal of H-Ras mediated integrin suppression,
using a range of specific enzyme inhibitors.
5.2 The ap-py CHO cell model
5.2.1 PAC1 binding and modulation of integrin status by cations
The aP-py system was first described by Hughes et al. (Hughes et al., 1997) and initial
experiments were used to define the binding of PAC1 antibody to aP-py cells, as
described in "Materials and Methods". Titration of PAC1 antibody for our system was
performed by Dr Y Lad as described (PhD Thesis). Initial experiments for the current
work confirmed that PAC1 antibody binds to ap-py cells, in contrast to an IgM isotype
control antibody. Figure 5.1 (upper panel) shows a representative histogram of FL1-
FITC Fluorescence against cell number. In ap-py cells transfected with Tac-a5 alone, a
reporter construct that does not affect integrin affinity, PAC1 antibody binds strongly,




Figure 5.1: PAC1 binding to ap-py CHO cells
Upper panel: PAC1 monoclonal antibody binds strongly to aP-py cells (infilled line),
by contrast to an IgM isotype control antibody (broken line) or carrier alone (narrow
line).
Lower panel: Effect of 5mMol EDTA and lOOmMol Mn2+ on PAC1 binding,
measured by intensity of fluorescence (arbitrary units, AU).
Results are representative of at least three sets of experiments.
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to binding shown with the IgM isotype-matched control antibody (4.3 ± 0.1) or
unstained controls (4.2 ± 0.1). In keeping with previous work, the chimasric integrin is
able to undergo conformational change by treatment with cations and Figure 5.1 (lower
panel) shows the effect of treatment with 5mM EDTA or lOOmM Mn2+. In the native
state, without treatment, mean fluorescence intensity was 21.1 ± 1.2 AU (mean ± SEM).
Addition of EDTA markedly reduced PAC1 binding to a mean fluorescence intensity of
4.6 ± 0.7 AU, whereas in the presence of exogenous Mn2+ there was a significant
increase in PAC1 binding, to a mean fluorescence intensity of 26.7 ± 2.8 AU. This
shows that the chimaeric integrin is constitutively activated and demonstrates that
integrin affinity may be modulated by cations. In addition the use of EDTA and
manganese permits a numerical estimate of integrin activation status, as described in
"Materials and Methods". Briefly, integrin affinity in the presence of 5mM EDTA is
taken to be the minimum possible (or most suppressed), whereas integrin affinity is
taken to be maximum (most activated) in the presence of lOOmM Mn2+. Under any test
conditions, therefore, the integrin activation status is represented by the activation index
(AI) calculated as a percentage lying between the suppressed (0%) and activated (100%)
states. In the above example, the AI for ap-py cells in their native state is 76.1% ± 6.2,
demonstrating that in this system integrins are predominantly in the activated state under
native conditions.
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5.2.2 H-Ras G12V suppresses integrin affinity
In order to determine the effect of Ras G12V expression on integrin affinity, the aP-py
cell system was used. Cells were transfected and integrin affinity status assessed as
described in "Materials and Methods". Figure 5.2 shows a representative dot-blot
display, demonstrating the effect of Ras G12V transfection on PAC1-FITC binding. In
these and subsequent experiments cDNA constructs were transfected together with
cDNA for the chimaeric construct Tac-a5. This contains the intracellular domain of the
a5 integrin conjoined with the extracellular domain of the IL-2 receptor. Expressed at
the cell surface by successfully transfected cells, the transfection efficiency may be
detected by flow cytometry using an antibody against the IL-2 receptor, Tac-R-PE (R-
phycoerythrin).
In Figure 5.2 integrin affinity is represented along the X axis by increasing PAC1
binding, whilst transfection status is represented along the Y axis, with the most highly
transfected cells exhibiting high Tac-a5 expression, as demonstrated by Tac-PE binding.
It has been assumed that transfection of Tac-a5 corresponds to transfection of other
cDNA constructs to a similar degree.
Figure 5.2 demonstrates that in the presence of lpg cDNA for Ras G12V, integrin
affinity was markedly reduced in the most transfected cells. In cells transfected with
Tac-a5 alone, the majority of highly transfected cells were in the upper right hand






10" 101 102 10J
EDTA
PAC1-FITC binding (arbitrary units)
NATIVE
H-Ras GI2V
Figure 5.2: H-Ras G12V transfection suppresses integrin affinity.
Dot-blot graphs showing the effect of transfection with H-Ras G12V on PAC1 binding. Integrin affinity
is reflected by PAC1-FITC binding, with elevated PAC1 binding represented by cells to the right of
dashed line x. Transfection status is assessed by Tac-PE binding, with high transfection represented by
cells above the dashed linej.
Upper panel, transfected with Tac-a5 alone, in the presence of 5mMol EDTA, there was an increase in
percentage of transfected cells in the low affinity state (upper left quadrant), addition of lOOmMol Mn2 t
activated integrins, with an increased percentage of transfected cells exhibiting high PAC1 binding
(upper right quadrant).
Lower panel, transfected with H-Ras GJ2V: transfection with H-Ras G12V resulted in a leftward shift in
PAC1 binding in transfected cells, that was not fully recoverable even in the presence of lOOmMol Mn2+.
Results are representative of at least three sets of experiments.
88.5%
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of transfected cells were in the upper left hand quadrant, representing a low affinity or
2+
suppressed integrin state, as previously described; lOOmM Mn increased integrin
activation state compared to normal. However, in the presence of Ras G12V the
majority of transfected cells demonstrated a reduced integrin affinity, with a leftward
shift in PAC1 binding. This was exaggerated with 5mM EDTA and was not fully
recoverable with lOOmM Mn2+. Because of this phenomenon, the AI in transfected cells
was calculated by taking the maximum natural affinity state to be that represented by
2+
PACl binding in Tac-a5 transfected cells in the presence of lOOmM Mn .
5.2.3 Titration of H-Ras G12V
The amount of H-Ras G12V cDNA required to adequately suppress integrins was
assessed by titration experiments. aP-py cells were transfected with increasing
quantities of H-Ras G12V and the integrin affinity assessed as above. Figure 5.3a
(iupper panel) shows the effect on AI of increasing quantities of H-Ras G12V. The AI
of cells transfected with Tac-a5 alone was 84.0% ± 2.3 (mean ± SEM). Transfection of
lpg ofH-Ras G12V cDNA suppressed the integrins to an AI of 38.4% ± 7.4. Increasing
quantities of G12V cDNA resulted in a further reduction in AI to a minimum of 31.2% ±
3.3, with 4pg of cDNA. By contrast, transfection with 5pg of a control vector
pCDNA3.1 made no difference to the AI (mean ± SEM = 83.4% ± 9.2).
In parallel with the above experiment, transfected cells were lysed as described in
"Materials and Methods" and, following equilibration for total protein loading, lysates
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Figure 5.3: Titration of H-Ras G12V
(a) Integrin status in a(3-py cells following transfection with increasing doses of
cDNA for H-Ras G12V, compared with untransfected cells or cells transfected with
the vector cDNA3.1 alone. Integrin status may be represented by an Activation Index
(upper panel) or, inversely, by a Suppression Index {lower panel).
(b) Western blot confirming increased expression of H-Ras, labelled via its HA tag,
with increasing dose of cDNA.
Results shown are mean +/- standard error of three experiments.
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were resolved on SDS-PAGE gels and probed for expression of H-Ras G12V. Figure
5.3b shows a representative blot demonstrating increasing expression of the Ras G12V
plasmid in cells transfected with increased quantities of cDNA.
It was noted that with increasing quantities of H-Ras G12V cDNA, there was a marked
increase in cell death following transfection, with a dramatic loss of recoverable cells.
Since excellent suppression was achieved with 2pg cDNA, with only moderate loss of
cells, this concentration of cDNA was used for future experiments.
5.2.4 R-Ras reverses H-Ras-mediated integrin suppression
It has previously been shown that the activated form of the small GTP-binding protein
R-Ras G38V can reverse H-Ras G12V mediated integrin suppression. This was
confirmed in transfection experiments in our aP-py system. Figure 5.4 (upper panel)
shows that when aP-py cells were transfected with 2/xg H-Ras G12V, integrin
suppression occurred in the most highly transfected cells, as indicated by reduced PAC1
binding by comparison with untransfected cells. However, in cells transfected with both
2/xg H-Ras G12V and 2/xg R-Ras G38V, this suppression was reversed so that the
integrins were expressed in an activated state once more and PAC1 binding was
restored. Figure 5.4 (graph) confirms this graphically: the AI of cells transfected with
H-Ras G12V alone was reduced (AI = 25.0% ± 2.6), but transfection with R-Ras G38V
alone (115.8% ± 9.4) increased AI compared to native cells (73.3% ± 3.6) and rescued
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Figure 5.4: R-Ras G38V reverses H-Ras-mediated integrin suppression.
Upper panels. Dot-blots showing integrin suppression by transfection of aP-py cells with H-Ras G12V (2pg).
As previously, a greater percentage of transfected cells {above line y) were shifted to the left compared with
control cells {not shown), an effect not fully retrieved by lOOmMol Mn2+. Transfection with H-Ras G12V
(2pg) plus R-Ras G38V (2pg) rescued integrins from H-Ras-mediated suppression, increasing the percentage
of transfected cells exhibiting high PAC1 binding {right of line x).
Lower panel. Graph demonstrating the effect on Activation Index of transfecting aP-py cells with H-Ras
G12V (2pg), R-Ras G38V (2pg), or both together, compared with Tac-a5 alone. (*** p < 0.001 compared
with Tac-a5 alone.)
Results are representative of at least five experiments.
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5.3 Cyclin D1 reduces integrin activation
It makes biological sense for integrin activation status to be modulated through the cell
cycle, e.g. to allow a degree of cell detachment during mitosis when cells round up to
divide. It was therefore hypothesized that proteins involved in the regulation of the cell
cycle may be regulators of integrin affinity. Since cyclin D1 levels have been found to
be elevated from G2, through M to G1 phase (Stacey, 2003), it was therefore
hypothesized that cyclin D1 may suppress integrin activation, in order to allow
rounding-up of the cell for mitosis.
Using the ap-py cell system, a dose-response study was performed. Figure 5.5 shows
that transfection with all doses of cDNA for cyclin D1 resulted in a significant reduction
in AI compared with control cells (AI = 65.4% ± 4.8), as assessed by PAC1 binding.
This was most marked with 2/xg cDNA of cyclin D1 (AI = 26.7% ± 3.8), but achieved
significance for all doses tested (p < 0.001). This finding supported the suggestion that
cyclin D1 might suppress integrin activation.
5.4 The effect of inhibitors
The mechanism by which R-Ras reverses H-Ras mediated integrin suppression is
entirely unknown and as part of this thesis it was proposed that a number of
pharmacological inhibitor agents might be assessed in the aP-py system, to see if they
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Figure 5.5: Cyclin D1 suppresses integrin activation.
Transfection of aP-py cells with cDNA for cyclin D1 induced suppression of
integrins, as measured by Activation Index. Compared with transfection with Tac-a5
alone, maximal suppression was achieved with 2pg cDNA for cyclin D1 (p < 0.001).
Results shown are mean +/- standard error of three experiments.
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influenced R-Ras reversal. For these early studies, therefore, cells transfected with both
H-Ras G12V and R-Ras G38V were treated with inhibitor agents and then assessed for
integrin activation as represented by PAC1 binding. The results of these early studies
highlighted a problem with the aP-py system, such that the experimental design was
adjusted in all subsequent experiments, as will be discussed below.
5.4.1 Okadaic acid may cause partial inhibition of R-Ras reversal
Okadaic acid is the toxin responsible for diarrhoeic shellfish poisoning. In vitro work
has shown it to be an inhibitor of protein phosphatases 1 and 2A and this has been
confirmed by intact cell studies (Haystead et al., 1989). It is useful as a specific probe
for identifying cellular processes regulated by phosphorylation/ dephosphorylation
events (Cohen et al., 1990). Figure 5.6 shows the influence of increasing concentrations
of okadaic acid on Al in aP-py cells transfected with both H-Ras G12V and R-Ras
G38V. In these experiments, okadaic acid was added to the culture medium 16-18 hours
prior to cell harvest and flow cytometry assay. By comparison to cells transfected with
Tac-a5 alone (Al = 69.7% ± 7.2), H-Ras G12V alone suppressed integrin status (Al =
22.0% ± 5.8), R-Ras G38V alone activated integrins (Al = 107.3% ± 6.5) and it
overcame H-Ras mediated suppression (Al = 59.8% ± 2.1), as expected. With
increasing concentrations of okadaic acid there was a steady decline in Al, so that at
30nM okadaic acid the Al was reduced to 47.6% ± 2.6, but at 300nM the Al was as low




Figure 5.6: Okadaic acid may inhibit R-Ras reversal.
Effect of increasing concentrations of okadaic acid on the ability of R-Ras G38V (2jag)
to reverse integrin suppression mediated by H-Ras G12V (2pg). By comparison with
the reversal seen with carrier solution alone (AI = 59.8% +/- 2.1), a marked suppression
of integrin activation status was observed in the presence of okadaic acid, achieving
significance at a concentration of lOOnM (Al = 22.1% +/- 2.7) (** p < 0.01). Data
represent the mean +/- standard error of two experiments. A marked fall-off of cell
population was noted with increased concentrations of okadaic acid {see text).
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"events" able to be gated on flow cytometry and a shift in the cell population on the dot-
blot graph.
5.4.2 Okadaic acid treatment effects are masked by cell death
The concerns raised by the above experiments were that the effect of partial inhibition of
R-Ras reversal of H-Ras mediated suppression was in fact due to cell death caused by
the DMSO carrier solution for the okadaic acid. This was suggested by the observation
that there was a visually observable loss of adherent cells in the petri dish following
treatment with okadaic acid. In addition, cell numbers detected through flow cytometry
were lower and the dot-blot distribution of cells, or "events", was shifted into the region
normally associated with cell debris.
In order to test this hypothesis, aP-py cells in the same experiment above, transfected
with both H-Ras G12V and R-Ras G38V, were treated with either a maximum
concentration (ljtrM) of DMSO alone, or with the maximum concentration of okadaic
acid (1/xM) in DMSO (1/rM). These were then subjected to analysis for cell death using
an Annexin V assay. Briefly, 5 x 106 cells were resuspended in 90/xl PBS, with 10/xl
Annexin V/buffer. Cells were incubated for 10 minutes at 4°C and then assessed by flow
cytometry, in which Annexin V positive cells are detected by increased FL1
fluorescence. Figure 5.7 shows that by comparison with control cells, there was an
increase in Annexin V positive cells following treatment with DMSO alone. However,
using the same gating analysis as had been used during the remainder of the experiment,
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Figure 5.7: Okadaic acid increases cell death.
Histogram graphs showing the effect of treating aP-py cells with carrier solution alone, a
maximum dose of DMSO (lpM), or maximum dose of DMSO plus okadaic acid (lpM). Cell
death was assessed by binding of Annexin V, measured (like FITC) in FL-1. The regions R1 and
R2 were arbitrarily set for untreated cells, such that 97.5% of the total cell population fell in R1
(;upper panel). Treatment with either DMSO alone (middle panel), or DMSO plus okadaic acid
(ilower panel), markedly increased the percentage of cells exhibiting positive Annexin V binding
(33% and 52%, respectively), indicating that these treatments increased cell death.
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there was an even greater increase in the proportion of Annexin V positive cells
following treatment with okadaic acid. Since Annexin V positive cells are dead or
apoptotic, this data supported the hypothesis that at least some of the effect of okadaic
acid in inhibiting R-Ras reversal was in fact due to an increased cell death.
5.4.3 To-Pro-3 for live/dead analysis
The ideal agent for discrimination between live and dead cells in the c/.p-py system
would be detectable in a different waveband from either FITC or PE, so that there is no
interference from the live/dead cell marker in assessment of FITC or PE fluorescence.
The commercial product To-Pro-3 was identified (Molecular Probes) with an emission
wavelength maximal at ~642nm. This is a cyanine dimer dye with high affinity for
nucleic acids with which it intercalates, yet it is cell-impermeant for live cells. Dead
cells are unable to exclude To-Pro-3 and fluoresce in the spectrum detected by FL-4.
Following discussion with Dr. Derek Davies (Flow Cytometry Laboratory, London
Research Institute), a final concentration of lOOnM To-Pro-3 was used. As can be
observed in Figure 5.8, addition of To-Pro-3 just prior to flow cytometry analysis
allowed dead, To-Pro-3 positive cells to be gated out on FL-4; the remaining live cells
being analysed in the usual way for FITC and PE binding.
5.4.4 Okadaic acid does not inhibit R-Ras reversal
Using the modified aP-py system, a variety of inhibitor agents were assessed for their
























Figure 5.8: To-Pro-3 permits live/dead analysis.
Graphs showing the use of To-Pro-3 in live/dead cell gating. In the upper panel, gate R1 was set to
gate out all To-Pro-3 positive cells, measured in FL-4. These would appear red in the dot-blot graph
of the whole cell population (inset), by reverse multi-channel gating. With larger numbers of cells
(middle and lower panels, note scale ofy-axis), not only did the number of dead, To-Pro-3 positive
cells become significant, but it could be seen from the dot-blot graphs (inset) that they were not
easily separable from the general cell population in terms of size and light scatter.
Representative ofmore than five sets of experiments.
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transfected according to standard protocol with H-Ras G12V, R-Ras G38V or both, in
the presence of the transfection marker Tac-a5. Approximately 3 hours prior to harvest
and analysis inhibitors were added to the culture medium to the final concentrations
indicated in the table below (Table 5a); wortmannin was added 30 minutes prior to
harvest. Cell harvest and preparation for cytometry were performed as usual, but with
the addition of the live/dead cell marker To-Pro-3 (final concentration lOOnM)
immediately prior to flow cytometry. Dead cells were gated out using FL-4 and analysis
was performed on the remaining live cells.
Table 5a: Inhibitors and concentrations
Inhibitor Agent Final Concentration Biochemical Target
Okadaic acid 50nM Protein phosphatases 1 / 2
LY294002 lOjuM PI 3-kinase
Wortmannin lOOnM PI 3-kinase
U-73122 1/rM Phospholipase C
PD 098059 30/xM MEK
Nocodazole lOOng/ml Microtubule formation
DMSO 0.005% Solvent
Figure 5.9 shows that, as baseline controls, H-Ras G12V transfection caused integrin
suppression (AI = 23.6% ± 1.7), whilst R-Ras G38V produced integrin activation (AI =
134.7% ± 14.6) and was able to reverse H-Ras mediated suppression (AI = 69.2% ± 6.4),
as predicted. Amongst cells transfected with both H-Ras G12V and R-Ras G38V, and
incubated overnight with different inhibitor agents, only okadaic acid (50nM) resulted in





Figure 5.9: Effect of inhibitor agents on R-Ras reversal.
Summary graph of the effects of a panel of inhibitor agents on the ability of R-Ras G38V
(2pg) to reverse integrin suppression mediated by H-Ras G12V (2pg). Using To-Pro-3 to
screen out dead cells, the following agents were screened for any significant inhibition of R-
Ras reversal: okadaic acid (Oka, 50nM); LY294002 (LY, lOpM); wortmannin (Wm, lOOnM);
U-73122 (lpM); PD 098059 (PD, 30pM); nocodazole (Noc, lOOng/ml). The carrier solution
was DMSO (0.005%). Results shown are mean +/- standard error of three experiments.
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With okadaic acid, AI was reduced to 50.1% ± 6.6; which was not significantly different
from integrin activation with H-Ras G12V alone. This reduction in AI was not seen in
cells incubated with DMSO carrier solution alone, suggesting that okadaic acid can
partially inhibit R-Ras reversal. However, nor was it significantly different from the AI
achieved with H-Ras G12V plus R-Ras G38V, so the conclusion must be that, although
suggestive, there is no firm evidence that okadaic acid inhibits R-Ras reversal. The
effect of incubation with other inhibitor agents was as follows: LY, AI = 66.2% ± 9.7;
wortmannin, AI = 66.3% ± 7.5; U-73122, AI = 64.2% ± 5.0; PD098059, AI - 69.1% ±
10.8; nocodazole, AI = 64.9% ± 5.8 (mean ± SEM of 3 experiments). None of these
agents produced any significant inhibition ofR-Ras reversal.
5.5 CD98 does not reverse H-Ras suppression
Since previous work has shown that the T-cell activation antigen, CD98, is a highly
specific activator of integrins, it was hypothesized that it might be able to reverse H-Ras
mediated integrin suppression. However, this did not appear to be the case, at least in
the aP-py system. Figure 5.10 shows that expression of CD98 appeared to have no
influence on AI. In cells transfected with cDNA for CD98, but not with H-Ras G12V or
R-Ras G38V, there was a slight increase in AI (85.9% ± 9.9) over cells tranfected with
Tac-a5 alone, but this did not achieve significance. H-Ras G12V significantly reduced




Tac H-Ras R-Ras CD98 H-Ras H-Ras
alone + +
R-Ras CD98
Figure 5.10: CD98 does not reverse H-Ras suppression.
Cells were transfected with cDNA for R-Ras G38V (2pg) or CD98 (2pg), in the presence or
absence of H-Ras G12V (2pg). H-Ras G12V mediates integrin suppression, which was
successfully reversed by R-Ras G38V; this effect was not observed with CD98. Results
shown are mean +/- standard error of three experiments.
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with CD98 (AI = 32.4% ± 4.0), in contrast to the reversal seen with R-Ras G38V (69.2%
± 6.4).
5.6 Discussion
This chapter describes data obtained in preliminary experiments directed at identifying
candidate signalling proteins involved in R-Ras reversal of H-Ras mediated integrin
suppression. The key features described are: (i) the establishment of the aP-py CHO
cell transfection system, permitting integrin activation status assessment by PAC1
binding; (ii) the influence of H-Ras G12V and R-Ras G38V on integrin activation; (iii)
the effect of cyclin D1 expression; (iv) the effect of a variety of inhibitor agents on R-
Ras reversal; (v) the effect of CD98. Of these, cyclin D1 appeared to reduce integrin
activation status, but no other agents used here significantly influence integrin activation
status in the studies shown. Finally, a significant problem was identified, namely that
increased cell death might mask or exaggerate these findings. Appropriate steps were
therefore taken to identify a live/dead cell marker that could be used, employing three-
colour cytometry.
Baseline studies on the aP-py CHO cell transfection system were in keeping with
experience in our own and other laboratories. It has been recognised for some time that
the divalent cations Mg2+ and Mn2+ promote integrin-ligand binding at a range of
concentrations. They occupy co-ordinating positions in the ligand-binding sites of both
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aA-domain-containing and aA-domain-lacking integrins: in the aA-domain itself, a
cation is sited at the apex as a key component of the MIDAS motif (Michishita et al.,
1993;Lee et al., 1995b); in aA-domain-lacking integrins, metal-binding sites have been
identified in the aA-like domain and in the (3 propeller (Cierniewski et al.,
1994;Tuckwell and Humphries, 1997). It was therefore entirely expected that binding of
2_|_the ligand-mimetic antibody PAC1 should be enhanced by Mn but eliminated by the
chelating agent EDTA. This cation-dependence and the interpretation that an
"Activation Index" could be derived from the ligand binding under these different
conditions, first proposed by Hughes et al. (Hughes et al., 1997), was critical to all
future work in this thesis.
Significant integrin suppression was achieved in Hughes' original report by transfection
with 1/rg cDNA and this has been our experience also. It is important to note that H-Ras
mediated integrin suppression was not associated with integrin phosphorylation and was
independent ofmRNA transcription and translation (Hughes et al., 1997). The pathway
through which H-Ras mediates integrin suppression was shown to be through Raf-1 and
MAP kinase, although more recent work by the same group has suggested that bulk
activation of the ERK/MAPK pathway is not required for integrin suppression (Hughes
et al., 2002).
In the present work, cyclin D1 expression was associated with integrin suppression in
the aP-py system. Since a cell must be more loosely adherent to its environment in
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order to undergo mitosis, cell cycle control must be intimately coordinated with integrin
activation and cellular adhesion - this is clearly visible as cells "round up" in vitro. A
corollary to this is that the protective effect brought about by integrin-mediated cell
adhesion would be reduced at these times. Historically it has long been recognised that
cell cycle is related to chemosensitivity, with cells in the log phase of growth much more
sensitive than those in the plateau phase (Martin and McNally, 1980). Previous studies
have shown that increased cyclin D1 expression is normally dependent upon Ras
activation during G2 phase (Hitomi and Stacey, 1999;Sa et al, 2002). Cyclin D1
transcription is stimulated through the Ras-MEK-ERK pathway in response to mitogen
activation and integrin-mediated adhesion. There are further layers of control of cyclin
D1 expression, due to post-transcriptional control mechanisms, since cyclin D1
accumulation occurs even in the presence of mRNA synthesis blockade (Stacey, 2003).
These further layers of control include regulation of protosome-dependent proteolysis
(Coqueret, 2002).
The present work does fit with this pattern of cell cycle control, in that the passage from
G2 to mitosis would require coordinated integrin suppression and this is what was
observed with overexpression of cyclin Dl. However, it also raises the possibility that
cyclin Dl contributes to the control of Ras-mediated suppression. This has not been
reported before; indeed, the bulk of the literature corresponds to the flow of information
the other way, i.e. control of cyclins by integrin-mediated adhesion. However, a recent
report notes modulation of cellular migration (an adhesion-dependent process) in
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prostate cancer cells in response to elevated levels of cdkl, associated with cyclin B2
(Manes et al., 2003). In addition there is emerging evidence that the downstream effects
of Ras signalling are dependent upon the cell cycle phase, such that Ras is only able to
stimulate cyclin D1 in G2 phase (Stacey and Kazlauskas, 2002). Thus it may be possible
that cyclins are involved in coordinating the regulation of integrin binding affinity, in an
inside-out signalling process.
In the present study transfection with CD98 did not appear to significantly affect integrin
affinity, although it might have been expected to do so, since it was able to rescue
integrins from dominant suppression by pi integrin cytoplasmic domains (Fenczik et al.,
1997b). However, CD98 did not reverse H-Ras mediated suppression in these initial
studies either, so the findings presented here are thus far in agreement. There was a
modest increase in integrin affinity in cells transfected with CD98 alone (compared with
normal), but this did not achieve statistical significance. It is difficult to know how to
interpret this. Cross-linking of CD98 has been implicated in pi integrin activation in
breast cancer cell lines (Chandrasekaran et al., 1999a), and in HIV-mediated cell fusion
(Ohta et al., 1994) and, as discussed in Chapter 3, there is clear evidence of a direct
association between CD98 and pi integrins. Further, Fenczik et al. have demonstrated
that the transmembrane and cytoplasmic portions of CD98 are the key domains
responsible for complementation of dominant suppression (Fenczik et al., 2001). CD98
is therefore intimately involved in pi integrin function and is perhaps best thought of as
a molecular facilitator within the plasma membrane.
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It was a disappointment that none of the inhibitor agents appeared to influence R-Ras
reversal of suppression. Of them all, the greatest effect was observed with okadaic acid.
This is a potent protein phosphatase 1 and 2 inhibitor, and is the compound thought to be
responsible for shellfish poisoning. Quoted IC50S are 10-15nM and 0.1 nM respectively
for the two phosphatases (Calbiochem), although some phosphatases reveal an IC50 of up
to 5fxM (Bialojan and Takai, 1988). Since the present study used 50nM it is possible that
the dose used was too low. However, this seems unlikely, since other studies on CHO
cells have shown an IC50 of 13nM (Huynh-Delerme et al., 2003). This group also
demonstrated that okadaic acid induced cell death in a significant proportion of CHO
cells in a time and concentration-dependent manner: at concentrations of 50nM (as for
the present work), cells were engaged in apoptosis by 20 hours, but at lOnM this was
delayed until 48 hours. When the initial studies with okadaic acid were performed in the
present work, cells had been incubated with okadaic acid for 16-18 hours. It is
unsurprising, therefore, that there was increased cell death. At the time, however, this
increased cell death resulted in the false impression of inhibition of reversal of integrin
suppression by okadaic acid, stimulating the search for a live/dead marker.
LY294002 is a competitive inhibitor for the ATP binding site of PI 3-kinase and has
been extensively used in our group with H69 SCLC cells. Previous studies have shown
an IC50 of 3.4 ± 1.4/iM in SCLC (Rintoul, PhD thesis 2001). This compares well with
published data (Vlahos et al., 1994) and it would therefore appear that the concentration
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used in the present study (10/rM) was reasonable. Wortmannin is a non-competitive
inhibitor of PI 3-kinase, extensively used by our group, with an IC50 of 8.0 ±2.1 in H69
SCLC (Rintoul, PhD thesis 2001); again this is comparable to the literature (Powis et al.,
1994) and the dose of lOOnM used in the present study would be expected to produce an
effect if one existed. This concurs with the findings of other groups that the PI 3-kinase
pathway is not involved in R-Ras reversal, in a variety of cell types including the aP-py
cell system (Sethi et al., 1999a;Kinashi et al., 2000;Self et al., 2001).
Nocodazole disrupts microtubule formation, interfering with their function during
mitosis. In vivo experiments on mammalian cells normally use doses of 0.04 - 10/rg/ml,
although higher doses have been used and the concentration used in the present study
(lOOnM) was both within this range and sufficient to effectively block mitosis in CHO
cells, as judged by an accumulation ofmitotic cells (unpublished observations).
U-73122 is an inhibitor of phospholipase C, a key enzyme that modulates
phosphoinositide levels, Ca2+ release and PKC activation. In human platelets and
neutrophils its IC50 is in the range 1 - 2.1/rM but it also acts as a potent inhibitor of
neutrophils adhesion, with an IC50 of 50nM (Calbiochem). In the present study it was
used at ljtiM, which is comparable with concentrations used by Vossmeyer et al., who
found that aipi-mediated adhesion of PC12 cells and CHO cells (transfected with al
integrin subunit) to laminin, collagen and fibronectin was inhibited at doses of 0.5 -
1.0/xM (Vossmeyer et al., 2002). This suggests that PLC is required for pi-dependent
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adhesion and the same group also showed that PLCy coimmunpoprecipitated with aipi
integrin, suggesting a direct physical association. In haematopoietic progenitor cells,
inhibition of PLC by up to 1/rM U-73122 led to reduced CD43-enhanced integrin-
dependent adhesion to fibronectin (Anzai et al., 1999). Thus, the weight of evidence
supports an effect of PLC in promoting integrin-mediated adhesion, but the present study
has not been able to observe this in the context ofR-Ras reversal of suppression.
PD098059 is a MAPK inhibitor that specifically inhibits MEK1. Published data in
Swiss 3T3 cells suggests an IC50 of 10/zM (Dudley et al., 1995); in CHO cells within
our group an IC50 of \2[iM was found and it was routinely used at a concentration of
30/xM (Lad, PhD thesis 2002). Initial reports found no evidence that the ERK/MAPK
pathway was involved in R-Ras reversal (Sethi et al., 1999a) and the current work
supports this, since PD098059 did not block the effect. Only weak evidence has been
found to propose R-Ras activation of the ERK/MAPK pathway: for example, an R-Ras
effector loop mutant was described by Osada et al. to have weak MAPK stimulating
activity (Osada et al., 1999); R-Ras has also been shown to have a synergistic effect with
IGF-1 in inhibition of apoptosis, through both MAPK and PI 3-kinase (Suzuki et al.,
1997). It seems likely, therefore, that any MAPK activity is more important for the anti-
apoptotic effects ofR-Ras, rather than integrin modulation.
In summary, this chapter has described the successful establishment of the a(3-py CHO
cell system for assessment of integrin activation status, together with initial assessment
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of potential modulators of integrin affinity. There was some evidence of integrin
suppression with cyclin Dl, suggesting a role for the cell cycle machinery in controlling
events at the cell surface, but a range of inhibitor agents has cast no specific light on
events downstream of R-Ras in reversal of suppression. No individual key signalling
protein was identified - nor, perhaps, was it likely to be using this rather broad sweep of
experimental technique. A more refined technique was felt necessary to identify specific
proteins, employing the aP-py cell system as a screening device to isolate candidate
proteins from a DNA library.
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Chapter 6
A Genetic Screen for Reversal of H-Ras Suppression
6.1 Introduction
The method described in Chapter 5 was unlikely to bring to light a specific protein that
reversed H-Ras-mediated integrin suppression - it was only ever likely to identify a
general pathway through which reversal of suppression might be mediated. Proteins
involved in reversal of H-Ras suppression would be expected to mediate integrin
activation. In order to identify possible novel proteins that are involved in this - and in
particular to try and identify mediators of R-Ras reversal of suppression - the ap-py cell
system was used in an expression cloning screening technique that has already been of
proven use in this field. By this method the transmembrane protein CD98 was isolated
as a protein capable of reversing pi integrins from trans-dominant suppression induced
by pi tails (Fenczik et al., 1997a); separately, PEA-15 was isolated for its ability to
reverse H-Ras G12V-mediated integrin suppression (Ramos et al., 1998).
To date no clear mechanism has been elucidated to explain how R-Ras is able to rescue
H-Ras-mediated integrin suppression. Although it does not appear to be a direct
activator of integrins, R-Ras strongly antagonized the Ras/Raf-initiated pathway
involved in integrin suppression in the aP-py cell system (Sethi et al., 1999a). This was
not due to simple competition between H- and R-Ras for the common effector Raf-1,
since R-Ras also reversed suppression induced by the activated variant Raf-BXB, which
lacks a Ras-binding domain. In addition, R-Ras had no influence on ERK2
phosphorylation by either H-Ras or Raf-BXB and nor was R-Ras reversal mediated by
the PI 3-kinase or Ral pathways. Other groups have supported the findings that neither
the ERK/MAPK pathway, nor the PI 3-kinase pathway are involved in R-Ras reversal, in
a variety of cell types (Kinashi et al., 2000;Self et al., 2001). Indeed, more recently
Hughes et al. have reported that H-Ras-mediated integrin suppression was itself not
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related to bulk activation of the ERK/MAPK pathway as initially believed, although it
was still mediated through Raf-1 (Hughes et al., 2002). This suggests the existence of
novel pathways through which integrin activation is regulated. There is, however, some
evidence that both PI 3-kinase and PKC may be important for R-Ras activity in some
cell types: R-Ras-induced adhesion and migration on collagen by breast epithelial cells
was both PI 3-kinase- and PKC-dependent, but not MAPK-dependent (Keely et al.,
1999). The mechanism for R-Ras reversal may therefore be cell-type and integrin
specific.
In a search for mediators of R-Ras reversal, it was postulated that cells expressing
activated p 1 integrins would express mRNA for proteins involved in integrin activation.
A cDNA library derived from such a cell population would thus contain cDNA for
candidate proteins that might be isolated with the aP-py cell system. For this reason, a
cDNA expression library (H4) derived from human promonocytic leukaemia U937 cells,
activated with phorbol 12-myristate 13-acetate, was obtained from the MRC Human
Genome Mapping Project and used to screen for genes capable of reversing H-Ras-
mediated integrin suppression. This library had been cloned into the pCDM8 expression
vector, which contains a CMV promoter and polyoma T antigen origin of replication, in
order to promote autosomal replication in aP-py cells.
6.2 Application of cDNA library
6.2.1 Library amplification
In order to produce enough cDNA for transfection, the library was amplified using
commercially competent TOP10/P3 E. coli (Invitrogen), following the manufacturer's
instructions. cDNA was recovered by use of Qiagen Midi-prep and the quality of cDNA
confirmed by UV spectral analysis. This confirmed a ratio of DNA/RNA of 2.04, which
was satisfactory for transfection purposes.
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Following amplification, the amplified cDNA was analysed by restriction enzyme digest
to ensure the amplification strategy had worked and to confirm that the amplified library
still contained pCDM8 expression vector. Hind III and Xhol both have digestion sites
flanking the insert cloning site for pCDM8. As shown in Figure 6.1, both digests
confirmed the presence of pCDM8: digestion of pCDM8 empty vector produced a band
of ~ 4.0kb, which is also seen in the library, together with a DNA smear of multiple
bands, representing the cDNA library inserts. With Xhol these range from ~750bp -
3.0kb, whilst with Hindlll they ranged from ~3.0kb - 12kb. Thus library amplification
was achieved successfully, without loss of the pCDM8 vector.
6.2.2 Transfection and library sorting
Preliminary experiments had previously been conducted by Dr. Y. Lad (PhD Thesis,
2001), establishing antibody dilutions and cell numbers to be used for transfection and
cell sorting. Due to the absence of an FL-4 channel on the cell sorter, the viability stain
7-AAD (observed in FL-3) replaced To-Pro-3.
Cell transfection and sorting was performed as described in "Materials and Methods".
Briefly, in 100mm plates, ap-py cells were transfected with: control pCDM8; H-Ras
G12V alone; H4 library alone; or H-Ras G12V plus H4. All plates were transfected with
Tac-a5 as a marker for transfection. The concentrations and quantities of cDNA were as
indicated in Table 6a. Transfection and cell culture followed standard technique.






H-Ras G12V 1 2/*g
Tac-a5 1.5 2Mg














Figure 6.1: Confirmation of successful library amplification.
TAE gels following restriction enzyme digest with Hind 111 (upper panel) and Xho 1 (lower panel).
A sample of positive control vector pCDM8 was digested alongside amplified H4 library (2pg) and
test samples derived from E. coli transformation, to look for the presence of the pCDM8 vector (see
later). In test samples no vector was observed, but pCDM8 vector was identified in the amplified
library (last column) in each digest. Xhol digestion also revealed the blank "stuffer" of the control
vector (~0.4kb) and a smear ofmultiple, different length plasmids in the amplified library.
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During cell sorting, those cells transfected with H-Ras G12V exhibited a marked
reduction in PAC1 binding compared with cells transfected with pCDM8 control vector,
as expected. Using these "standards", cells transfected with H-Ras G12V plus H4 were
sorted and collected from two Gates, R2 and R4. Cells in R2 exhibited exceptionally
high PAC1 binding, in the face of H-Ras G12V transfection and therefore represented
cells which may have been transfected with cDNA strongly promoting integrin
activation. Cells in R4 also exhibited positive PAC1 binding in the face of transfection
with H-Ras G12V, but were less positive than those in R2, which was thus a tighter
gated population. The total number of cells (or, strictly speaking, "events") collected in
Gates R2 and R4 were 97,731 and 262,232, respectively. The sorting analysis is
illustrated in Figure 6.2.
Following cell sorting, Hirt extraction was performed on the gated cells to extract the
transfected plasmids within, as described in "Materials and Methods". Plasmid DNA
was digested with the Dpn I restriction enzyme, prior to transformation of TOP10/P3 E.
coli. From Gate R2, following transformation and overnight culture on antibiotic-
restricted plates, a total of 82 colonies were initially recovered. From Gate R4, a total of
622 colonies were recovered.
6.3 Analysis of Gate R2
From Gate R2 82 colonies were picked and grown up in Agar broth, with appropriate
antibiotic restriction; seven failed to grow and were lost. To identify and confirm that
the remaining 75 contained the correct pCDM8 plasmid, samples were miniprepped
(Wizard Miniprep, as described in "Materials and Methods") and a number were
subjected to DNA digest by Hind III, alongside the H4 library, with pCDM8 vector as
positive control. As can be seen in Figure 6.1, although the pCDM8 control vector and
H4 library clearly demonstrate the ~ 4.0kb band as before, no evidence of the pCDM8
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PAC1-FITC
Figure 6.2: Cell sorting analysis template.
Dot-blot graphs summarising the cell sorting of transfected cells in the genetic screen. aP-py cells
transfected with Tac-a5, H-Ras G12V and the H4 cDNA library were subject to cell sorting.
The total cell population was first gated according to the viability stain 7-AAD, which was taken up
by dead cells (upper panels, blue) and excluded by live cells (upper panels, red). Highly transfected
cells exhibited strong Tac-PE fluorescence (above dashed line, y). Those that exhibited elevated
PAC1-FITC binding (right ofdashed line, x) were gated and collected in two populations, R2 and R4
(lower panel). Of these, R2 exhibited exceptionally high PAC1 binding and R4 positive PAC1
binding. Both populations suggested integrin activation in the face ofH-Ras G12V transfection
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vector was observed in any of the test samples. This was repeated for a number of
samples using Xhol, with similar results, illustrated in Figure 6.1. The implication from
these experiments was that although the colonies had grown on antibiotic-restricted
plates and LB broth, nevertheless they did not carry the pCDM8 plasmid, nor any
potential candidate cDNA.
In order to confirm this as far as possible, it was determined that all R2 candidate
samples should be tested for the presence of pCDM8 vector by polymerase chain
reaction (PCR). 5ml cultures were prepared for all 75 colonies, under antibiotic
restriction, and from these Wizard Minipreps were performed to isolate cDNA at
concentrations of 45 - 85ng//xl, with DNA/RNA ratios of 1.53 - 2.63. From the known
map of pCDM8 vector, forward and reverse primers were selected and ordered from
MWG-Biotech. The PCR regime was as follows in Table 6b:
Table 6b: PCR protocol






Repeat Steps 3-5 x 25 then stop
A test PCR using pCDM8 vector (4ng//xl) or distilled water control confirmed that a
PCR product could be identified after 25 cycles of PCR with pCDM8 vector as substrate,
but not with H2O alone (data not shown). PCR was therefore performed on all 75
samples, using 2/xl of each sample, with positive (pCDM8 vector) and negative (distilled
H2O) controls. Following PCR, samples were separated on Southern blot in TAE gels
and visualized with UV light. Figure 6.3 shows all 75 test lanes, with controls. This
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Figure 6.3: Gate R2 cells do not contain the pCDM8 vector.
TAE gel showing results of PCR, using pCDM8 vector as positive control and distilled water as
negative control, following 25 cycles of PCR. The PCR product was clearly identifiable in the
positive control lanes alone (arrowed). Successfully transformed and cultured samples from Gate R2
comprised the test samples. By comparison with the positive control pCDM8, none of the test
















Figure 6.4: PCR confirms presence of pCDM8 in transfection library.
TAE gel showing results of PCR, using pCDM8 vector as positive control and distilled water as
negative control (lane 1). Both the original, unamplified EI4 library (lane 3) and the amplified EI4
library used for transfection (lane 4) show the PCR product identified from the pCDM8 positive
control lane (lane 2).
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PCR product of ~500bp, none of the 75 test samples showed the presence of the pCDM8
vector.
To confirm that the amplified H4 library which had been used for transfection and cell
sorting had definitely contained the pCDM8 vector, PCR was performed on the original
H4 library and the amplified H4 library cDNA, using the above primers. Samples were
run out and analysed using a TAE gel as before. Figure 6.4 shows that the PCR product
can be identified in the pCDM8 positive control (lane 2), the original H4 library (lane 3)
and the amplified H4 library used for transfection (lane 4), but not in a negative control
(lane 1).
The conclusion from this series of experiments was that none of the colonies grown from
Gate R2 contained bacteria carrying the pCDM8 plasmid and, by inference, candidate
cDNA from the H4 library.
6.4 Analysis of Gate R4
6.4.1 PCR screening of samples from cDNA for pCDM8 vector
A total of 622 colonies were recovered following transformation of the Gate R4. These
were retrieved in four batches (A-D). To ensure efficiency of further studies it was felt
important, given this large number of samples and the negative results in Gate R2, to use
PCR as a relatively fast technique for screening Gate R4 for the presence of pCDM8 and
enabling negative samples to be discarded.
Initial screening was performed on Batches A (16 samples) and B (57 samples). Qiagen
Minipreps were prepared for all samples according to the manufacturer's guidelines,
resulting in cDNA at concentrations of 20 - 45ng//xl, with DNA/RNA ratios of 1.75 -
2.33. Batch A samples were subject to PCR as before and samples analysed by Southern
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Figure 6.5: A number of Gate R4 samples contain pCDM8.
(a) TAE gel showing PCR results for the 13 samples of Batch A. Only samples 8 and 13 exhibited the
PCR product corresponding to pCDM8 vector, as confirmed in the positive control lane.
(b) TAE gel showing the result of Xho 1 restriction enzyme digest for Batch A samples. Again,
samples 8 and 13 were the only positive lanes, supporting the findings of PCR.
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keeping with a positive control. Restriction enzyme digest with Xho I performed on the
same cDNA samples confirmed this result, with all other Batch A samples exhibiting no
vector (Figure 6.5b). From this it was concluded that the PCR was sensitive and
specific; it was therefore used for Batch B. Figure 6.6 shows that PCR identified 45
positive samples out of a possible 57 in Batch B.
6.4.2 PCR screening of samples from bacterial colonies for pCDM8 vector
Despite this success, the logistics of screening Batches C and D, which had 342 and 207
samples respectively {i.e. a total of 549 samples), prompted the decision to try PCR
directly from bacterial samples, without the necessity for miniprepping samples of
cDNA. All bacterial colonies were plated onto gridded 10cm x 10cm agarose plates for
further culture and ease of management. In order to test the PCR regime for sensitivity
and specificity, PCR was performed directly from colonies from Batch A, in which
samples 8 and 13 had been convincingly shown to be the only positive samples.
Preparation of samples for PCR was as described in "Materials and Methods", using the
PCR regime in Table 6c.
Table 6c: PCR protocol






Repeat Steps 3-5 x 35 then stop
Figure 6.7 shows that once again only samples 8 and 13 were identified as carrying the
pCDM8 vector, in keeping with a positive control lane {lane 2), suggesting the PCR
regime was sensitive and specific. This was therefore used for further screening of





Figure 6.6: PCR results for Gate R4, Batch B.
Miniprepped cDNA from all 57 samples of Gate R4, Batch B were subjected to PCR under the
conditions described. The compilation TAE gel shows that the pCDM8 PCR product was observed in
the positive control lane (lane 2), together with 45 of the 57 test samples. A negative control (distilled









Figure 6.7: PCR directly from bacterial colonies.
Samples were taken directly from colonies of transformed bacteria for Gate R4, Batch A, grown under
antibiotic restriction. The TAE gel shows that the pCDM8 PCR product was observed in the positive
control lane (lane 2), together with samples 8 and 13. A negative control (distilled water, lane 1)
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Figure 6.8: PCR for Gate R4, Batch C.
Samples were taken directly from colonies of transformed bacteria for Gate R4, Batch C, grown under
antibiotic restriction. The TAE gels show representative PCR results for the 342 colonies tested in
Batch C. Positive PCR products were identified in a number of samples, whilst negative results were
also numerous. Notably, a number of positive controls were negative (arrowed); these included
samples from Batch A/8 or A/13, or the pCDM8 vector itself (positive control, +). Distilled water
was used for negative control samples (-). Ladder shown in kilo-basepairs.
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negative control for this PCR regimen; for positive controls, both control pCDM8 empty
vector and samples from either Batch A/8 or /13 were utilised.
The results from Batch C are illustrated in part in Figure 6.8. This demonstrates that
although a number of positive samples were clearly identified, there were also occasions
when the positive controls were not positive for PCR product. There were no occasions
when the negative control appeared positive, however. This implied that in fact this
PCR regimen was producing false negative results and might be failing to identify
samples containing the pCDM8 vector.
On review of the PCR conditions, it was felt that the annealing temperature (59°C) might
be too stringent for the primers, producing false negative results. Analysis of the base
makeup of the primers suggested annealing temperatures of 56.6°C and 54.6°C for the
forward (F2) and reverse (Rl) primers, respectively. The annealing temperature was
reduced and times adjusted according to the new regime (Table 6d).
Table 6d: PCR protocol









Repeat Steps 6-8 x 33 then stop
Batch A samples were again used for preliminary testing of the adjusted protocol, results
of which demonstrated a correctly weighted PCR product for samples 8 and 13, with the
remaining samples producing incorrectly sized products compared with pCDM8 control,
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or no product at all (Figure 6.9). This test confirmed that the new protocol was, at very
least, still specific for pCDM8 and suitable for further screening.
Batches C and D were subjected to PCR screening for the presence of the pCDM8 vector
under the new PCR protocol. The results are shown in Figure 6.10, which demonstrates
that multiple samples were able to produce a positive PCR product, of the correct
weight, when compared to positive control pCDM8 empty vector. Of particular note,
the new protocol demonstrated multiple positive samples previously deemed negative by
the first protocol. These were therefore true positives, which might otherwise have been
lost. The interpretation of this was that either these were true positives, containing
pCDM8 vector (and therefore potential candidate cDNA), or they were false positives,
despite PCR products of identical size to the pCDM8 positive control. Although the
latter seemed less likely, at least retention of these samples would not result in loss of
potential candidate cDNA, as might otherwise have been the case.
A total of 479 samples from Batches A - D were identified by PCR screening as
carrying the pCDM8 vector. For all positive samples, fresh colonies were plated onto
gridded, 10cm x 10cm, antibiotic-restricted agarose plates (A - E). Colonies were re¬
classified according to plate and number (A1 - 99; B1 - 99; etc) for the next stage of
screening.
6.4.3 Screening of sample pools for pCDM8 vector
Further screening was performed using the ap-py cell system to identify samples with an
ability to reverse H-Ras G12V integrin suppression. Samples were first pooled into
groups of 10 samples each, where A1 contained pooled cDNA from samples Al-10, A2
contained pooled cDNA from samples A11-20, etc.. For each pool, 500ml cultures were
set up and cDNA prepared using Promega Maxiprep, as described in "Materials and
Methods". cDNA was resuspended in nuclease-free H2O and was of satisfactory purity
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Figure 6.9: Adjusted regime for PCR directly from bacterial colonies.
Samples were taken directly from colonies of transformed bacteria for Gate R4, Batch A, grown under
antibiotic restriction. The TAE gel shows that the pCDM8 PCR product was observed in the positive
control lane {lane 2), together with samples 8 and 13. A negative control (distilled water, lane 1)
demonstrated no PCR product. All other samples produced either a product of incorrect size, or no










Figure 6.10: PCR identifies colonies expressing pCDM8 vector.
Samples were taken directly from colonies of transformed bacteria for Gate R4, Batches C and D,
grown under antibiotic restriction. The TAE gels show representative PCR results for the 549
colonies tested. Positive PCR products were identified in a number of samples; negative results were
less frequent than with the former PCR regimen. All positive controls were consistently positive
(positive control, +). Distilled water was used for negative control samples (-). Ladder shown is in
kilo-basepairs.
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appropriate pCDM8 vector and cDNA inserts, sample pools were subject to Xho I
restriction enzyme digest. Figure 6.11 (upper panel) shows that pools A1 and A2
contain the pCDM8 vector and multiple inserts of different weights (lanes 4 and 5), as
would be expected and as demonstrated in other single samples identified by PCR
screening (above). By contrast, when not digested, pools A1 and A2 demonstrate a
slightly larger band, representing the intact vector plus insert(s) (lanes 2 and 3). Figure
6.11 (lower three panels) shows that in all 49 sample pools (A1 - E9) the pCDM8 vector
was identified, together with a variety of different sized inserts. Thus all the sample
pools A1 - E9 contained the pCDM8 vector and candidate cDNA.
6.4.4 Screening of sample pools for candidate cDNA
Sample pools A1 - E9 were subjected to screening using the aP-py CHO cell system.
For each experiment, 10 pools were tested, ap-py cells underwent transfection with
control or test sample cDNA as indicated in the table below (Table 6e).






H-Ras G12V + R-Ras G38V 2/xg + 2/xg
Tac-a5
H-Ras G12V + pCDM8 control vector 2/xg + 4/xg
H-Ras G12V + pooled cDNA (A1 - E9) 2/xg + 4/xg
Transfection, cell harvest and preparation for flow cytometric analysis were all
performed according to standard protocol, as described in "Materials and Methods".
The results are shown in Figure 6.12a - e. This shows that for all experiments, control
samples behaved as predicted: H-Ras G12V induced integrin suppression; pCDM8




Figure 6.11: Sample pools contain pCDM8 vector and candidate cDNA inserts.
Upper panel: TAE gel confirming the presence of vector pCDM8. Individual samples from Gate R4,
Batch B were subject to Xho 1 restriction enzyme digest, together with sample pools A1 and A2;
sample pools A1 and A2 were also run in the undigested state. Undigested sample pools A1 and A2
{lanes 2 and 3) ran at a greater size than when digested {lanes 4 and 5); digested pools revealed
inserts of multiple size. All digested samples confirmed the presence of pCDM8 vector,
corresponding to the positive control {lane I).
Lower three panels'. TAE gel showing the results of Xho 1 restriction enzyme digest for all pooled
samples A1 - E9. This confirms the presence of pCDM8 and multiple candidate inserts for all pooled







Figure 6.12 (a-e): Screening of sample pools for reversal of H-Ras suppression.
Using the a[3-py CHO cell system, sample pools A1 - E9 were screened for their ability to reverse H-
Ras G12V-mediated integrin suppression. In the presence of Tac-a5, cells were transfected with H-
Ras alone or H-Ras plus pooled cDNA, as indicated. The Activation Index was compared with the
suppression achieved by transfection with H-Ras alone (dashed line). Reversal by R-Ras G38V was












































suppression; R-Ras G38V significantly reversed H-Ras G12V-mediated suppression.
The effect of pooled sample cDNA on integrin activation status was compared with the
degree of integrin suppression achieved by H-Ras G12V in each experiment. The
majority of pools demonstrated no ability to reverse H-Ras-mediated suppression.
Those three pools that demonstrated the best ability to reverse H-Ras suppression (Pools
A3, B2 and E8) were deemed most likely to contain candidate cDNA for proteins able to
activate integrins.
6.4.5 Screening of individual samples for candidate cDNA
For all samples in the candidate pools A3, B2 and E8, individual cDNA samples were
prepared from 10ml cultures of bacterial colonies in antibiotic-restricted LB broth,
followed by Wizard Miniprep. These individual cDNA were then tested in the ap-py
system under the same protocol as for the pooled samples (Section 6.4.4). The results
are shown in Figure 6.13a - c. From this screen, 11 candidate cDNA were identified
that appeared to demonstrate some ability to reverse H-Ras-mediated integrin
suppression. To confirm that these candidate cDNA still contained the pCDM8 vector,
they were subject to restriction enzyme digest with Xho I. Figure 6.14 shows that all 11
candidate cDNA contained the pCDM8 vector, as seen in the control lane (lane 1). In
addition, each carried an insert, which was of variable size, ranging from ~750kb -
3.5kb.
These 11 candidate cDNA were then subjected to a further round of screening under the
same protocol as before, confirming that several of these cDNAs appeared to reverse H-
Ras mediated suppression (data not shown). Of these, sample 480 appeared to give
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H-Ras G12V
Figure 6.13 (a-c): Screening of individual cDNAs for reversal of H-Ras suppression.
Individual cDNA samples from sample pools A3 (21-30), B2 (111-120) and E9 (471-480) were tested
in the aP-py CHO cell system for their ability to reverse H-Ras G12V-mediated integrin suppression,
as previously. Reversal by R-Ras G38V was taken as a positive control in each batched experiment.
Control pCDM8 vector had no influence on H-Ras-mediated suppression.
246
pCDM8
+ ve 21 22 23 25 26 27 111 114 118 120 480
Figure 6.14: Screening of best candidate cDNAs for presence of pCDM8 vector.
Xho 1 restriction enzyme digest confirmed that all candidate samples still retained expression of
pCDM8, as compared with empty vector alone (lane 1). In addition, each candidate sample exhibited
an additional band consistent with a cDNA insert.
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6.5. Studies on Sample 480
6.5.1 Sample 480 demonstrates reversibility of H-Ras suppression
A number of early studies were conducted to assess the ability of 480 to reverse H-Ras
mediated suppression. All these studies used the aP-py cell system and in some the
standard flow cytometric analysis of PAC1 binding was refined to enable cells to be
sorted and collected at analysis, so that further protein analysis could be performed.
The result of a pilot dose-response study is shown in Figure 6.15, comparing the effect
of different doses of 480 cDNA on reversing H-Ras suppression. It can be seen that,
whether H-Ras was used at 1/xg or 2/xg/10cm plate, increasing the dose of 480 to 4/xg or
10/xg (for 1/xg H-Ras only) resulted in an increase in integrin activation; the reversal
appeared more marked if only 1/xg H-Ras G12V was used for transfection. The use of
4/xg of 480 alone did not obviously induce integrin activation above the resting state. In
order to make the assay as sensitive as possible, it was concluded that 1/xg H-Ras G12V
should be used for transfection in further experiments.
A further series of experiments was conducted to observe the ability of 480 to reverse
integrin suppression mediated by 1/xg H-Ras, the results of which are shown in Figure
6.16. This demonstrates that cells transfected with increasing doses of 480 exhibited a
progressively increasing Activation Index. Cells transfected with H-Ras G12V and 5/xg
of control pCDM8 exhibited a mean AI (± SEM) of 38.6% (± 0.8). By comparison, H-
Ras G12V plus 0.5/xg 480 exhibited a degree of reversal, with an increased AI of 55.0%
(± 3.9), rising to an AI of 64.5% (± 4.4) with 1/xg (p < 0.05) and 72.9% (± 2.8) with 5/xg
480 (p < 0.01); this contrasts with the reversal seen with 1/xg ofR-Ras G38V, to an AI of
92.7% (±8.1).
These results demonstrated that, in the presence of a constant amount of cDNA for H-
Ras G12V, transfection with increasing amounts of cDNA for 480 resulted in a reversal
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Figure 6.15: Pilot study of Clone 480 and reversal of H-Ras.
Initial titration experiment to assess the ability of cDNA 480 to reverse H-Ras-mediated integrin
suppression. Increasing doses of cDNA 480 were transfected into a(3-py CHO cells in the presence of
lpg or 2pg ofH-Ras G12V. An apparent dose-response curve was noted. Reversal by R-Ras G38V
was taken as a positive control. Maximum doses of control pCDM8 vector had no influence on
Activation Index.
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Figure 6.16: Clone 480 reverses H-Ras-mediated integrin suppression.
Increasing doses of cDNA 480 were transfected into aP-py CHO cells in the presence of lpg of H-
Ras G12V. A dose-response curve was noted, with significant reversal achieved at lpg of 480.
Reversal by R-Ras G38V was taken as a positive control. Maximum doses of control pCDM8 vector
(5pg) had no influence on Activation Index. Graph represents the mean of three experiments.
(*, p<0.05; **, p< 0.001).
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of H-Ras-mediated suppression. This may have been a true effect, or the result of
reduced transcription of H-Ras G12V.
6.5.2 Analysis of protein expression
To establish whether transfection with increased quantities of 480 was reducing H-Ras
G12V expression, cell populations were probed for the expression of H-Ras G12V as
denoted by the presence of the HA tag. Flow cytometry of transfected cells was refined
so that cells underwent sorting and collection at the same time. Cells that exhibited
significant transfection, defined by elevated Tac-a5 expression, were collected in HBSS
at 4°C for each experimental condition. Samples were pelleted at lOOOrpm for 1 minute
and excess HBSS aspirated. The cells were then lysed in 100/xl MAPK lysis buffer,
prior to protein assay. Alternatively, for some experiments, parallel samples of
transfected cells were harvested by direct lysis from culture plates, as described in
"Materials and Methods", and assessed for protein concentration.
Figure 6.17 shows the results of a titration experiment, in which lysates of sorted cells,
having been equilibrated for protein loading, were run out on Western blots and probed
for the presence of the HA tag for H-Ras G12V expression. Increasing doses of cDNA
480 resulted in reversal of H-Ras suppression (Figure 6.17, graph). In the sorted cells
expression of H-Ras diminished with increasing dose of 480 cDNA. However, when
this Western blot was stripped and re-probed for actin and Tac-a5, expression of both
these proteins also declined in parallel (Figure 6.17, Western blots, upper panel). This
suggested that although higher doses induced loss of H-Ras expression, this might
simply be a result of higher cell death in these samples, not in itself surprising. To try
and confirm this, attempts were made to equilibrate the loading of samples for cell
number. According to the cell sorting data, the following numbers of events were






















Figure 6.17: Clone 480 reverses integrin suppression in the face of H-Ras expression.
Graph: Representative graph showing effect of increasing doses of clone 480 on the AI, in the face of
H-Ras transfection (lpg). Cells were sorted concurrently with flow cytometric analysis and lysates
used for protein analysis.
Western blots: (Upper panel) When loaded according to protein concentration, increased doses of
clone 480 resulted in an apparent decrease in expression ofH-Ras, labelled by the HA-tag. However,
this was parallelled by decreased actin and Tac-a5 expression. (Lower panel) When loaded
according to estimated cell number, supported by equivalence in actin expression, the decline in H-
Ras expression was much less marked.
252
Table 6f: Events sortedfor each condition
Sample "Events" sorted
Tac alone 1277323
Tac, H-Ras G12V 598557
H-Ras + pCDM8 control 350378
H-Ras + R-Ras 450667
H-Ras + lpg 480 208262
H-Ras + 3[ig 480 96538
H-Ras + 6fig 480 106885
H-Ras + 10/ng 480 97183
When samples were re-probed, having been loaded according to the number of events
collected at sorting, the results were improved (Figure 6.17, Western blots, lower
panel). More even loading of actin was apparent, but when stripped and re-probed for
HA-tag / H-Ras G12V expression, some decline in H-Ras expression was still observed
with the highest doses of 480 (lanes 6 and 7). Nevertheless, it can be seen that an effect
of 480 on reversing integrin suppression was observed at least in the face of H-Ras
G12V expression (Figure 6.17, graph).
In samples from parallel plates, equilibrated for protein, it appeared that even with good
equilibration of actin loading, H-Ras expression diminished with higher doses of 480
(Figure 6.18). However, this was not the case with transfection with the maximum dose
of pCDM8 control vector, in which H-Ras expression remained robust (lane 5). This
was difficult to interpret. It remains possible that higher doses of 480 were indeed
suppressing H-Ras G12V expression, thereby producing an apparent reversal of integrin
suppression. An alternative explanation, accounting for the preservation of H-Ras
expression in the presence of maximum doses of pCDM8 control vector, is that higher











Figure 6.18: Clone 480 reverses integrin suppression in the face of H-Ras expression.
Graph: Representative graph showing effect of increasing doses of clone 480 on the AI, in the face of
H-Ras transfection (lpg). Parallel transfection plates were lysed and equilibrated for protein, then
used for protein analysis.
Western blots: When loaded according to protein concentration, as evidenced by equivalence in actin
expression (upper panel), increased doses of clone 480 resulted in a decrease in expression of H-Ras,
labelled by the HA-tag (lower panel). This was not observed with transfection with pCDM8 (10 pg)
{lane 5).
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transfected cells died, leaving a greater proportion of untransfected or less transfected
cells from which lysates were obtained. This would particularly be the case in those
Western blots derived from the parallel plates, where the cell populations were unsorted.
6.5.3 Analysis of sequence
The sequence of 480 was obtained by sending a sample of cDNA to a commercial
company (Genetix), with forward and reverse primers. From earlier studies (Figure
6.14), it was known that Xho I restriction enzyme digest resulted in an insert of
approximately lkb. When the results of forward and reverse sequencing were analysed,
it confirmed that there was an overlap between the two and the contiguous sequence for
480 was derived. This is shown in Figure 6.19, with Xho I digest sites highlighted.
Also highlighted are potential transcription start sites, designated by the sequence ATG
(methionine). Using BLAST software (www.ncbi.nlm.nih.gov/BLAST/), the sequence
was analysed for the most probable reading frame from which a candidate protein could
be translated. As indicated in Figure 6.19, the only reading frame to result in a protein
of any length was the 5'3' frame 3. This yielded the following cDNA and corresponding
protein sequence:





























Presumptive reading frame for clone 480




HCTAAAGQPARGHPRKPVCGHPQSLSPSTSVPPTGPKPTL Stop S S C S P
Met RRPTTSACVSSCGGSRVRGPPASSNGGSSSCRSAGPTATCCPWSF
SVTRSAHRASASWLATASWNLP Met T S T Met D T Y S P L E
Figure 6.19: Clone 480 sequences.
Upper panel. Contiguous sequence of the plasmid cDNA for clone 480, derived from overlapping forward
and reverse sequences. Putative start sites are marked by methionine ATG sequences {green); Xho 1
restriction enzyme sites TCGAC were also noted (underlined), including one within the 480 sequence. Lower
panel. Best-fit reading frame for clone 480. Translation start sites are indicated by methionine {Met, green)-,









The Clone 480 cDNA sequence was analysed by use of a BLAST search and
corresponds to the C-terminal part of a large gene termed KIAA0233, which has
previously been sequenced but not fully characterized (Nagase et al., 1996) (Figure
6.20). Clone 480 exhibits 98% identity with an extensive region of KLA0233, covering
base pairs 5067 - 5656, with only 11/603 gaps (1%). The full length of the gene is
~6kb, with a locus of 16q24.3 and it codes for a predicted 230kDa protein. The
predicted amino acid sequence of the first 98 residues from Clone 480 is identical to
residues 1689 - 1786 of KIA0233 protein. Using a web-based Simple Modular
Architecture Research Tool (SMART) protein analysis (www.smart.embl-
heidelberg.de/), the amino acid sequence of KIA0233 predicts a protein having 22
(possibly 23) transmembrane domains (Figure 6.21). Colloquially, it has thus been
christened "Nessie". The region corresponding to Clone 480 commences within the
predicted 21st transmembrane region (residues 1684 - 1706). The Nessie protein is
apparently evolutionarily conserved since it has been identified in a variety of species
other than Homo sapiens; these include M. musculus, R. norvegiens, F. rubripes, D.




1 ccatggacct gcgccctgag ctgcccacca ccctgggccc cgtcagcctg cgccagctgg
61 ggctggagca cacccgctac ccctgtctgg accttggtgc catgttgctc tacaccctga
121 ccttctggct cctgctgcgc cagtttgtga aagagaagct gctgaagtgg gcagagtctc
181 cagctgcgct gacggaggtc accgtggcag acacagagcc tacgcggacg cagacgctgt
241 tgcagagcct gggggagctg gtgaagggcg tgtacgccaa gtactggatc tatgtgtgtg
301 ctggcatgtt catcgtggtc agcttcgccg gccgcctcgt ggtctacaag attgtctaca
361 tgttcctctt cctgctctgc ctcaccctct tccaggtcta ctacagcctg tggcggaagc
421 tgctcaaggc cttctggtgg ctcgtggtgg cctacaccat gctggtcctc atcgccgtct
481 acaccttcca gttccaggac ttccctgcct actggcgcaa cctcactggc ttcaccgacg
541 agcagctggg ggacctgggc ctggagcagt tcagcgtatc cgagctcttc tccagcatcc
601 tggtgcccgg cttcttcctc ctggcctgca tcctgcagct gcactacttc cacaggccct
661 tcatgcagct caccgacatg gagcacgtgt ccctgcctgg cacgcgcctc ccgcgctggg
721 ctcacaggca ggatgcagtg agtgggaccc cactgctgcg ggaggagcag caggagcatc
781 agcagcagca gcaggaggag gaggaggagg aggactccag ggacgagggg ctgggcgtgg
841 ccactcccca ccaggccacg caggtgcctg aaggggcagc caagtggggc ctggtggctg
901 agcgcctgct ggagctggca gccggcttct cggacgtcct ctcacgcgtg caggtgttcc
961 tgcggcggct gctggagctt cacgttttca agctggtggc cctgtacacc gtctgggtgg
1021 ccctgaagga ggtgtcggtg atgaacctgc tgctggtggt gctgtgggcc ttcgccctgc
1081 cctacccacg cttccggccc atggcctcct gcctgtccac cgtgtggacc tgcgtcatca
1141 tcgtgtgtaa gatgctgtac cagctcaagg ttgtcaaccc ccaggagtat tccagcaact
1201 gcaccgagcc cttccccaac agcaccaact tgctgcccac ggagatcagc cagtccctgc
1261 tgtaccgggg gcccgtggac cctgccaact ggtttggggt gcggaaaggg ttccccaacc
1321 tgggctacat ccagaaccac ctgcaagtgc tgctgctgct ggtattcgag gccatcgtgt
1381 accggcgcca ggagcactac cgccggcagc accagctggc cccgctgcct gcccaggccg
1441 tgtttgccag cggcacccgc cagcagctgg accaggatct gctcggctgc ctcaagtact
1501 tcatcaactt cttcttctac aaattcgggc tggagatctg cttcctgatg gccgtgaacg
1561 tgatcgggca gcgcatgaac tttctggtga ccctgcacgg ttgctggctg gtggccatcc
1621 tcacccgcag gcaccgccag gccattgccc gcctctggcc caactactgc ctcttcctgg
1681 cgctgttcct gctgtaccag tacctgctgt gcctggggat gcccccggcc ctgtgcattg
1741 attatccctg gcgctggagc cgggccgtcc ccatgaactc cgcactcatc aagtggctgt
1801 acctgcctga tttcttccgg gcccccaact ccaccaacct catcagcgac tttctcctgc
1861 tgctgtgcgc ctcccagcag tggcaggtgt tctcagctga gcgcacagag gagtggcagc
1921 gcatggctgg cgtcaacacc gaccgcctgg agccgctgcg gggggagccc aaccccgtgc
1981 ccaactttat ccactgcagg tcctaccttg acatgctgaa ggtggccgtc ttccgatacc
2041 tgttctggct ggtgctggtg gtggtgtttg tcacgggggc cacccgcatc agcatcttcg
2101 ggctgggcta cctgctggcc tgcttctacc tgctgctctt cggcacggcc ctgctgcaga
2161 gggacacacg ggcccgcctc gtgctgtggg actgcctcat tctgtacaac gtcaccgtca
2221 tcatctccaa gaacatgctg tcgctcctgg cctgcgtctt cgtggagcag atgcagaccg
2281 gcttctgctg ggtcatccag ctcttcagcc ttgtatgcac cgtcaagggc tactatgacc
2341 ccaaggagat gatggacaga gaccaggact gcctgctgcc tgtggaggag gctggcatca
2401 tctgggacag cgtctgcttc ttcttcctgc tgctgcagcg ccgcgtcttc cttagccatt
2461 actacctgca cgtcagggcc gacctccagg ccaccgccct gctagcctcc aggggcttcg
2521 ccctctacaa cgctgccaac ctcaagagca ttgacttcca ccgcaggata gaggagaagt
2581 ccctggccca gctgaaaaga cagatggagc gtatccgtgc caagcaggag aagcacaggc
2641 agggccgggt ggaccgcagt cgcccccagg acaccctggg ccccaaggac cccggcctgg
2701 agccagggcc cgacagtcca gggggctcct ccccgccacg gaggcagtgg tggcggccct
2761 ggctggacca cgccacagtc atccactccg gggactactt cctgtttgag tccgacagtg
2821 aggaagagga ggaggctgtt cctgaagacc cgaggccgtc ggcacagagt gccttccagc
2881 tggcgtacca ggcatgggtg accaacgccc aggcggtgct gaggcggcgg cagcaggagc
2941 aggagcaggc aaggcaggaa caggcaggac agctacccac aggaggtggt cccagccagg
3001 aggtggagcc agcagagggc cccgaggagg cagcggcagg ccggagccat gtggtgcaga
3061 gggtgctgag cacggcgcag ttcctgtgga tgctggggca ggcgctagtg gatgagctga
3121 cacgctggct gcaggagttc acccggcacc acggcaccat gagcgacgtg ctgcgggcag
3181 agcgctacct cctcacacag gagctcctgc agggcggcga agtgcacagg ggcgtgctgg
3241 atcagctgta cacaagccag gccgaggcca cgctgccagg ccccaccgag gcccccaatg


































































































































































































































































































































































Figure 6.20 Published sequence of KIA0233
Full nucleotide sequence for KIA0233, taken from Nagase T, (1996). Clone 480 represents







Signal peptide 1 48 Low complexity 969 990
Transmembrane 94 113 Low complexity 1002 1013
Tm 117 136 Tm 1203 1234
Tm 143 165 Tm 1244 1266
Tm 195 217 Low complexity 1335 1346
Low complexity 254 270 Low complexity 1378 1390
Tm 337 359 Low complexity 1400 1419
Low complexity 460 471 Low complexity 1426 1440
Tm 499 521 Tm 1475 1497
Tm 551 573 Tm 1517 1537
Tm 674 691 Tm 1544 1566
Tm 698 717 Tm 1576 1593
Tm 732 754 Tm 1614 1636
Tm 761 778 Tm 1646 1663
Tm 798 817 Tm 1684 1706
Coiled coil 853 882 Tm 1944 1966
Low complexity 897 912 Low complexity 2006 2013
Low complexity 936 950
Figure 6.21 Predicted structure of KIA0233 protein.
Protein structure for KIA0233 was predicted using SMART protein analysis and predicts for
a protein containing 22 transmembrane domains, shown schematically {above).
Transmembrane domains are shown in blue, a coiled coil region is shown in green; multiple
segments of low compositional complexity are shown in red There is an initial signal
peptide (dark grey).
Lower table. Amino acid residue map of confidently predicted domains. Key:
transmembrane domain {I'm).
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6.6 Appendix to Chapter 6: further studies on Clone 480
Substantial further work has been done on the nature and relevance of Clone 480 since
the end of the period allotted for this thesis. This work has direct relevance to the
present thesis and as such a brief summary of the current findings is presented here. For
taking on this work, the author is grateful for the efforts of Dr. Yatish Lad and Dr. Brian
McHugh.
In the first instance, the above dose-response tests were successfully repeated by Dr. Lad
to ensure that the results quoted were not investigator-dependent. It was clearly
important that some means of localizing Clone 480 expression should be established and
therefore Clone 480 was successfully tagged with Myc on the 3' end and tested once
again for activity. It was again found that 1/ig of 480-Myc could reverse H-Ras G12V-
mediated suppression. By probing for Myc expression on Western blotting it was
established that Clone 480 was being expressed. Immunofluorescence experiments in
CHO aP-py cells also demonstrated that this expression appeared to be localized around
the nucleus, possibly in the endoplasmic reticulum.
The full-length form of KIAA0233/Nessie was obtained from a Japanese group (The
Kazusa DNA Research Institute,) and tagged with Myc at the C-terminus for analysis.
Full length Nessie-Myc also rescues integrins from H-Ras G12V-mediated suppression,
although there is some suppression of H-Ras expression in these experiments. The
Nessie protein is expressed and is detectable at greater than 250kDa on Western blots; in
immunofluorescence experiments, the full-length protein, like the Clone 480, localizes to
the endoplasmic reticulum. There does not appear to be any plasma membrane
expression.
In addition to rescuing H-Ras G12V suppression, Nessie appears to rescue suppression
induced by the effector mutants H-Ras T35S and H-Ras D38N, but only partially rescues
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the activated Raf mutant Raf(BxBCAAX). On its own, Nessie activates integrins and
enhances activation observed with R-Ras. None of these effects appear to be related to
activation or suppression of the MAPK/ERK pathway, since Nessie alone does not
influence ERK phosphorylation, nor does it inhibit ERK phosphorylation by El-Ras
G12V.
6.7 Discussion
This chapter describes the application of a genetic screen to isolate potential regulators
of integrin activation. Thus the screen was performed in the aP-py CHO cell system,
with cells transfected with H-Ras and gating out those cells with activated integrins
despite H-Ras expression. This work builds on that of the previous chapter. In
particular, the use of To-Pro-3 as a live/dead cell marker has become standard technique
and played a role in filtering out spurious "noise" from the dead cell population. The
result of this screening process has been the identification of a novel gene, now termed
Nessie, which appears to reverse H-Ras G12V-mediated integrin suppression.
It was disappointing to discover that there were no positive clones in the more tightly
gated population of cells defined by Gate R2, since this would have provided a rapid
focus for further efforts. None of these 82 colonies appeared to contain the pCDM8
vector or, therefore, candidate cDNA. This appears surprising in the first instance, since
they all grew under strict antibiotic restriction, which should have identified only
pCDM8-expressing bacteria. However, discussion with others who have performed
such genetic screens suggests that false positive colonies will appear and that this is
presumably due to acquisition of antibiotic resistance, either from the pCDM8 vector or
de novo {personal communication, Dr. L. Vernon-Wilson). This was supported by the
finding that a significant proportion (23%) of Gate R4 colonies apparently contained no
pCDM8 vector either.
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This aP-py CHO cell system has already been used to identify a number of proteins
related to integrin activation. In 1997, Fenczik et al. used it to identify CD98 as a
specific activator of integrins (Fenczik et al., 1997a). In that study, CD98 was the only
protein isolated for its ability to rescue integrins from dominant suppression induced by
overexpression of pi integrin cytoplasmic domains, so-called complementation of
dominant suppression (CODS). The same expression cloning technique identified PEA-
15 as a protein able to reverse H-Ras-mediated integrin suppression, in a strategy similar
to the one taken in the current work (Ramos et al., 1998). PEA-15 is a death effector
domain-containing protein, found in a family of proteins that normally regulate
apoptosis through this death effector domain (DED). In PEA-15, however, the DED is
required for regulation of integrin function. PEA-15 also appeared to be downstream of
R-Ras G38V, since a dominant negative R-Ras prevented PEA-15 reversal of integrin
suppression.
In the case of PEA-15 it was demonstrated that H-Ras expression levels in PEA-15
transfected cells remained comparable to cells transfected with H-Ras alone. This was
clearly critical if it was to be argued that reversal of H-Ras-mediated suppression by
PEA-15 was not due simply to a loss of H-Ras expression. Within the limits of the
initial studies on Clone 480, it was felt that there was good evidence that reversal of
suppression was observed despite reasonable preservation of H-Ras expression.
However, these experiments were limited by the lack of an expression marker for Clone
480 itself and therefore cannot conclusively rule out an effect of overexpression.
Without such a marker it proved difficult to satisfactorily differentiate between the two
possibilities of (a) a true reversal of H-Ras suppression and (b) a loss of H-Ras G12V
expression. Although analysis of protein expression suggested that H-Ras expression
was diminishing as a result of diminishing cell survival, an alternative possibility might
also be that Clone 480 was targeting H-Ras to the ER, from which it was not being
adequately released during preparation of cell lysates. Such an effect would certainly
compound any loss of H-Ras expression due to decreased cell survival. In fact,
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subsequent experiments with 480-Myc and Nessie-Myc have strengthened the view that
the reversal of suppression is a true phenomenon, rather than simply the effect of
expressing a large protein that localises to the ER (Dr. B. McHugh, personal
communication). Current studies using truncated forms of Nessie, lacking the 480
region, should further establish whether the effect is true reversal.
It was noted that there were differences between the predicted amino acid sequences of
Clone 480 and the corresponding region of KIA0233 - only the first 98 amino acid
residues for Clone 480 concur with the predicted sequence of KLA0233 (Figure 6.22).
This is relatively easily explained. If the two DNA sequences are aligned using BLAST
software, there is an extra guanine in Clone 480 that results in a frameshift. Thereafter,
the reading frame will differ between the two sequences, and hence also the amino acid
sequence (Figure 6.23).
Nessie does not immediately appear to be a candidate for a link between R-Ras and
reversal of suppression. A number of recent papers have begun to pull apart the
mechanism of R-Ras reversal. Analysing the closely related H-Ras and R-Ras proteins,
it appears that the C-terminal 53 amino acid residues are sufficient to confer upon R-Ras
its specific biological properties, in terms of morphological changes, reactive oxygen
species production and reversal of suppression (Hansen et al., 2002). R-Ras reversal has
been shown to be dependent upon the presence of a proline-rich motif, similar to an SH3
domain-binding site (Wang et al., 2000). Additionally, the tyrosine 66 residue, located
in the effector domain, is a point of critical phosphorylation/dephosphorylation events
controlling R-Ras activity. This is a target for the ephrin receptor tyrosine kinase,
EphB2: transfection with activated EphB2 causes reduced cellular adhesion, associated
with phosphorylation at this site (Zou et al., 1999). Interestingly, this is also the site of
phosphorylation for an activated form of Src (Src527), which has been found in human





































Figure 6.22 Full predicted sequence ofKIA0233 protein.
The full amino acid sequence predicted for the protein coded by KIA0233 (taken from
Nagase T, 1996), showing the region represented by Clone 480 in red. Only the first 98
amino acid residues predicted for Clone 480 concur with those within the predicted sequence
for KIA0233 (residues 1689 - 1786, in bold). Thereafter the predicted sequence for Clone
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5067 atgggtggcctcatcatcctcttcctcatcgccatcatctggttcccgctgctcttcatg
61 tcgctggtgcgctccgtggttggggttgtcaaccagcccatcgatgtcaccgtcaccctc
I I I I I II I I I I I I I I II II I II I I I I I I II I II II I I I I I I I I I I I II I I I I II I I I I II
5127 tcgctggtgcgctccgtggttggggttgtcaaccagcccatcgatgtcaccgtcaccctc
121 aagctgggcggctatgagccgctgttcaccatgagcgcccagcagccgtccatcatcccc
I I I I I I I I I I I I II I I I I I II I I I I I I I I I I II I I I I I I I I I I I I I I I I I II I I I I I I I I
5187 aagctgggcggctatgagccgctgttcaccatgagcgcccagcagccgtccatcatcccc
181 ttcacggcccaggcctatgaggagctgtcccggcagtttgacccccagccgctggccatg
I I I II I I II II I I II I I I I II I I I I I I I II I I II I I I II I I II I II I I II I I I I I I I I II
5247 ttcacggcccaggcctatgaggagctgtcccggcagtttgacccccagccgctggccatg
241 cagttcatcagccagtacagccctgaggacatcgtcacggcgcagattgagggc age etc
I I I II I I I I I I II I I I I I I I I I I I I I I I II I I II II I I I I I I II I I I I I I I I I
5307 cagttcatcagccagtacagccctgaggacatcgtcacggcgcagattgagggca-cetc
I I I I
301 cnggggcgatgtggcgcaatcagtccccccagccgtgcccagatngaagcgggagctcta
I MINI II I I II II II I II II II II I II I II II I I I II II II I I II I I I I I II II
5366 c-ggggcgctgtggcgc-atcagtccccccagccgtgcccagat-gaagcgggagctcta
361 caacnggcacggccgacatcaccctgcgcttcacctggaacttccagagggacctggcga
I I I I I I I II I I I I II I I II I II I II I I II I I II II I I I I II I I I I II I I II I II I I I I I
5423 caac-ggcacggccgacatcaccctgcgcttcacctggaacttccagagggacctggcga
421 agggaggcactgtggagtatgccaacgagaagcacatgctggcncctggccccccaacag
II I I I II I I I I I I I I I I I I I I I I II I I I I I I I II I I I I II I I I I I I I I I II II I I II I
5482 agggaggcactgtggagtatgccaacgagaagcacatgctggc-cctgg-cccccaacag
481 cactgcacggcggcagctggccagcctgctcgagggcaccctcggaaaccagtctgtggt
I I I II I I II I I I I II I I I II I I I I II I I I I I I I I II I I I I I II I II I I I I I I I II I I
5540 cactgcacggcggcagctggccagcctgctcgagggca-cctcgg--accagtctgtggt
541 catccccaatctctttccccaagtacatccgtgcccccaacgggcccgaagccaaccctg





Figure 6.23 Mismatching between Clone 480 and KIA0233.
Alignment of the nucleotide sequences for Clone 480 (Query) and KIA0233 (Sbjct),
commencing at the first ATG/methionine start site in Clone 480, shows that the two
sequences are identical as far as base pair 296 of Clone 480 (highlighted). Here an extra
guanine base is found in Clone 480, not present in KIA0233. As a consequence of this,
there would be a frame-shift in the reading frame of Clone 480, ifworking from the original
predicted sequence: the predicted amino acid sequences would therefore differ from this
point on.
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Signalling events downstream of R-Ras remain poorly understood. R-Ras can activate
the PI 3-kinase pathway, but although it binds to the common effector Raf-1, it does not
activate Raf-1 or the ERK/MAPK pathway, nor the JNK pathway (Marte et al.,
1997;Self et al., 2001). The PI 3-kinase pathway has recently been demonstrated to be
important in controlling monocyte adhesion and migration in the context of
atherosclerosis (Cole et al., 2003). Microinjection of R-Ras into a macrophage cell line
has shown activation of aMp2 integrins via Rapl (Self et al., 2001). Recent studies
have shown that R-Ras localises to focal adhesions in the lipid membrane and that the C-
terminal residues confer this property (Furuhjelm and Peranen, 2003); unlike H-Ras,
which migrates out of lipid rafts upon activation, activated R-Ras remains localised
(Hansen et al., 2003), where it has been shown to promote adhesion through
phosphorylation of FAK and pl30(Cas) (Kwong et al., 2003).
The protein identified in this chapter, Nessie, appears to promote reversal of integrin
suppression, yet how 480/Nessie might achieve this is quite unclear. The parent protein
is extremely large, with multiple transmembrane domains. To date, those proteins
recognised to be involved in regulation of integrin affinity have either been small
signalling molecules, such as the Ras family of GTPases, or proteins that localise to the
plasma membrane, where they could potentially regulate affinity in the context of a
membrane lipid rafts, such as CD98, P3-endonexin or, now most prominently, R-Ras
itself. However, so far both 480-Myc and Nessie-Myc have only ever localised to the
ER, not to the plasma membrane where Nessie might have been expected to influence
integrin affinity.
Potential mechanisms by which Nessie might regulate integrin affinity might include
sequestration of important signalling molecules, such as H-Ras or its mediators, such
that they are unavailable to cause integrin suppression. The author is unaware of any
evidence to support this. Intriguingly, however, a recent report by Werner et al. has
linked the functional effects of R-Ras with the ER (Koopman et al., 2003). This group
267
has observed that activated R-Ras alters the handling of Ca2+ by the ER, with increased
leak of Ca2+ from the ER and a decrease in frequency of cholecystokinin-induced Ca2+
oscillations. Observing that this reduction in ER Ca2+ stores resembles the effect ofBcl-
2, it has been suggested that these effects may underlie both the antiapoptotic effect of
R-Ras and its modulatory role on integrin affinity, through alterations in the activity of
downstream effector molecules. Thus it is now interesting to speculate whether Nessie,
as a large transmembrane protein situated in the ER, may be involved in the regulation
of ion exchange, with downstream effects on integrins as a result. In addition, the large
number of transmembrane domains predicted in Nessie might be in keeping with a
function as an ion channel. This need not necessarily be influenced by R-Ras in any
way.
In summary, this chapter has presented the results of an expression cloning screen
designed to identify proteins involved in the reversal of integrin suppression. In
particular, it was hoped to identify potential downstream effectors of R-Ras.
Preliminary findings appear promising: a cDNA clone demonstrated reversal of H-Ras-
mediated suppression in the face of continued H-Ras expression. This appears to be a
fragment of a larger, novel gene encoding a large protein with multiple transmembrane
domains. Further studies by colleagues have reproduced the author's findings and
confirmed them with the whole protein; outstanding issues still require clarification, in
particular confirmation that this is not simply an overexpression effect.
268
Chapter 7
Conclusions and Future Directions
This thesis has covered three main areas of study relating to integrins and lung cancer:
the association between pi integrin and the transmembrane protein CD98; the
expression of CD98 and its ligand galectin-3 within a variety of lung cancers; and a
search for regulatory pathways involved in the modulation of integrin affinity in a model
cell system. Briefly summarised, this work has confirmed the physical association of
CD98 and pi integrin, as well as demonstrating that cross-linking CD98 results in
integrin-like signalling and functional effects. Histochemically, there was a striking
differential expression of galectin-3 between SCLC and NSCLC samples. Finally, a
novel gene and protein - now termed Nessie because of multiple predicted
transmembrane domains - have been identified with an apparent ability to rescue H-Ras-
mediated integrin suppression.
The setting of this work is the field of lung cancer, in particular small cell lung cancer.
Survival figures for lung cancer as a whole are poor. Primarily the reason for this is the
late presentation of the disease, such that even for non-small cell lung cancer only a
minority of patients have the chance of potentially curative surgery. Additionally, until
recently NSCLC was deemed insensitive to chemotherapy and it is only over the last
decade or so that more aggressive chemotherapy regimes are being used for good
performance status patients with inoperable NSCLC. By comparison, SCLC, described
even by politicians as "the most aggressive form" of lung cancer, is initially
chemosensitive. Perhaps this is just as well, since the vast majority of patients present
with metastatic disease and it is very rarely operable. The tragedy remains, however,
that even with chemotherapy, SCLC almost inevitably relapses with more resistant
disease. Behind this thesis lies the proposition that a better understanding of the cell
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biology of lung cancer, the reasons for early metastasis and for the development of
resistance to chemotherapy, will lead to more rational and effective treatments.
Key to this is an understanding of integrin function and the way in which they integrins
link a cell to its local milieu. Extracellular matrix-mediated protection is now
increasingly understood to confer protection from chemotherapeutic agents and has been
demonstrated in a number of cell types (Boudreau et al., 1995;Hoyt et al., 1996;Sethi et
al., 1999c;Hazlehurst et al., 2000). A cytoprotective effect, mediated through pi
integrins, prevents chemotherapy-induced caspase-3 activation and apoptosis, despite
persistent DNA damage. Hence, SCLC cells adhered to ECM may escape
chemotherapy-induced cell death and subsequent drug-resistant clones are selected with
an increasing burden of genetic damage. This is an excellent model to explain why
partial responses and local recurrence of SCLC are often seen after chemotherapy and
why there is no unifying genetic change causing chemoresistance in SCLC cells.
The work presented here contributes to our understanding of how a specific regulator of
integrin affinity, CD98, may be involved in the augmentation of integrin-ECM binding.
This would be predicted to have a direct effect on protection for chemotherapeutic
agents, which indeed is confirmed in vitro. Furthermore, it supports other work
suggesting that integrin-mediated PI 3-kinase signalling is a key signalling pathway
involved in ECM-mediated protection. The intracellular signalling mechanisms
mediating pi integrin-induced drug resistance are beginning to be defined. Tyrphostin-
25, a selective inhibitor of protein tyrosine kinase (PTK), blocks adhesion-mediated drug
resistance in SCLC cells. PI 3-kinase acts as a direct biochemical link between a
phosphoinositide pathway and a number of proteins containing tyrosine kinase activity.
PI 3-kinase requires tyrosine phosphorylation for full activation and would thus be a
target for PTK activity. Both PI 3-kinase and PKB suppress anoikis and the induction of
chemotherapy-induced chemoresistance (Schmidt et al., 2002). The introduction of a
constitutively active form of PKB to A549 lung non-small cell lung cancer (NSCLC)
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cells resulted in profoundly decreased chemosensitivity to mitoxantrone and cisplatin.
PKB has been shown by other groups to be constitutively activated in NSCLC and to
confer resistance to both radiation- and chemotherapy-induced apoptosis (Brognard et
al., 2001).
It is exciting to hypothesize how differential expression of galectin-3 between SCLC and
NSCLC may be linked with the different cellular phenotypes, the former so
chemosensitive and of high metastatic potential. In particular, although it is hard to put
much weight on a single sample, it is striking that the one sample of SCLC taken after
chemotherapy demonstrated dramatically positive galectin-3 expression - quite opposite
to all other SCLC samples, yet akin to NSCLC samples. Given that relapsed SCLC
becomes increasingly chemoresistant, like NSCLC, this suggests that this change may be
accompanied by increased galectin-3 expression.
Clearly this is too far to extend these results at present. Nevertheless, it opens up a
whole series of relatively simple studies that may be highly elucidating. These would
include an assessment of a range of cell lines in vitro for endogenous galectin-3
expression, including NSCLC, SCLC and known chemoresistant SCLC. It would also
be interesting to assess whether recurrent chemotherapeutic treatment could induce
galectin-3 expression and, more importantly, whether transfection with an expression
vector for galectin-3 conferred chemoresistance. At a clinical level, it has now become
important to assess galectin-3 expression in a larger series of lung cancer patients, both
SCLC and NSCLC. Such a study would include samples before treatment with
chemotherapy and preferably at a later time point of relapse, which may be death; the
objective would be to see whether galectin-3 expression is a useful marker clinically for
predicting response to chemotherapy and progression of disease. Additionally, the
relationship between galectin-3 expression and metastatic potential should be examined.
This may of particular importance in NSCLC, where metastasis prevents curative
surgery and may occur post-surgery, as relapsed disease. If galectin-3 expression were
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to predict the likelihood of metastatic relapse following surgery, this would be an
important tool in targeting adjuvant therapies such as aggressive chemotherapy or cranial
radiotherapy.
Little interest has yet been paid in the literature to the fact that galectin-3 is a ligand for
CD98, but if galectin-3 is indeed inducible at the cell surface or secreted, then it would
appear to have the ability to cross-link CD98, augmenting integrin survival signalling.
Chemoresistance is a far more complex entity than this conveniently tidy model, but it
would be an interesting model to test, nevertheless, and the creation of a galectin-3
knockout mouse would be a useful adjunct for these studies (Colnot et al.,
1998a;Pugliese et al., 2001).
The discovery of a novel gene involved in modulating integrin affinity is scientifically
exciting. However, at the time of completion of this thesis much work was still required
to ensure this was a valid interpretation of the results. Some of this work has been done
and supports the findings of the original Clone 480: the results have been replicated and
the use of Myc tagging has enabled clarification of protein expression levels;
additionally, the results seem to hold true for the parent - and much larger - protein,
full-length Nessie. Providing overexpression effects have been satisfactorily excluded,
this work will have isolated a novel protein to stand with the relatively small band
already described as activators of integrins. However, it appears to differ from those
others most markedly in its large size and structure, as well as its apparent location in the
endoplasmic reticulum. As already discussed in Chapter 6, further work is ongoing to
exclude overexpression effects. It will then be interesting to establish exactly how
Nessie is influencing integrin affinity. As an early step it would seem prudent to
develop an antibody to the native protein, so that its cellular location can be pinpointed
under normal cellular conditions. If it indeed localises solely to the ER and not the
plasma membrane, further studies might include assessments of Ca2+ control, as well as
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co-immunoprecipitation experiments to look for associations between Nessie and Ras-
family signalling proteins.
The regulation of integrins therefore lies at the heart of this work. At first glance, the
accumulating evidence for ECM-mediated protection from apoptosis sits somewhat
paradoxically with the clinical finding of highly metastatic disease, as found in SCLC.
However, integrin-ligand binding is a highly dynamic process, with rapid changes in
integrin affinity and avidity. Biologically this is intuitive, since the requirement for
cellular adhesion to a basement membrane must vary in different phases of cellular
behaviour: for example, during mitosis, cells are seen to "round up", becoming largely
detached from underlying matrix so that cellular division can occur satisfactorily. Data
from this thesis support the proposition that cyclin Dl, a key driver of the cell cycle,
promotes integrin suppression. A link from the cell cycle back to the cell surface and
adhesion - effectively, inside-out signalling - requires further corroboration and detailed
study.
Integrin-ligand binding must also be highly dynamic for active migration to occur. An
optimum degree of cell-matrix adhesion must exist and be alterable both over very short
distances (from the leading edge of a cell to the trailing edge) and over very short time¬
frames. Lauffenburger and Horwitz argue that cell motility is a balance between
contractile forces pulling the cell forward over a surface and adhesive forces between the
cell and substratum. If adhesive forces are too strong the cell becomes unable to move,
but if there is too little adhesion no tensile force can be generated to transmit to the
cytoskeleton and allow movement (Lauffenburger and Horwitz, 1996). These models
predict a bell-shaped curve for the rate of migration against the strength of cell adhesion.
We can therefore picture SCLC cells in more than one phase of cellular behaviour. At
times they may be strongly adherent to ECM, with an integrin-mediated survival
advantage in the face of chemotherapy. When less strongly adhered to ECM proteins,
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they will be more mobile and have a greater propensity to metastasize - during which
process they have a survival advantage due to their autocrine/paracrine growth loops, but
may be more susceptible to chemotherapy-induced apoptosis. Chemotherapy would
selectively spare those cells most adherent and most protected. This may explain why
clinical recurrence of SCLC tends to occur in the same sites as the initial disease, where
there would be the highest likelihood of a subpopulation of cells with strong cell-ECM
contacts. On a cellular level, increased cellular adhesion to ECM broadly correlates with
increased chemoresistance, although clearly at very high doses of chemotherapy all cells
would succumb. The converse is that the less adherent a cell is, the more susceptible it
is to chemotherapy. The relationship of adhesion to cell motility, however, would
exhibit a peak of cell motility limited by excessive adhesion in one direction, but
insufficient tensile force in the other. These relationships of cell motility and cellular
chemoresistance against the strength of cell adhesion are represented schematically in
Figure 7.1.
There is now some direct evidence to support this model in SCLC. Kraus et al. have
shown that spontaneously adherent sublines of SCLC are phenotypically different from
the parent line: they exhibit upregulation of cyclin D1 and of integrin subunits a2, (33
and p4. Moreover, they were significantly more resistant to either chemotherapy or
ionising radiation compared with the parent lines, in a PKB-dependent manner (Kraus et
al., 2002). In squamous cell carcinomas, alterations in integrin expression have also
been observed to influence susceptibility to anoikis. Using retroviral vectors to
introduce av integrins to av-negative cells, it has recently been shown that a switch
from avp5 expression to avP6 expression resulted in protection from anoikis, again
associated with PKB activation (Janes and Watt, 2004). These results point to the
critical importance of tight regulation of integrin expression and indicate how loss of
integrin regulation may promote neoplasia.
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Figure 7.1: Relationship between adhesion and motility or chemoresistance
Schematic graph representing theoretical relationship between cellular adhesion to underlying matrix
and both cellular motility and chemoresistance. Cells that are weakly adherent to ECM (extreme left
ofgraph) may be unable to generate the tensile forces necessary for migration and will receive little
by way of integrin-mediated survival signals - they will therefore be most vulnerable to
chemotherapy. As adherence to underlying matrix increases, tensile forces are generated, resulting in
increased motility, until such a point as adhesive forces become more difficult to overcome.
Increasing adherence results in increased integrin-mediated cell-survival signalling and therefore
increasing chemoresistance. Cells that are most strongly adherent to ECM (extreme right ofgraph)
will be unable to overcome adhesive forces and will be immotile; however, they will receive strong
integrin-mediated survival signals and be the most chemoresistant.
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In conclusion, this work has answered some questions regarding integrins in the context
of lung cancer. Inevitably, it has opened up more avenues of enquiry. Some of these
have immediate clinical application to lung cancer; others are less directly accessible to
clinical medicine, but remain important areas of study if we are to fully comprehend
mechanisms of cellular control in normality and disease. Such basic scientific studies
will ultimately result in more intelligent therapies for diseases, whether neoplastic or
degenerative. It is upon such foundations that medicine should be constructed.
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